WO2020173426A1 - 基于戊二酰亚胺骨架的含硫化合物及其应用 - Google Patents
基于戊二酰亚胺骨架的含硫化合物及其应用 Download PDFInfo
- Publication number
- WO2020173426A1 WO2020173426A1 PCT/CN2020/076578 CN2020076578W WO2020173426A1 WO 2020173426 A1 WO2020173426 A1 WO 2020173426A1 CN 2020076578 W CN2020076578 W CN 2020076578W WO 2020173426 A1 WO2020173426 A1 WO 2020173426A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dione
- sulfanyl
- thio
- piperidine
- group
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 624
- KNCYXPMJDCCGSJ-UHFFFAOYSA-N piperidine-2,6-dione Chemical group O=C1CCCC(=O)N1 KNCYXPMJDCCGSJ-UHFFFAOYSA-N 0.000 title claims description 194
- 229910052717 sulfur Inorganic materials 0.000 title claims description 58
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 title claims description 16
- 239000011593 sulfur Substances 0.000 title claims description 16
- 150000003839 salts Chemical class 0.000 claims abstract description 216
- 239000012453 solvate Substances 0.000 claims abstract description 194
- 239000000203 mixture Substances 0.000 claims abstract description 191
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 51
- -1 terpentyl Chemical group 0.000 claims description 624
- 125000000217 alkyl group Chemical group 0.000 claims description 286
- 238000000034 method Methods 0.000 claims description 158
- 125000003545 alkoxy group Chemical group 0.000 claims description 111
- 229910052736 halogen Inorganic materials 0.000 claims description 109
- 150000002367 halogens Chemical class 0.000 claims description 108
- 125000001424 substituent group Chemical group 0.000 claims description 103
- 238000002360 preparation method Methods 0.000 claims description 80
- 125000000623 heterocyclic group Chemical group 0.000 claims description 78
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 77
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 70
- 125000002947 alkylene group Chemical group 0.000 claims description 62
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 60
- CYJAWBVQRMVFEO-UHFFFAOYSA-N piperazine-2,6-dione Chemical compound O=C1CNCC(=O)N1 CYJAWBVQRMVFEO-UHFFFAOYSA-N 0.000 claims description 56
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 54
- 238000010304 firing Methods 0.000 claims description 53
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 52
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 51
- 125000004043 oxo group Chemical group O=* 0.000 claims description 50
- 125000003118 aryl group Chemical group 0.000 claims description 49
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 46
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 43
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 43
- 125000005948 methanesulfonyloxy group Chemical group 0.000 claims description 39
- 125000001072 heteroaryl group Chemical group 0.000 claims description 38
- 241000009298 Trigla lyra Species 0.000 claims description 35
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 33
- 125000005951 trifluoromethanesulfonyloxy group Chemical group 0.000 claims description 33
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 31
- 208000034578 Multiple myelomas Diseases 0.000 claims description 31
- 201000011510 cancer Diseases 0.000 claims description 31
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 31
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 30
- GWVMLCQWXVFZCN-UHFFFAOYSA-N isoindoline Chemical compound C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 claims description 30
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 29
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 29
- 125000003107 substituted aryl group Chemical group 0.000 claims description 29
- 230000000306 recurrent effect Effects 0.000 claims description 27
- ZLBWZEARBDLCFH-UHFFFAOYSA-N 3h-pyridine-2,6-dione Chemical compound O=C1CC=CC(=O)N1 ZLBWZEARBDLCFH-UHFFFAOYSA-N 0.000 claims description 26
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 26
- 150000002576 ketones Chemical class 0.000 claims description 26
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 25
- 229910052757 nitrogen Inorganic materials 0.000 claims description 24
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 23
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 23
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Natural products C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 22
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 20
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 20
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 19
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 claims description 19
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 19
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 claims description 19
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 18
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims description 18
- 125000005549 heteroarylene group Chemical group 0.000 claims description 18
- 125000005843 halogen group Chemical group 0.000 claims description 17
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims description 17
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 17
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 16
- 229910052770 Uranium Inorganic materials 0.000 claims description 16
- 125000000732 arylene group Chemical group 0.000 claims description 16
- 229910052796 boron Inorganic materials 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 16
- 229910052720 vanadium Inorganic materials 0.000 claims description 16
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 125000004076 pyridyl group Chemical group 0.000 claims description 15
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 claims description 14
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 14
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 14
- 208000004346 Smoldering Multiple Myeloma Diseases 0.000 claims description 14
- 125000003277 amino group Chemical group 0.000 claims description 14
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 14
- 229910052760 oxygen Inorganic materials 0.000 claims description 14
- 208000010721 smoldering plasma cell myeloma Diseases 0.000 claims description 14
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 14
- 210000001541 thymus gland Anatomy 0.000 claims description 14
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 13
- 229910052739 hydrogen Inorganic materials 0.000 claims description 13
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 13
- 125000000335 thiazolyl group Chemical group 0.000 claims description 13
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 12
- 229910052731 fluorine Inorganic materials 0.000 claims description 12
- 125000005842 heteroatom Chemical group 0.000 claims description 12
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 12
- 125000003386 piperidinyl group Chemical group 0.000 claims description 12
- 150000003242 quaternary ammonium salts Chemical group 0.000 claims description 12
- 125000006413 ring segment Chemical group 0.000 claims description 12
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 12
- 125000005717 substituted cycloalkylene group Chemical group 0.000 claims description 12
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 11
- 239000001301 oxygen Substances 0.000 claims description 11
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 11
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 10
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 9
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 9
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims description 9
- 208000032839 leukemia Diseases 0.000 claims description 9
- 125000002757 morpholinyl group Chemical group 0.000 claims description 9
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 9
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 9
- 206010025323 Lymphomas Diseases 0.000 claims description 8
- 208000007502 anemia Diseases 0.000 claims description 8
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 8
- 125000001041 indolyl group Chemical group 0.000 claims description 8
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 8
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims description 8
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 8
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 8
- 125000004193 piperazinyl group Chemical group 0.000 claims description 8
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 8
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 8
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 7
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 7
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 7
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 7
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 7
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 7
- 125000003670 adamantan-2-yl group Chemical group [H]C1([H])C(C2([H])[H])([H])C([H])([H])C3([H])C([*])([H])C1([H])C([H])([H])C2([H])C3([H])[H] 0.000 claims description 7
- 125000003725 azepanyl group Chemical group 0.000 claims description 7
- 208000015322 bone marrow disease Diseases 0.000 claims description 7
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 7
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 7
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 7
- 208000004235 neutropenia Diseases 0.000 claims description 7
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 claims description 7
- 201000009295 smoldering myeloma Diseases 0.000 claims description 7
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 6
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 6
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 6
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 claims description 6
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 6
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 6
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 6
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 6
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 6
- 239000011737 fluorine Substances 0.000 claims description 6
- 239000007789 gas Substances 0.000 claims description 6
- GXHFUVWIGNLZSC-UHFFFAOYSA-N meldrum's acid Chemical compound CC1(C)OC(=O)CC(=O)O1 GXHFUVWIGNLZSC-UHFFFAOYSA-N 0.000 claims description 6
- 230000001131 transforming effect Effects 0.000 claims description 6
- 125000004361 3,4,5-trifluorophenyl group Chemical group [H]C1=C(F)C(F)=C(F)C([H])=C1* 0.000 claims description 5
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 claims description 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 5
- 125000002393 azetidinyl group Chemical group 0.000 claims description 5
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 125000001153 fluoro group Chemical group F* 0.000 claims description 5
- 230000000155 isotopic effect Effects 0.000 claims description 5
- 206010028537 myelofibrosis Diseases 0.000 claims description 5
- 125000002958 pentadecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 5
- 208000011580 syndromic disease Diseases 0.000 claims description 5
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000002252 acyl group Chemical group 0.000 claims description 4
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 239000000460 chlorine Substances 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 4
- 125000004342 dicyclopropylmethyl group Chemical group [H]C1([H])C([H])([H])C1([H])C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 4
- AEDIXYWIVPYNBI-UHFFFAOYSA-N heptanamide Chemical compound CCCCCCC(N)=O AEDIXYWIVPYNBI-UHFFFAOYSA-N 0.000 claims description 4
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims description 4
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 125000001624 naphthyl group Chemical group 0.000 claims description 4
- 125000002971 oxazolyl group Chemical group 0.000 claims description 4
- 125000003566 oxetanyl group Chemical group 0.000 claims description 4
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 claims description 4
- 125000003003 spiro group Chemical group 0.000 claims description 4
- 125000005505 thiomorpholino group Chemical group 0.000 claims description 4
- 125000002889 tridecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 claims description 3
- SCVJRXQHFJXZFZ-KVQBGUIXSA-N 2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione Chemical compound C1=2NC(N)=NC(=S)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)O1 SCVJRXQHFJXZFZ-KVQBGUIXSA-N 0.000 claims description 3
- QMLVECGLEOSESV-RYUDHWBXSA-N Danofloxacin Chemical compound C([C@@H]1C[C@H]2CN1C)N2C(C(=CC=1C(=O)C(C(O)=O)=C2)F)=CC=1N2C1CC1 QMLVECGLEOSESV-RYUDHWBXSA-N 0.000 claims description 3
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims description 3
- 125000004423 acyloxy group Chemical group 0.000 claims description 3
- 210000001185 bone marrow Anatomy 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 238000007918 intramuscular administration Methods 0.000 claims description 3
- 238000007913 intrathecal administration Methods 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 3
- 229910052740 iodine Inorganic materials 0.000 claims description 3
- 125000005485 noradamantyl group Chemical group 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 229910052702 rhenium Inorganic materials 0.000 claims description 3
- 229910021481 rutherfordium Inorganic materials 0.000 claims description 3
- 238000007920 subcutaneous administration Methods 0.000 claims description 3
- 238000011200 topical administration Methods 0.000 claims description 3
- 229910052721 tungsten Inorganic materials 0.000 claims description 3
- 229910052727 yttrium Inorganic materials 0.000 claims description 3
- IFNWESYYDINUHV-UHFFFAOYSA-N 2,6-dimethylpiperazine Chemical compound CC1CNCC(C)N1 IFNWESYYDINUHV-UHFFFAOYSA-N 0.000 claims description 2
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 claims description 2
- ZVHKDTPHSGYLFA-UHFFFAOYSA-N 3-[7-[7-(3-azaspiro[5.5]undecan-3-yl)heptylsulfanyl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C1CCC2(CC1)CCN(CC2)CCCCCCCSC3=CC=CC4=C3CN(C4=O)C5CCC(=O)NC5=O ZVHKDTPHSGYLFA-UHFFFAOYSA-N 0.000 claims description 2
- UYECXPBROBCWDK-UHFFFAOYSA-N 3-[7-[7-(6-azaspiro[2.5]octan-6-yl)heptylsulfanyl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3SCCCCCCCN4CCC5(CC5)CC4 UYECXPBROBCWDK-UHFFFAOYSA-N 0.000 claims description 2
- WSSIOEGTHQTVJN-UHFFFAOYSA-N 3-[7-[7-(tert-butylamino)heptylsulfanyl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound CC(C)(C)NCCCCCCCSC1=CC=CC2=C1CN(C2=O)C3CCC(=O)NC3=O WSSIOEGTHQTVJN-UHFFFAOYSA-N 0.000 claims description 2
- ZRNBQCBAJLJLDG-UHFFFAOYSA-N 3-[7-[8-(4,4-difluoropiperidin-1-yl)octylsulfanyl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3SCCCCCCCCN4CCC(CC4)(F)F ZRNBQCBAJLJLDG-UHFFFAOYSA-N 0.000 claims description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
- GIBPTWPJEVCTGR-UHFFFAOYSA-N 6-azaspiro[2.5]octane Chemical compound C1CC11CCNCC1 GIBPTWPJEVCTGR-UHFFFAOYSA-N 0.000 claims description 2
- KXJVWNBVRRZEHH-UHFFFAOYSA-N 7,7-dimethylbicyclo[2.2.1]heptane-2,3-dione Chemical compound C1CC2C(=O)C(=O)C1C2(C)C KXJVWNBVRRZEHH-UHFFFAOYSA-N 0.000 claims description 2
- XCUAIINAJCDIPM-XVFCMESISA-N N(4)-hydroxycytidine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=NO)C=C1 XCUAIINAJCDIPM-XVFCMESISA-N 0.000 claims description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 2
- BVCRERJDOOBZOH-UHFFFAOYSA-N bicyclo[2.2.1]heptanyl Chemical group C1C[C+]2CC[C-]1C2 BVCRERJDOOBZOH-UHFFFAOYSA-N 0.000 claims description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 2
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 claims description 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 2
- 210000003281 pleural cavity Anatomy 0.000 claims description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 2
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims description 2
- 125000004546 quinazolin-4-yl group Chemical group N1=CN=C(C2=CC=CC=C12)* 0.000 claims description 2
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 claims description 2
- 125000004149 thio group Chemical group *S* 0.000 claims 97
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 17
- 239000004202 carbamide Substances 0.000 claims 17
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical group CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims 6
- WJJMNDUMQPNECX-UHFFFAOYSA-N dipicolinic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=N1 WJJMNDUMQPNECX-UHFFFAOYSA-N 0.000 claims 4
- 125000002249 indol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([*])=C([H])C2=C1[H] 0.000 claims 4
- QRCYUEWGGBWKRL-UHFFFAOYSA-N 1-(3-oxo-1h-isoindol-2-yl)piperidine-2,6-dione Chemical compound C1C2=CC=CC=C2C(=O)N1N1C(=O)CCCC1=O QRCYUEWGGBWKRL-UHFFFAOYSA-N 0.000 claims 3
- 125000004939 6-pyridyl group Chemical group N1=CC=CC=C1* 0.000 claims 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims 3
- 208000025316 Richter syndrome Diseases 0.000 claims 3
- 125000005594 diketone group Chemical group 0.000 claims 3
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 3
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 claims 3
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 3
- SOOPBZRXJMNXTF-UHFFFAOYSA-N 2,6-Piperidinedicarboxylic acid Chemical compound OC(=O)C1CCCC(C(O)=O)N1 SOOPBZRXJMNXTF-UHFFFAOYSA-N 0.000 claims 2
- JZTPKAROPNTQQV-UHFFFAOYSA-N 3-fluorobenzonitrile Chemical compound FC1=CC=CC(C#N)=C1 JZTPKAROPNTQQV-UHFFFAOYSA-N 0.000 claims 2
- OFNWMZRPXFBZPX-UHFFFAOYSA-N 8-methyl-3,8-diazabicyclo[3.2.1]octane Chemical compound C1NCC2CCC1N2C OFNWMZRPXFBZPX-UHFFFAOYSA-N 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical group CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 claims 2
- IPWFJLQDVFKJDU-UHFFFAOYSA-N pentanamide Chemical compound CCCCC(N)=O IPWFJLQDVFKJDU-UHFFFAOYSA-N 0.000 claims 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 claims 2
- RSJKGSCJYJTIGS-UHFFFAOYSA-N undecane Chemical compound CCCCCCCCCCC RSJKGSCJYJTIGS-UHFFFAOYSA-N 0.000 claims 2
- 210000003462 vein Anatomy 0.000 claims 2
- FPFWHMXLMNFDFN-UHFFFAOYSA-N 1-methyl-3-[3-oxo-7-[7-(spiro[3.3]heptan-2-ylamino)heptylsulfanyl]-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound CN1C(=O)CCC(C1=O)N2CC3=C(C2=O)C=CC=C3SCCCCCCCNC4CC5(C4)CCC5 FPFWHMXLMNFDFN-UHFFFAOYSA-N 0.000 claims 1
- MJONLGZTNIUBOD-UHFFFAOYSA-N 2,3-dihydro-1H-indole-4-sulfonamide Chemical compound N1CCC=2C(=CC=CC1=2)S(=O)(=O)N MJONLGZTNIUBOD-UHFFFAOYSA-N 0.000 claims 1
- 125000003764 2,4-dimethylpentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- BWGKRFPQXLZMGK-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-4-(7-piperidin-1-ylheptylsulfanyl)isoindole-1,3-dione Chemical compound C1CCN(CC1)CCCCCCCSC2=CC=CC3=C2C(=O)N(C3=O)C4CCC(=O)NC4=O BWGKRFPQXLZMGK-UHFFFAOYSA-N 0.000 claims 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- QIFJASJJDSEUFV-UHFFFAOYSA-N 2-methylazetidin-3-ol Chemical compound CC1NCC1O QIFJASJJDSEUFV-UHFFFAOYSA-N 0.000 claims 1
- WVKPYYLOFMTDHB-UHFFFAOYSA-N 2-norbornyl radical Chemical group C1CC2[CH]CC1C2 WVKPYYLOFMTDHB-UHFFFAOYSA-N 0.000 claims 1
- ZOWOWNJKWHBKOZ-UHFFFAOYSA-N 3-(7-octylsulfanyl-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione Chemical compound CCCCCCCCSC1=CC=CC2=C1CN(C2=O)C3CCC(=O)NC3=O ZOWOWNJKWHBKOZ-UHFFFAOYSA-N 0.000 claims 1
- IZLCJURPAXXLLR-UHFFFAOYSA-N 3-[3-oxo-7-[7-(N-phenylanilino)heptylsulfanyl]-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3SCCCCCCCN(C4=CC=CC=C4)C5=CC=CC=C5 IZLCJURPAXXLLR-UHFFFAOYSA-N 0.000 claims 1
- MHKNPRRSPDCTJQ-UHFFFAOYSA-N 3-[3-oxo-7-[8-(quinazolin-4-ylamino)octylsulfanyl]-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3SCCCCCCCCNC4=NC=NC5=CC=CC=C54 MHKNPRRSPDCTJQ-UHFFFAOYSA-N 0.000 claims 1
- SVOGBPZPTDBVTF-UHFFFAOYSA-N 3-[6-[7-[1-(1-adamantyl)ethylamino]heptylsulfanyl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound CC(C12CC3CC(C1)CC(C3)C2)NCCCCCCCSC4=CC5=C(C=C4)C(=O)N(C5)C6CCC(=O)NC6=O SVOGBPZPTDBVTF-UHFFFAOYSA-N 0.000 claims 1
- SUPWFFTXNAOFRO-UHFFFAOYSA-N 3-[6-[8-(diethylamino)octylsulfanyl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound CCN(CC)CCCCCCCCSC1=CC2=C(C=C1)C(=O)N(C2)C3CCC(=O)NC3=O SUPWFFTXNAOFRO-UHFFFAOYSA-N 0.000 claims 1
- TUOMYHIYIGTVTC-UHFFFAOYSA-N 3-[6-[8-(dimethylamino)octylsulfanyl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound CN(C)CCCCCCCCSC1=CC2=C(C=C1)C(=O)N(C2)C3CCC(=O)NC3=O TUOMYHIYIGTVTC-UHFFFAOYSA-N 0.000 claims 1
- QXYKCLHQRLVDLT-UHFFFAOYSA-N 3-[6-[8-(methylamino)octylsulfanyl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound CNCCCCCCCCSC1=CC2=C(C=C1)C(=O)N(C2)C3CCC(=O)NC3=O QXYKCLHQRLVDLT-UHFFFAOYSA-N 0.000 claims 1
- YLAZZGSOOLUQIO-UHFFFAOYSA-N 3-[6-[8-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]octylsulfanyl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound CN1CCN(CC1)C2CCN(CC2)CCCCCCCCSC3=CC4=C(C=C3)C(=O)N(C4)C5CCC(=O)NC5=O YLAZZGSOOLUQIO-UHFFFAOYSA-N 0.000 claims 1
- ILRDKNMJXPKHJQ-UHFFFAOYSA-N 3-[7-(8-morpholin-4-yloctylsulfanyl)-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound O=C(C1=CC=CC(SCCCCCCCCN2CCOCC2)=C1C1)N1C(CCC(N1)=O)C1=O ILRDKNMJXPKHJQ-UHFFFAOYSA-N 0.000 claims 1
- LNDAOYSCJYWJQY-UHFFFAOYSA-N 3-[7-[12-(diethylamino)dodecylsulfanyl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound CCN(CC)CCCCCCCCCCCCSC1=CC=CC2=C1CN(C2=O)C3CCC(=O)NC3=O LNDAOYSCJYWJQY-UHFFFAOYSA-N 0.000 claims 1
- XCHREIXFCRXARC-UHFFFAOYSA-N 3-[7-[2-(2-morpholin-4-ylethoxy)ethylsulfanyl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3SCCOCCN4CCOCC4 XCHREIXFCRXARC-UHFFFAOYSA-N 0.000 claims 1
- FSOJKCZXNBUWQT-UHFFFAOYSA-N 3-[7-[2-[2-[2-(2-adamantylamino)ethoxy]ethoxy]ethylsulfanyl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3SCCOCCOCCNC4C5CC6CC(C5)CC4C6 FSOJKCZXNBUWQT-UHFFFAOYSA-N 0.000 claims 1
- OTZBRMCWTHUYMK-UHFFFAOYSA-N 3-[7-[2-[4-[2-(1-adamantylamino)ethyl]phenyl]ethylsulfanyl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3SCCC4=CC=C(C=C4)CCNC56CC7CC(C5)CC(C7)C6 OTZBRMCWTHUYMK-UHFFFAOYSA-N 0.000 claims 1
- IHRTZIQJHCXMTC-UHFFFAOYSA-N 3-[7-[7-(2,2-difluoro-5-azaspiro[2.4]heptan-5-yl)heptylsulfanyl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3SCCCCCCCN4CCC5(C4)CC5(F)F IHRTZIQJHCXMTC-UHFFFAOYSA-N 0.000 claims 1
- NVJPAUFGEKGEDN-UHFFFAOYSA-N 3-[7-[7-(2,2-difluoro-6-azaspiro[2.5]octan-6-yl)heptylsulfanyl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3SCCCCCCCN4CCC5(CC4)CC5(F)F NVJPAUFGEKGEDN-UHFFFAOYSA-N 0.000 claims 1
- GNBVFLTXCUTTEK-UHFFFAOYSA-N 3-[7-[7-(3,5-dimethylpiperidin-1-yl)heptylsulfanyl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound CC1CC(CN(C1)CCCCCCCSC2=CC=CC3=C2CN(C3=O)C4CCC(=O)NC4=O)C GNBVFLTXCUTTEK-UHFFFAOYSA-N 0.000 claims 1
- XBRQLISOQFBBCX-UHFFFAOYSA-N 3-[7-[7-(N-methylanilino)heptylsulfanyl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound CN(CCCCCCCSC1=CC=CC2=C1CN(C2=O)C3CCC(=O)NC3=O)C4=CC=CC=C4 XBRQLISOQFBBCX-UHFFFAOYSA-N 0.000 claims 1
- VLNYMERIKKXKKR-UHFFFAOYSA-N 3-[7-[7-(diethylamino)heptylsulfanyl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound CCN(CC)CCCCCCCSC1=CC=CC2=C1CN(C2=O)C3CCC(=O)NC3=O VLNYMERIKKXKKR-UHFFFAOYSA-N 0.000 claims 1
- BDYJFQPQJHKALD-UHFFFAOYSA-N 3-[7-[7-[(1-cyclopropyl-2,2,2-trifluoroethyl)amino]heptylsulfanyl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C1CC1C(C(F)(F)F)NCCCCCCCSC2=CC=CC3=C2CN(C3=O)C4CCC(=O)NC4=O BDYJFQPQJHKALD-UHFFFAOYSA-N 0.000 claims 1
- PHIYWBQPWSYSMF-UHFFFAOYSA-N 3-[7-[7-[(3-chloro-1-adamantyl)amino]heptylsulfanyl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3SCCCCCCCNC45CC6CC(C4)CC(C6)(C5)Cl PHIYWBQPWSYSMF-UHFFFAOYSA-N 0.000 claims 1
- IPTVTTCSFHXYNE-UHFFFAOYSA-N 3-[7-[7-[(4-chloro-1-adamantyl)amino]heptylsulfanyl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3SCCCCCCCNC45CC6CC(C4)C(C(C6)C5)Cl IPTVTTCSFHXYNE-UHFFFAOYSA-N 0.000 claims 1
- SSQKILGAHIUURI-UHFFFAOYSA-N 3-[7-[8-(1-adamantylamino)octylsulfanyl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3SCCCCCCCCNC45CC6CC(C4)CC(C6)C5 SSQKILGAHIUURI-UHFFFAOYSA-N 0.000 claims 1
- UCAAHKHIPBCEAM-UHFFFAOYSA-N 3-[7-[8-(1-benzofuran-7-ylamino)octylsulfanyl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3SCCCCCCCCNC4=CC=CC5=C4OC=C5 UCAAHKHIPBCEAM-UHFFFAOYSA-N 0.000 claims 1
- NIXCBUAXMTXWIJ-UHFFFAOYSA-N 3-[7-[8-(diethylamino)octylsulfanyl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound CCN(CC)CCCCCCCCSC1=CC=CC2=C1CN(C2=O)C3CCC(=O)NC3=O NIXCBUAXMTXWIJ-UHFFFAOYSA-N 0.000 claims 1
- YTNKPGUDVBTTJO-UHFFFAOYSA-N 3-[7-[8-(dimethylamino)octylsulfanyl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound CN(C)CCCCCCCCSC1=CC=CC2=C1CN(C2=O)C3CCC(=O)NC3=O YTNKPGUDVBTTJO-UHFFFAOYSA-N 0.000 claims 1
- HWWCSJGXFAMYGK-UHFFFAOYSA-N 3-[7-[8-[(6,7-difluoroquinazolin-4-yl)amino]octylsulfanyl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3SCCCCCCCCNC4=NC=NC5=CC(=C(C=C54)F)F HWWCSJGXFAMYGK-UHFFFAOYSA-N 0.000 claims 1
- BCGQKEGJRKAWER-UHFFFAOYSA-N 3-[7-[8-[1-(2,6-dichloro-3-fluorophenyl)ethylamino]octylsulfanyl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound CC(C1=C(C=CC(=C1Cl)F)Cl)NCCCCCCCCSC2=CC=CC3=C2CN(C3=O)C4CCC(=O)NC4=O BCGQKEGJRKAWER-UHFFFAOYSA-N 0.000 claims 1
- OBKLLRDBFMVGOJ-UHFFFAOYSA-N 3-[7-[8-[4-[(3,3-difluorocyclobutyl)methyl]piperazin-1-yl]octylsulfanyl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3SCCCCCCCCN4CCN(CC4)CC5CC(C5)(F)F OBKLLRDBFMVGOJ-UHFFFAOYSA-N 0.000 claims 1
- JGPXUJVUWYGLLC-UHFFFAOYSA-N 3-[7-[9-(diethylamino)nonylsulfanyl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound CCN(CC)CCCCCCCCCSC1=CC=CC2=C1CN(C2=O)C3CCC(=O)NC3=O JGPXUJVUWYGLLC-UHFFFAOYSA-N 0.000 claims 1
- QZBZXTPIWUOQOR-UHFFFAOYSA-N 3-[7-[9-[di(propan-2-yl)amino]nonylsulfanyl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound CC(C)N(CCCCCCCCCSC1=CC=CC2=C1CN(C2=O)C3CCC(=O)NC3=O)C(C)C QZBZXTPIWUOQOR-UHFFFAOYSA-N 0.000 claims 1
- AOWKBGVDZXHVSK-UHFFFAOYSA-N 3-[7-[[4-[2-(3,5-dimethylpiperidin-1-yl)ethyl]phenyl]methylsulfanyl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound CC1CC(CN(C1)CCC2=CC=C(C=C2)CSC3=CC=CC4=C3CN(C4=O)C5CCC(=O)NC5=O)C AOWKBGVDZXHVSK-UHFFFAOYSA-N 0.000 claims 1
- VXEAZXTYYOZJPG-UHFFFAOYSA-N 3-[7-[[4-[2-(4-methylsulfonylpiperazin-1-yl)ethyl]phenyl]methylsulfanyl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound CS(=O)(=O)N1CCN(CC1)CCC2=CC=C(C=C2)CSC3=CC=CC4=C3CN(C4=O)C5CCC(=O)NC5=O VXEAZXTYYOZJPG-UHFFFAOYSA-N 0.000 claims 1
- MRXGVNAXTCYJEH-UHFFFAOYSA-N 3-[7-[[4-[2-(diethylamino)ethyl]phenyl]methylsulfanyl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound CCN(CC)CCC1=CC=C(C=C1)CSC2=CC=CC3=C2CN(C3=O)C4CCC(=O)NC4=O MRXGVNAXTCYJEH-UHFFFAOYSA-N 0.000 claims 1
- ZMUXWYVAWPZXAX-XZQOPNAISA-N 3-[7-[[4-[2-[(3aR,7aS)-1,3,3a,4,5,6,7,7a-octahydroisoindol-2-yl]ethyl]phenyl]methylsulfanyl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C1CC[C@H]2CN(C[C@H]2C1)CCC3=CC=C(C=C3)CSC4=CC=CC5=C4CN(C5=O)C6CCC(=O)NC6=O ZMUXWYVAWPZXAX-XZQOPNAISA-N 0.000 claims 1
- AGVBJZRQOQBGHG-UHFFFAOYSA-N 3-[7-[[5-[(oxan-2-ylmethylamino)methyl]furan-2-yl]methylsulfanyl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C1CCOC(C1)CNCC2=CC=C(O2)CSC3=CC=CC4=C3CN(C4=O)C5CCC(=O)NC5=O AGVBJZRQOQBGHG-UHFFFAOYSA-N 0.000 claims 1
- VLRGXXKFHVJQOL-UHFFFAOYSA-N 3-chloropentane-2,4-dione Chemical compound CC(=O)C(Cl)C(C)=O VLRGXXKFHVJQOL-UHFFFAOYSA-N 0.000 claims 1
- LDLAEUFQUOXALI-UHFFFAOYSA-N 3-methylazetidin-3-ol Chemical compound CC1(O)CNC1 LDLAEUFQUOXALI-UHFFFAOYSA-N 0.000 claims 1
- DFGGNDJOFSKFOW-UHFFFAOYSA-N 4-[7-(1-adamantylamino)heptylsulfanyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione Chemical compound C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)SCCCCCCCNC45CC6CC(C4)CC(C6)C5 DFGGNDJOFSKFOW-UHFFFAOYSA-N 0.000 claims 1
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
- OOPJHRKUFYUHFX-UHFFFAOYSA-N 5-[7-(1-adamantylamino)heptylsulfanyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione Chemical compound C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C=C(C=C3)SCCCCCCCNC45CC6CC(C4)CC(C6)C5 OOPJHRKUFYUHFX-UHFFFAOYSA-N 0.000 claims 1
- 241000196324 Embryophyta Species 0.000 claims 1
- QNOMGVXMXCEUSR-UHFFFAOYSA-N N-(2-chloro-6-methylphenyl)-2-[8-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-4-yl]sulfanyl]octylamino]-1,3-thiazole-5-carboxamide Chemical compound CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NCCCCCCCCSC3=CC=CC4=C3CN(C4=O)C5CCC(=O)NC5=O QNOMGVXMXCEUSR-UHFFFAOYSA-N 0.000 claims 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 claims 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 125000002785 azepinyl group Chemical group 0.000 claims 1
- GMWFCJXSQQHBPI-UHFFFAOYSA-N azetidin-3-ol Chemical compound OC1CNC1 GMWFCJXSQQHBPI-UHFFFAOYSA-N 0.000 claims 1
- PBIUUJCEMUAWJJ-UHFFFAOYSA-N azetidine-3-carbonitrile Chemical compound N#CC1CNC1 PBIUUJCEMUAWJJ-UHFFFAOYSA-N 0.000 claims 1
- 150000003857 carboxamides Chemical class 0.000 claims 1
- 229910052802 copper Inorganic materials 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- SWXVUIWOUIDPGS-UHFFFAOYSA-N diacetone alcohol Chemical compound CC(=O)CC(C)(C)O SWXVUIWOUIDPGS-UHFFFAOYSA-N 0.000 claims 1
- 229910003460 diamond Inorganic materials 0.000 claims 1
- 239000010432 diamond Substances 0.000 claims 1
- 229950001902 dimevamide Drugs 0.000 claims 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- 125000004246 indolin-2-yl group Chemical group [H]N1C(*)=C([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 claims 1
- LPAGFVYQRIESJQ-UHFFFAOYSA-N indoline Chemical compound C1=CC=C2NCCC2=C1 LPAGFVYQRIESJQ-UHFFFAOYSA-N 0.000 claims 1
- 210000001370 mediastinum Anatomy 0.000 claims 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 1
- 210000000066 myeloid cell Anatomy 0.000 claims 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 claims 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 1
- 230000037452 priming Effects 0.000 claims 1
- 125000005493 quinolyl group Chemical group 0.000 claims 1
- 150000003254 radicals Chemical class 0.000 claims 1
- 229910052703 rhodium Inorganic materials 0.000 claims 1
- 229940081974 saccharin Drugs 0.000 claims 1
- 235000019204 saccharin Nutrition 0.000 claims 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 claims 1
- 125000005156 substituted alkylene group Chemical group 0.000 claims 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 495
- 239000007787 solid Substances 0.000 description 188
- 238000005481 NMR spectroscopy Methods 0.000 description 167
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 154
- 239000000758 substrate Substances 0.000 description 147
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 111
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 66
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 63
- 238000006243 chemical reaction Methods 0.000 description 56
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 40
- 239000002904 solvent Substances 0.000 description 39
- 239000003480 eluent Substances 0.000 description 37
- 230000002829 reductive effect Effects 0.000 description 36
- 238000003756 stirring Methods 0.000 description 35
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 29
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
- 239000000543 intermediate Substances 0.000 description 27
- 239000012071 phase Substances 0.000 description 24
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 22
- 229910000027 potassium carbonate Inorganic materials 0.000 description 20
- 238000001914 filtration Methods 0.000 description 18
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 17
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 17
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical group CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 16
- 125000004432 carbon atom Chemical group C* 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 15
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 14
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 14
- 150000001412 amines Chemical class 0.000 description 14
- 239000000523 sample Substances 0.000 description 14
- 229960003433 thalidomide Drugs 0.000 description 14
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 13
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 13
- 125000002619 bicyclic group Chemical group 0.000 description 13
- 125000002950 monocyclic group Chemical group 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 12
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 12
- 238000000926 separation method Methods 0.000 description 12
- 229910052786 argon Inorganic materials 0.000 description 11
- 239000012043 crude product Substances 0.000 description 11
- 239000013067 intermediate product Substances 0.000 description 11
- 238000002953 preparative HPLC Methods 0.000 description 11
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 240000007594 Oryza sativa Species 0.000 description 9
- 235000007164 Oryza sativa Nutrition 0.000 description 9
- 235000009566 rice Nutrition 0.000 description 9
- 238000004440 column chromatography Methods 0.000 description 8
- 229960004942 lenalidomide Drugs 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 229920006395 saturated elastomer Polymers 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- DKGAVHZHDRPRBM-UHFFFAOYSA-N tert-butyl alcohol Substances CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 8
- 239000012065 filter cake Substances 0.000 description 7
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 229960000688 pomalidomide Drugs 0.000 description 7
- 239000002994 raw material Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000004809 thin layer chromatography Methods 0.000 description 7
- LVWSZGCVEZRFBT-UHFFFAOYSA-N 1,7-dibromoheptane Chemical compound BrCCCCCCCBr LVWSZGCVEZRFBT-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 6
- 230000029936 alkylation Effects 0.000 description 6
- 238000005804 alkylation reaction Methods 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000007429 general method Methods 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 6
- 125000001425 triazolyl group Chemical group 0.000 description 6
- YUQZORJBQCPFLM-UHFFFAOYSA-N 3-[7-(8-bromooctylsulfanyl)-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound BrCCCCCCCCSC1=C2CN(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O YUQZORJBQCPFLM-UHFFFAOYSA-N 0.000 description 5
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 5
- 102100034826 Homeobox protein Meis2 Human genes 0.000 description 5
- 101001019057 Homo sapiens Homeobox protein Meis2 Proteins 0.000 description 5
- QZWNXXINFABALM-UHFFFAOYSA-N adamantan-2-amine Chemical compound C1C(C2)CC3CC1C(N)C2C3 QZWNXXINFABALM-UHFFFAOYSA-N 0.000 description 5
- BEWYHVAWEKZDPP-UHFFFAOYSA-N bornane Chemical compound C1CC2(C)CCC1C2(C)C BEWYHVAWEKZDPP-UHFFFAOYSA-N 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 235000019000 fluorine Nutrition 0.000 description 5
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 5
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 5
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 5
- AYMUQTNXKPEMLM-UHFFFAOYSA-N 1-bromononane Chemical compound CCCCCCCCCBr AYMUQTNXKPEMLM-UHFFFAOYSA-N 0.000 description 4
- BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 4
- 239000004342 Benzoyl peroxide Substances 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 101000941994 Homo sapiens Protein cereblon Proteins 0.000 description 4
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 235000019400 benzoyl peroxide Nutrition 0.000 description 4
- 239000007810 chemical reaction solvent Substances 0.000 description 4
- 229940043279 diisopropylamine Drugs 0.000 description 4
- 229940124622 immune-modulator drug Drugs 0.000 description 4
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 4
- 150000003141 primary amines Chemical group 0.000 description 4
- 125000000168 pyrrolyl group Chemical group 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 4
- 229940086542 triethylamine Drugs 0.000 description 4
- 239000003643 water by type Substances 0.000 description 4
- MDFWXZBEVCOVIO-WEDXCCLWSA-N (1r,3s,4r)-4,7,7-trimethylbicyclo[2.2.1]heptan-3-amine Chemical compound C1C[C@@]2(C)[C@@H](N)C[C@]1([H])C2(C)C MDFWXZBEVCOVIO-WEDXCCLWSA-N 0.000 description 3
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 3
- DKEGCUDAFWNSSO-UHFFFAOYSA-N 1,8-dibromooctane Chemical compound BrCCCCCCCCBr DKEGCUDAFWNSSO-UHFFFAOYSA-N 0.000 description 3
- WGAXVZXBFBHLMC-UHFFFAOYSA-N 1,9-dibromononane Chemical compound BrCCCCCCCCCBr WGAXVZXBFBHLMC-UHFFFAOYSA-N 0.000 description 3
- XSOHXMFFSKTSIT-UHFFFAOYSA-N 1-adamantylmethanamine Chemical compound C1C(C2)CC3CC2CC1(CN)C3 XSOHXMFFSKTSIT-UHFFFAOYSA-N 0.000 description 3
- LIZKZVQBLDHKCY-UHFFFAOYSA-N 3-azaspiro[5.5]undecane Chemical compound C1CCCCC21CCNCC2 LIZKZVQBLDHKCY-UHFFFAOYSA-N 0.000 description 3
- 102000015367 CRBN Human genes 0.000 description 3
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- XTUVJUMINZSXGF-UHFFFAOYSA-N N-methylcyclohexylamine Chemical compound CNC1CCCCC1 XTUVJUMINZSXGF-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 3
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 3
- 229930006742 bornane Natural products 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 3
- 125000000532 dioxanyl group Chemical group 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 125000002883 imidazolyl group Chemical group 0.000 description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 125000001715 oxadiazolyl group Chemical group 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 125000005649 substituted arylene group Chemical group 0.000 description 3
- 238000010189 synthetic method Methods 0.000 description 3
- WMXCDAVJEZZYLT-UHFFFAOYSA-N tert-butylthiol Chemical compound CC(C)(C)S WMXCDAVJEZZYLT-UHFFFAOYSA-N 0.000 description 3
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 3
- 150000003573 thiols Chemical group 0.000 description 3
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 2
- ZGYIXVSQHOKQRZ-COIATFDQSA-N (e)-n-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-[(3s)-oxolan-3-yl]oxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound N#CC1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZGYIXVSQHOKQRZ-COIATFDQSA-N 0.000 description 2
- RBZMSGOBSOCYHR-UHFFFAOYSA-N 1,4-bis(bromomethyl)benzene Chemical compound BrCC1=CC=C(CBr)C=C1 RBZMSGOBSOCYHR-UHFFFAOYSA-N 0.000 description 2
- SKUFHZAEFGZSQK-UHFFFAOYSA-N 1-(2,4-dihydroxyphenyl)-1-hexanone Chemical compound CCCCCC(=O)C1=CC=C(O)C=C1O SKUFHZAEFGZSQK-UHFFFAOYSA-N 0.000 description 2
- MVXVYAKCVDQRLW-UHFFFAOYSA-N 1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CN=C2NC=CC2=C1 MVXVYAKCVDQRLW-UHFFFAOYSA-N 0.000 description 2
- MPQLCQKBYRSPNA-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisoindole-1,3-dione Chemical compound O=C1C2=CC(F)=CC=C2C(=O)N1C1CCC(=O)NC1=O MPQLCQKBYRSPNA-UHFFFAOYSA-N 0.000 description 2
- AWXCFZRHPUBHBO-UHFFFAOYSA-N 3-(3-oxo-7-sulfanyl-1H-isoindol-2-yl)piperidine-2,6-dione Chemical compound SC1=C2CN(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O AWXCFZRHPUBHBO-UHFFFAOYSA-N 0.000 description 2
- KILAOCVWBCNNMO-UHFFFAOYSA-N 3-(6-benzylsulfanyl-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione Chemical compound C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC(=C3)SCC4=CC=CC=C4 KILAOCVWBCNNMO-UHFFFAOYSA-N 0.000 description 2
- AKCGNJSNWZEWFO-UHFFFAOYSA-N 3-(7-benzylsulfanyl-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione Chemical compound C(C1=CC=CC=C1)SC1=C2CN(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O AKCGNJSNWZEWFO-UHFFFAOYSA-N 0.000 description 2
- DWPIPTNBOVJYAD-UHFFFAOYSA-N 3-aminoadamantan-1-ol Chemical compound C1C(C2)CC3CC1(N)CC2(O)C3 DWPIPTNBOVJYAD-UHFFFAOYSA-N 0.000 description 2
- LQKLVOWNBKJRJE-UHFFFAOYSA-N 3-bicyclo[1.1.1]pentanylazanium;chloride Chemical compound Cl.C1C2CC1(N)C2 LQKLVOWNBKJRJE-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- OZRFWLLFSGXBOH-UHFFFAOYSA-N 4,4,5,5,5-pentafluoropentane-1-thiol Chemical compound FC(F)(F)C(F)(F)CCCS OZRFWLLFSGXBOH-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical compound N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 description 2
- SCZFMUWTABGOGF-UHFFFAOYSA-N BrC1=C2CN(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O Chemical compound BrC1=C2CN(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O SCZFMUWTABGOGF-UHFFFAOYSA-N 0.000 description 2
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical group C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 101000599038 Homo sapiens DNA-binding protein Ikaros Proteins 0.000 description 2
- 101000599042 Homo sapiens Zinc finger protein Aiolos Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 244000178870 Lavandula angustifolia Species 0.000 description 2
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 2
- AFBPFSWMIHJQDM-UHFFFAOYSA-N N-methylaniline Chemical compound CNC1=CC=CC=C1 AFBPFSWMIHJQDM-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 102100037798 Zinc finger protein Aiolos Human genes 0.000 description 2
- 150000003973 alkyl amines Chemical class 0.000 description 2
- 229960003805 amantadine Drugs 0.000 description 2
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 2
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 2
- 125000005605 benzo group Chemical group 0.000 description 2
- 229940073608 benzyl chloride Drugs 0.000 description 2
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical group [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 2
- 229940008099 dimethicone Drugs 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 238000004896 high resolution mass spectrometry Methods 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 125000005946 imidazo[1,2-a]pyridyl group Chemical group 0.000 description 2
- 125000002632 imidazolidinyl group Chemical group 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 239000002198 insoluble material Substances 0.000 description 2
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 2
- 125000001786 isothiazolyl group Chemical group 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 239000001102 lavandula vera Substances 0.000 description 2
- 235000018219 lavender Nutrition 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 2
- NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- UDGSVBYJWHOHNN-UHFFFAOYSA-N n',n'-diethylethane-1,2-diamine Chemical compound CCN(CC)CCN UDGSVBYJWHOHNN-UHFFFAOYSA-N 0.000 description 2
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 125000000160 oxazolidinyl group Chemical group 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 125000005551 pyridylene group Chemical group 0.000 description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000003335 secondary amines Chemical group 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 2
- 229940048181 sodium sulfide nonahydrate Drugs 0.000 description 2
- WMDLZMCDBSJMTM-UHFFFAOYSA-M sodium;sulfanide;nonahydrate Chemical compound O.O.O.O.O.O.O.O.O.[Na+].[SH-] WMDLZMCDBSJMTM-UHFFFAOYSA-M 0.000 description 2
- GXRHXOCHXRWKAR-UHFFFAOYSA-N spiro[3.3]heptan-2-amine;hydrochloride Chemical compound Cl.C1C(N)CC11CCC1 GXRHXOCHXRWKAR-UHFFFAOYSA-N 0.000 description 2
- LMUMMJCCZMWLEN-UHFFFAOYSA-N spiro[3.3]heptyl Chemical group [CH]1CCC11CCC1 LMUMMJCCZMWLEN-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000000967 suction filtration Methods 0.000 description 2
- 125000004354 sulfur functional group Chemical group 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 2
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- 125000001984 thiazolidinyl group Chemical group 0.000 description 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 2
- 230000034512 ubiquitination Effects 0.000 description 2
- 238000010798 ubiquitination Methods 0.000 description 2
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- MAYZWDRUFKUGGP-VIFPVBQESA-N (3s)-1-[5-tert-butyl-3-[(1-methyltetrazol-5-yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol Chemical compound CN1N=NN=C1CN1C2=NC(C(C)(C)C)=NC(N3C[C@@H](O)CC3)=C2N=N1 MAYZWDRUFKUGGP-VIFPVBQESA-N 0.000 description 1
- 125000006833 (C1-C5) alkylene group Chemical group 0.000 description 1
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 description 1
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 1
- KBOAVUSWPXRQBC-UHFFFAOYSA-N 1,1,1,2,2-pentafluoropentane Chemical group CCCC(F)(F)C(F)(F)F KBOAVUSWPXRQBC-UHFFFAOYSA-N 0.000 description 1
- UOCLXMDMGBRAIB-UHFFFAOYSA-N 1,1,1-trichloroethane Chemical compound CC(Cl)(Cl)Cl UOCLXMDMGBRAIB-UHFFFAOYSA-N 0.000 description 1
- GTQHJCOHNAFHRE-UHFFFAOYSA-N 1,10-dibromodecane Chemical compound BrCCCCCCCCCCBr GTQHJCOHNAFHRE-UHFFFAOYSA-N 0.000 description 1
- SIBVHGAPHVRHMJ-UHFFFAOYSA-N 1,11-dibromoundecane Chemical compound BrCCCCCCCCCCCBr SIBVHGAPHVRHMJ-UHFFFAOYSA-N 0.000 description 1
- OXHOPZLBSSTTBU-UHFFFAOYSA-N 1,3-bis(bromomethyl)benzene Chemical group BrCC1=CC=CC(CBr)=C1 OXHOPZLBSSTTBU-UHFFFAOYSA-N 0.000 description 1
- CWNOIUTVJRWADX-UHFFFAOYSA-N 1,3-dimethyladamantane Chemical compound C1C(C2)CC3CC1(C)CC2(C)C3 CWNOIUTVJRWADX-UHFFFAOYSA-N 0.000 description 1
- FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 description 1
- SGRHVVLXEBNBDV-UHFFFAOYSA-N 1,6-dibromohexane Chemical compound BrCCCCCCBr SGRHVVLXEBNBDV-UHFFFAOYSA-N 0.000 description 1
- APWRZPQBPCAXFP-UHFFFAOYSA-N 1-(1-oxo-2H-isoquinolin-5-yl)-5-(trifluoromethyl)-N-[2-(trifluoromethyl)pyridin-4-yl]pyrazole-4-carboxamide Chemical compound O=C1NC=CC2=C(C=CC=C12)N1N=CC(=C1C(F)(F)F)C(=O)NC1=CC(=NC=C1)C(F)(F)F APWRZPQBPCAXFP-UHFFFAOYSA-N 0.000 description 1
- ZHUAKSGTDRKKNB-UHFFFAOYSA-N 1-(2-bromoethyl)-4-(bromomethyl)benzene Chemical compound BrCCC1=CC=C(CBr)C=C1 ZHUAKSGTDRKKNB-UHFFFAOYSA-N 0.000 description 1
- IAZCKSJRRRXZEY-UHFFFAOYSA-N 1-(2-bromoethyl)-4-methylbenzene Chemical compound CC1=CC=C(CCBr)C=C1 IAZCKSJRRRXZEY-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
- VMKOFRJSULQZRM-UHFFFAOYSA-N 1-bromooctane Chemical compound CCCCCCCCBr VMKOFRJSULQZRM-UHFFFAOYSA-N 0.000 description 1
- YZWKKMVJZFACSU-UHFFFAOYSA-N 1-bromopentane Chemical compound CCCCCBr YZWKKMVJZFACSU-UHFFFAOYSA-N 0.000 description 1
- CYNYIHKIEHGYOZ-UHFFFAOYSA-N 1-bromopropane Chemical compound CCCBr CYNYIHKIEHGYOZ-UHFFFAOYSA-N 0.000 description 1
- MICMHFIQSAMEJG-UHFFFAOYSA-N 1-bromopyrrolidine-2,5-dione Chemical compound BrN1C(=O)CCC1=O.BrN1C(=O)CCC1=O MICMHFIQSAMEJG-UHFFFAOYSA-N 0.000 description 1
- DFPYXQYWILNVAU-UHFFFAOYSA-N 1-hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1.C1=CC=C2N(O)N=NC2=C1 DFPYXQYWILNVAU-UHFFFAOYSA-N 0.000 description 1
- JJWOMLRJNXMLSO-UHFFFAOYSA-N 1-methylsulfonylpiperidine Chemical compound CS(=O)(=O)N1CCCCC1 JJWOMLRJNXMLSO-UHFFFAOYSA-N 0.000 description 1
- ZHYYBDZASCMDMP-UHFFFAOYSA-N 1-piperidin-4-ylpiperazine Chemical compound C1CNCCC1N1CCNCC1 ZHYYBDZASCMDMP-UHFFFAOYSA-N 0.000 description 1
- PKYCUVCLFSWSDJ-UHFFFAOYSA-N 2-(1-adamantyl)ethyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OCCC1(C2)CC(C3)CC2CC3C1 PKYCUVCLFSWSDJ-UHFFFAOYSA-N 0.000 description 1
- DKZXFLGOWQUQTA-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindole-4-sulfonamide Chemical compound C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)S(=O)(=O)N DKZXFLGOWQUQTA-UHFFFAOYSA-N 0.000 description 1
- CRAUTELYXAAAPW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindole-1,3-dione Chemical compound O=C1C=2C(F)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O CRAUTELYXAAAPW-UHFFFAOYSA-N 0.000 description 1
- LCKOQEKZIDARQX-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-4-methylsulfanylisoindole-1,3-dione Chemical compound CSC1=CC=CC2=C1C(=O)N(C2=O)C3CCC(=O)NC3=O LCKOQEKZIDARQX-UHFFFAOYSA-N 0.000 description 1
- STRYRBVTKIKRID-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-4-sulfanylisoindole-1,3-dione Chemical compound O=C1NC(CCC1N1C(C2=CC=CC(=C2C1=O)S)=O)=O STRYRBVTKIKRID-UHFFFAOYSA-N 0.000 description 1
- CODRBWYEIGUCOV-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-5-sulfanylisoindole-1,3-dione Chemical compound SC1=CC2=C(C=C1)C(=O)N(C1CCC(=O)NC1=O)C2=O CODRBWYEIGUCOV-UHFFFAOYSA-N 0.000 description 1
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-Phenylethanol Natural products OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 1
- AETVBWZVKDOWHH-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-(1-ethylazetidin-3-yl)oxypyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)OC1CN(C1)CC AETVBWZVKDOWHH-UHFFFAOYSA-N 0.000 description 1
- NAMYKGVDVNBCFQ-UHFFFAOYSA-N 2-bromopropane Chemical compound CC(C)Br NAMYKGVDVNBCFQ-UHFFFAOYSA-N 0.000 description 1
- 125000004326 2H-pyran-2-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])(*)O1 0.000 description 1
- IDWRJRPUIXRFRX-UHFFFAOYSA-N 3,5-dimethylpiperidine Chemical compound CC1CNCC(C)C1 IDWRJRPUIXRFRX-UHFFFAOYSA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- UWUNVKPCOBNNKW-UHFFFAOYSA-N 3-(3-oxo-6-sulfanyl-1H-isoindol-2-yl)piperidine-2,6-dione Chemical compound C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC(=C3)S UWUNVKPCOBNNKW-UHFFFAOYSA-N 0.000 description 1
- OSWGGVWNVAQGJI-UHFFFAOYSA-N 3-(3-oxo-7-pentylsulfanyl-1H-isoindol-2-yl)piperidine-2,6-dione Chemical compound O=C1N(CC2=C(C=CC=C12)SCCCCC)C1C(NC(CC1)=O)=O OSWGGVWNVAQGJI-UHFFFAOYSA-N 0.000 description 1
- GYYZVIOKNNDCTL-UHFFFAOYSA-N 3-(3-oxo-7-propan-2-ylsulfanyl-1H-isoindol-2-yl)piperidine-2,6-dione Chemical compound C(C)(C)SC1=C2CN(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O GYYZVIOKNNDCTL-UHFFFAOYSA-N 0.000 description 1
- ZJTRXGVMGXKLSI-UHFFFAOYSA-N 3-(3-oxo-7-propylsulfanyl-1H-isoindol-2-yl)piperidine-2,6-dione Chemical compound O=C1N(CC2=C(C=CC=C12)SCCC)C1C(NC(CC1)=O)=O ZJTRXGVMGXKLSI-UHFFFAOYSA-N 0.000 description 1
- CMRQAKJTXKOGSF-UHFFFAOYSA-N 3-(6-bromo-3-oxo-1h-isoindol-2-yl)piperidine-2,6-dione Chemical compound C1C2=CC(Br)=CC=C2C(=O)N1C1CCC(=O)NC1=O CMRQAKJTXKOGSF-UHFFFAOYSA-N 0.000 description 1
- LBMJAMAARXAGBW-UHFFFAOYSA-N 3-(6-methylsulfanyl-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione Chemical compound CSC1=CC2=C(C=C1)C(=O)N(C2)C3CCC(=O)NC3=O LBMJAMAARXAGBW-UHFFFAOYSA-N 0.000 description 1
- CZWBVZLBPCWOPU-UHFFFAOYSA-N 3-(6-tert-butylsulfanyl-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione Chemical compound CC(C)(C)SC1=CC2=C(C=C1)C(=O)N(C2)C3CCC(=O)NC3=O CZWBVZLBPCWOPU-UHFFFAOYSA-N 0.000 description 1
- WDEJUEDFRKGLGY-UHFFFAOYSA-N 3-(7-decylsulfanyl-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione Chemical compound C(CCCCCCCCC)SC1=C2CN(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O WDEJUEDFRKGLGY-UHFFFAOYSA-N 0.000 description 1
- DPFUQPKJASUBCF-UHFFFAOYSA-N 3-(7-ethylsulfanyl-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione Chemical compound C(C)SC1=C2CN(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O DPFUQPKJASUBCF-UHFFFAOYSA-N 0.000 description 1
- GYMODSUIOZBWQP-UHFFFAOYSA-N 3-(7-methylsulfanyl-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione Chemical compound CSC1=C2CN(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O GYMODSUIOZBWQP-UHFFFAOYSA-N 0.000 description 1
- JEROIXRVUMMGSQ-UHFFFAOYSA-N 3-(7-methylsulfonyl-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione Chemical compound CS(=O)(=O)C1=C2CN(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O JEROIXRVUMMGSQ-UHFFFAOYSA-N 0.000 description 1
- QPVCJZYNLJXOAV-UHFFFAOYSA-N 3-(7-tert-butylsulfanyl-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione Chemical compound C(C)(C)(C)SC1=C2CN(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O QPVCJZYNLJXOAV-UHFFFAOYSA-N 0.000 description 1
- RQFUZUMFPRMVDX-UHFFFAOYSA-N 3-Bromo-1-propanol Chemical compound OCCCBr RQFUZUMFPRMVDX-UHFFFAOYSA-N 0.000 description 1
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
- MIMXHWSVCKHFKO-UHFFFAOYSA-N 3-[3-oxo-7-(7-thiomorpholin-4-ylheptylsulfanyl)-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound O=C(C1=CC=CC(SCCCCCCCN2CCSCC2)=C1C1)N1C(CCC(N1)=O)C1=O MIMXHWSVCKHFKO-UHFFFAOYSA-N 0.000 description 1
- TZMWVNLAXIBEJJ-MXZZFKPCSA-N 3-[3-oxo-7-[[4-[[[(1R,2S,4R)-1,7,7-trimethyl-2-bicyclo[2.2.1]heptanyl]amino]methyl]phenyl]methylsulfanyl]-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C[C@@]12CC[C@@H](C1(C)C)C[C@@H]2NCC3=CC=C(C=C3)CSC4=CC=CC5=C4CN(C5=O)C6CCC(=O)NC6=O TZMWVNLAXIBEJJ-MXZZFKPCSA-N 0.000 description 1
- ALWKFCFMGVUBHU-UHFFFAOYSA-N 3-[7-(3-hydroxypropylsulfanyl)-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3SCCCO ALWKFCFMGVUBHU-UHFFFAOYSA-N 0.000 description 1
- KIQISCHVOPNHTM-UHFFFAOYSA-N 3-[7-(5-aminopentylsulfanyl)-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound NCCCCCSC1=C2CN(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O KIQISCHVOPNHTM-UHFFFAOYSA-N 0.000 description 1
- RZPOCYOZFGMSDY-UHFFFAOYSA-N 3-[7-(5-hydroxypentylsulfanyl)-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3SCCCCCO RZPOCYOZFGMSDY-UHFFFAOYSA-N 0.000 description 1
- GFJFDEXBISHRMN-UHFFFAOYSA-N 3-[7-(6-bromohexylsulfanyl)-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound BrCCCCCCSC1=C2CN(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O GFJFDEXBISHRMN-UHFFFAOYSA-N 0.000 description 1
- QTEAMPJGTMBUTK-UHFFFAOYSA-N 3-[7-(6-morpholin-4-ylhexylsulfanyl)-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound O=C(C1=CC=CC(SCCCCCCN2CCOCC2)=C1C1)N1C(CCC(N1)=O)C1=O QTEAMPJGTMBUTK-UHFFFAOYSA-N 0.000 description 1
- OOHAHVHWSVSZTH-UHFFFAOYSA-N 3-[7-(7-anilinoheptylsulfanyl)-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3SCCCCCCCNC4=CC=CC=C4 OOHAHVHWSVSZTH-UHFFFAOYSA-N 0.000 description 1
- FSMHGVZBAHMQKF-UHFFFAOYSA-N 3-[7-(7-bromoheptylsulfanyl)-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound BrCCCCCCCSC1=C2CN(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O FSMHGVZBAHMQKF-UHFFFAOYSA-N 0.000 description 1
- QAEVVCDHHGFDPJ-UHFFFAOYSA-N 3-[7-(7-morpholin-4-ylheptylsulfanyl)-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3SCCCCCCCN4CCOCC4 QAEVVCDHHGFDPJ-UHFFFAOYSA-N 0.000 description 1
- BSUDRQVBJPEKRJ-UHFFFAOYSA-N 3-[7-(8-aminooctylsulfanyl)-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound NCCCCCCCCSC1=C2CN(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O BSUDRQVBJPEKRJ-UHFFFAOYSA-N 0.000 description 1
- LPQGPNUPKZSQAJ-UHFFFAOYSA-N 3-[7-(8-hydroxyoctylsulfanyl)-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3SCCCCCCCCO LPQGPNUPKZSQAJ-UHFFFAOYSA-N 0.000 description 1
- LMAJLRYWSDZJAY-UHFFFAOYSA-N 3-[7-(9-bromononylsulfanyl)-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound BrCCCCCCCCCSC1=C2CN(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O LMAJLRYWSDZJAY-UHFFFAOYSA-N 0.000 description 1
- SBGZVNXBFWGFIX-UHFFFAOYSA-N 3-[7-(9-morpholin-4-ylnonylsulfanyl)-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3SCCCCCCCCCN4CCOCC4 SBGZVNXBFWGFIX-UHFFFAOYSA-N 0.000 description 1
- BYTZJWGUWYIVMI-UHFFFAOYSA-N 3-[7-[5-(3-azaspiro[5.5]undecan-3-yl)pentylsulfanyl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C1CCC2(CC1)CCN(CC2)CCCCCSC3=CC=CC4=C3CN(C4=O)C5CCC(=O)NC5=O BYTZJWGUWYIVMI-UHFFFAOYSA-N 0.000 description 1
- XCHPLKPXIONJRC-UHFFFAOYSA-N 3-[7-[5-(methylamino)pentylsulfanyl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound CNCCCCCSC1=CC=CC2=C1CN(C2=O)C3CCC(=O)NC3=O XCHPLKPXIONJRC-UHFFFAOYSA-N 0.000 description 1
- DGLDAQDMXVRQAU-UHFFFAOYSA-N 3-[7-[6-(3-azaspiro[5.5]undecan-3-yl)hexylsulfanyl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C1CCC2(CC1)CCN(CC2)CCCCCCSC3=CC=CC4=C3CN(C4=O)C5CCC(=O)NC5=O DGLDAQDMXVRQAU-UHFFFAOYSA-N 0.000 description 1
- ZIVMHKYQWZEQJE-UHFFFAOYSA-N 3-[7-[6-(cyclohexylamino)hexylsulfanyl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C1CCC(CC1)NCCCCCCSC2=CC=CC3=C2CN(C3=O)C4CCC(=O)NC4=O ZIVMHKYQWZEQJE-UHFFFAOYSA-N 0.000 description 1
- BQEVOQHSFAPSDC-UHFFFAOYSA-N 3-[7-[6-[1-(1-adamantyl)ethylamino]hexylsulfanyl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound CC(C12CC3CC(C1)CC(C3)C2)NCCCCCCSC4=CC=CC5=C4CN(C5=O)C6CCC(=O)NC6=O BQEVOQHSFAPSDC-UHFFFAOYSA-N 0.000 description 1
- SSSVCZRMWCMEPS-UHFFFAOYSA-N 3-[7-[7-(1-adamantylmethylamino)heptylsulfanyl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3SCCCCCCCNCC45CC6CC(C4)CC(C6)C5 SSSVCZRMWCMEPS-UHFFFAOYSA-N 0.000 description 1
- AAPQZTLIHFFKRB-UHFFFAOYSA-N 3-[7-[7-(1-bicyclo[1.1.1]pentanylamino)heptylsulfanyl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3SCCCCCCCNC45CC(C4)C5 AAPQZTLIHFFKRB-UHFFFAOYSA-N 0.000 description 1
- YDPBJMZEHFWTBO-UHFFFAOYSA-N 3-[7-[7-(azocan-1-yl)heptylsulfanyl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C1CCCN(CCC1)CCCCCCCSC2=CC=CC3=C2CN(C3=O)C4CCC(=O)NC4=O YDPBJMZEHFWTBO-UHFFFAOYSA-N 0.000 description 1
- VNCCWRAIHJJURK-UHFFFAOYSA-N 3-[7-[7-(cyclopentylamino)heptylsulfanyl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C1CCC(C1)NCCCCCCCSC2=CC=CC3=C2CN(C3=O)C4CCC(=O)NC4=O VNCCWRAIHJJURK-UHFFFAOYSA-N 0.000 description 1
- GFYTXTFLXVOJFS-UHFFFAOYSA-N 3-[7-[7-[(3,5-dimethyl-1-adamantyl)amino]heptylsulfanyl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound CC12CC3CC(C1)(CC(C3)(C2)NCCCCCCCSC4=CC=CC5=C4CN(C5=O)C6CCC(=O)NC6=O)C GFYTXTFLXVOJFS-UHFFFAOYSA-N 0.000 description 1
- GUUJAWFISIWCPG-UHFFFAOYSA-N 3-[7-[7-[(4,4-dimethylcyclohexyl)amino]heptylsulfanyl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound CC1(CCC(CC1)NCCCCCCCSC2=CC=CC3=C2CN(C3=O)C4CCC(=O)NC4=O)C GUUJAWFISIWCPG-UHFFFAOYSA-N 0.000 description 1
- GODHIZDMFAKUQE-UHFFFAOYSA-N 3-[7-[7-[1-adamantyl(methyl)amino]heptylsulfanyl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound CN(CCCCCCCSC1=CC=CC2=C1CN(C2=O)C3CCC(=O)NC3=O)C45CC6CC(C4)CC(C6)C5 GODHIZDMFAKUQE-UHFFFAOYSA-N 0.000 description 1
- BGUJCCBADJELRE-UHFFFAOYSA-N 3-[7-[8-(2-adamantylamino)octylsulfanyl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3SCCCCCCCCNC4C5CC6CC(C5)CC4C6 BGUJCCBADJELRE-UHFFFAOYSA-N 0.000 description 1
- YGQAAAWOAPWKGX-UHFFFAOYSA-N 3-[7-[8-(3,5-dimethylpiperazin-1-yl)octylsulfanyl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound CC1CN(CC(N1)C)CCCCCCCCSC2=CC=CC3=C2CN(C3=O)C4CCC(=O)NC4=O YGQAAAWOAPWKGX-UHFFFAOYSA-N 0.000 description 1
- TVSLYXTURHWSCZ-UHFFFAOYSA-N 3-[7-[8-(4-methylpiperazin-1-yl)octylsulfanyl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound CN1CCN(CC1)CCCCCCCCSC2=CC=CC3=C2CN(C3=O)C4CCC(=O)NC4=O TVSLYXTURHWSCZ-UHFFFAOYSA-N 0.000 description 1
- WOPOBGZHTZKLDF-UHFFFAOYSA-N 3-[7-[8-(methylamino)octylsulfanyl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound CNCCCCCCCCSC1=CC=CC2=C1CN(C2=O)C3CCC(=O)NC3=O WOPOBGZHTZKLDF-UHFFFAOYSA-N 0.000 description 1
- UWNPVSWHCHBONI-UHFFFAOYSA-N 3-[7-[8-[2-(diethylamino)ethylamino]octylsulfanyl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound CCN(CC)CCNCCCCCCCCSC1=CC=CC2=C1CN(C2=O)C3CCC(=O)NC3=O UWNPVSWHCHBONI-UHFFFAOYSA-N 0.000 description 1
- UYPHQYKJFHYPMY-UHFFFAOYSA-N 3-[7-[[4-(morpholin-4-ylmethyl)phenyl]methylsulfanyl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound O1CCN(CC1)CC1=CC=C(CSC2=C3CN(C(C3=CC=C2)=O)C2C(NC(CC2)=O)=O)C=C1 UYPHQYKJFHYPMY-UHFFFAOYSA-N 0.000 description 1
- HXLBTQCSUGXUKC-UHFFFAOYSA-N 3-[7-[[4-[(1-adamantylamino)methyl]phenyl]methylsulfanyl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3SCC4=CC=C(C=C4)CNC56CC7CC(C5)CC(C7)C6 HXLBTQCSUGXUKC-UHFFFAOYSA-N 0.000 description 1
- UZXHXSXLOCGSLK-UHFFFAOYSA-N 3-[7-[[4-[2-(4-methylpiperazin-1-yl)ethyl]phenyl]methylsulfanyl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound CN1CCN(CC1)CCC2=CC=C(C=C2)CSC3=CC=CC4=C3CN(C4=O)C5CCC(=O)NC5=O UZXHXSXLOCGSLK-UHFFFAOYSA-N 0.000 description 1
- YCPULGHBTPQLRH-UHFFFAOYSA-N 3-aminopiperidine-2,6-dione;hydron;chloride Chemical compound Cl.NC1CCC(=O)NC1=O YCPULGHBTPQLRH-UHFFFAOYSA-N 0.000 description 1
- RQKFYFNZSHWXAW-UHFFFAOYSA-N 3-chloro-p-toluidine Chemical compound CC1=CC=C(N)C=C1Cl RQKFYFNZSHWXAW-UHFFFAOYSA-N 0.000 description 1
- GMOBHRQSNDDZAD-UHFFFAOYSA-N 3-chloroadamantane-1-carboxylic acid Chemical compound C1C(C2)CC3CC2(Cl)CC1(C(=O)O)C3 GMOBHRQSNDDZAD-UHFFFAOYSA-N 0.000 description 1
- GVRRXASZZAKBMN-UHFFFAOYSA-N 4-chloroquinazoline Chemical compound C1=CC=C2C(Cl)=NC=NC2=C1 GVRRXASZZAKBMN-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- IRPVABHDSJVBNZ-RTHVDDQRSA-N 5-[1-(cyclopropylmethyl)-5-[(1R,5S)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl]pyrazol-3-yl]-3-(trifluoromethyl)pyridin-2-amine Chemical compound C1=C(C(F)(F)F)C(N)=NC=C1C1=NN(CC2CC2)C(C2[C@@H]3CN(C[C@@H]32)C2COC2)=C1 IRPVABHDSJVBNZ-RTHVDDQRSA-N 0.000 description 1
- WJVQJXVMLRGNGA-UHFFFAOYSA-N 5-bromopentan-1-ol Chemical compound OCCCCCBr WJVQJXVMLRGNGA-UHFFFAOYSA-N 0.000 description 1
- XVMKZAAFVWXIII-UHFFFAOYSA-N 5-fluoro-2-benzofuran-1,3-dione Chemical compound FC1=CC=C2C(=O)OC(=O)C2=C1 XVMKZAAFVWXIII-UHFFFAOYSA-N 0.000 description 1
- WTFUTSCZYYCBAY-SXBRIOAWSA-N 6-[(E)-C-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-N-hydroxycarbonimidoyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C/C(=N/O)/C1=CC2=C(NC(O2)=O)C=C1 WTFUTSCZYYCBAY-SXBRIOAWSA-N 0.000 description 1
- 125000006164 6-membered heteroaryl group Chemical group 0.000 description 1
- SMRFYQLRMFOKCW-UHFFFAOYSA-N 7-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-4-yl]sulfanyl]-N,N-di(propan-2-yl)heptanamide Chemical compound CC(C)N(C(C)C)C(=O)CCCCCCSC1=CC=CC2=C1CN(C2=O)C3CCC(=O)NC3=O SMRFYQLRMFOKCW-UHFFFAOYSA-N 0.000 description 1
- GNOJPGVCCHQDRR-UHFFFAOYSA-N 7-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-4-yl]sulfanyl]heptanoic acid Chemical compound O=C1NC(CCC1N1C(C2=CC=CC(=C2C1)SCCCCCCC(=O)O)=O)=O GNOJPGVCCHQDRR-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- GMXIEASXPUEOTG-UHFFFAOYSA-N 8-bromooctan-1-ol Chemical compound OCCCCCCCCBr GMXIEASXPUEOTG-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 1
- 101100275770 Caenorhabditis elegans cri-3 gene Proteins 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000031639 Chromosome Deletion Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102100037799 DNA-binding protein Ikaros Human genes 0.000 description 1
- 102100040138 DNA-directed RNA polymerase II subunit GRINL1A, isoforms 4/5 Human genes 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000870895 Homo sapiens DNA-directed RNA polymerase II subunit GRINL1A Proteins 0.000 description 1
- 101001037037 Homo sapiens DNA-directed RNA polymerase II subunit GRINL1A, isoforms 4/5 Proteins 0.000 description 1
- 101001039696 Homo sapiens Lysophospholipid acyltransferase 7 Proteins 0.000 description 1
- 101000613798 Homo sapiens OTU domain-containing protein 7B Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- XETQTCAMTVHYPO-UHFFFAOYSA-N Isocamphan von ungewisser Konfiguration Natural products C1CC2C(C)(C)C(C)C1C2 XETQTCAMTVHYPO-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 102100040986 Lysophospholipid acyltransferase 7 Human genes 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- RJUFJBKOKNCXHH-UHFFFAOYSA-N Methyl propionate Chemical compound CCC(=O)OC RJUFJBKOKNCXHH-UHFFFAOYSA-N 0.000 description 1
- 208000009233 Morning Sickness Diseases 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- JCYUHASGDZGWGO-UHFFFAOYSA-N N-(1-adamantyl)-7-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-4-yl]sulfanyl]heptanamide Chemical compound C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3SCCCCCCC(=O)NC45CC6CC(C4)CC(C6)C5 JCYUHASGDZGWGO-UHFFFAOYSA-N 0.000 description 1
- KMNZGFQOMQQLBC-UHFFFAOYSA-N N-(2-adamantyl)-7-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-4-yl]sulfanyl]heptanamide Chemical compound C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3SCCCCCCC(=O)NC4C5CC6CC(C5)CC4C6 KMNZGFQOMQQLBC-UHFFFAOYSA-N 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- LAKCISOODUQWCS-UHFFFAOYSA-N N-[6-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-4-yl]sulfanyl]hexyl]adamantane-1-carboxamide Chemical compound C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3SCCCCCCNC(=O)C45CC6CC(C4)CC(C6)C5 LAKCISOODUQWCS-UHFFFAOYSA-N 0.000 description 1
- PHSPJQZRQAJPPF-UHFFFAOYSA-N N-alpha-Methylhistamine Chemical compound CNCCC1=CN=CN1 PHSPJQZRQAJPPF-UHFFFAOYSA-N 0.000 description 1
- IDRGFNPZDVBSSE-UHFFFAOYSA-N OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F Chemical compound OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F IDRGFNPZDVBSSE-UHFFFAOYSA-N 0.000 description 1
- 102100040562 OTU domain-containing protein 7B Human genes 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102100026459 POU domain, class 3, transcription factor 2 Human genes 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102100032783 Protein cereblon Human genes 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical class [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 1
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 1
- MUCRYNWJQNHDJH-OADIDDRXSA-N Ursonic acid Chemical compound C1CC(=O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C MUCRYNWJQNHDJH-OADIDDRXSA-N 0.000 description 1
- 208000034850 Vomiting in pregnancy Diseases 0.000 description 1
- JFBZPFYRPYOZCQ-UHFFFAOYSA-N [Li].[Al] Chemical compound [Li].[Al] JFBZPFYRPYOZCQ-UHFFFAOYSA-N 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- JIMXXGFJRDUSRO-UHFFFAOYSA-N adamantane-1-carboxylic acid Chemical compound C1C(C2)CC3CC2CC1(C(=O)O)C3 JIMXXGFJRDUSRO-UHFFFAOYSA-N 0.000 description 1
- ADJJLNODXLXTIH-UHFFFAOYSA-N adamantane-1-thiol Chemical compound C1C(C2)CC3CC2CC1(S)C3 ADJJLNODXLXTIH-UHFFFAOYSA-N 0.000 description 1
- 229910001573 adamantine Inorganic materials 0.000 description 1
- 125000005571 adamantylene group Chemical group 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 125000005213 alkyl heteroaryl group Chemical group 0.000 description 1
- 125000005529 alkyleneoxy group Chemical group 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- NEHMKBQYUWJMIP-UHFFFAOYSA-N anhydrous methyl chloride Natural products ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- JZCCFEFSEZPSOG-UHFFFAOYSA-L copper(II) sulfate pentahydrate Chemical compound O.O.O.O.O.[Cu+2].[O-]S([O-])(=O)=O JZCCFEFSEZPSOG-UHFFFAOYSA-L 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- KZZKOVLJUKWSKX-UHFFFAOYSA-N cyclobutanamine Chemical compound NC1CCC1 KZZKOVLJUKWSKX-UHFFFAOYSA-N 0.000 description 1
- 125000004976 cyclobutylene group Chemical group 0.000 description 1
- 125000004977 cycloheptylene group Chemical group 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000005725 cyclohexenylene group Chemical group 0.000 description 1
- 125000004956 cyclohexylene group Chemical group 0.000 description 1
- NISGSNTVMOOSJQ-UHFFFAOYSA-N cyclopentanamine Chemical compound NC1CCCC1 NISGSNTVMOOSJQ-UHFFFAOYSA-N 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000004979 cyclopentylene group Chemical group 0.000 description 1
- 125000004980 cyclopropylene group Chemical group 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- DIOQZVSQGTUSAI-NJFSPNSNSA-N decane Chemical compound CCCCCCCCC[14CH3] DIOQZVSQGTUSAI-NJFSPNSNSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000012954 diazonium Substances 0.000 description 1
- GDGUATCKWWKTLM-UHFFFAOYSA-N dicyclopropylmethanamine Chemical compound C1CC1C(N)C1CC1 GDGUATCKWWKTLM-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical class [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- OCLXJTCGWSSVOE-UHFFFAOYSA-N ethanol etoh Chemical compound CCO.CCO OCLXJTCGWSSVOE-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- FOTXAJDDGPYIFU-UHFFFAOYSA-N ethylcyclopropane Chemical compound CCC1CC1 FOTXAJDDGPYIFU-UHFFFAOYSA-N 0.000 description 1
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 1
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 125000005567 fluorenylene group Chemical group 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 description 1
- 230000008975 immunomodulatory function Effects 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- WMILMIDBWBQPAB-UHFFFAOYSA-N methyl 3-bromo-2-(bromomethyl)benzoate Chemical compound COC(=O)C1=CC=CC(Br)=C1CBr WMILMIDBWBQPAB-UHFFFAOYSA-N 0.000 description 1
- MKQQTCSBXHAYQL-UHFFFAOYSA-N methyl 3-bromo-2-methylbenzoate Chemical compound COC(=O)C1=CC=CC(Br)=C1C MKQQTCSBXHAYQL-UHFFFAOYSA-N 0.000 description 1
- 229940017219 methyl propionate Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- DIOQZVSQGTUSAI-UHFFFAOYSA-N n-butylhexane Natural products CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 1
- WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
- VEBLEROFGPOMPB-UHFFFAOYSA-N n-methylcyclopropanamine Chemical compound CNC1CC1 VEBLEROFGPOMPB-UHFFFAOYSA-N 0.000 description 1
- 125000004957 naphthylene group Chemical group 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- VWBWQOUWDOULQN-UHFFFAOYSA-N nmp n-methylpyrrolidone Chemical compound CN1CCCC1=O.CN1CCCC1=O VWBWQOUWDOULQN-UHFFFAOYSA-N 0.000 description 1
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical compound C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 1
- 125000005593 norbornanyl group Chemical group 0.000 description 1
- 125000005574 norbornylene group Chemical group 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000000010 osteolytic effect Effects 0.000 description 1
- NYGCBQKDTGBHSC-UHFFFAOYSA-N oxan-2-ylmethanamine Chemical compound NCC1CCCCO1 NYGCBQKDTGBHSC-UHFFFAOYSA-N 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000011112 process operation Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000005550 pyrazinylene group Chemical group 0.000 description 1
- DVUBDHRTVYLIPA-UHFFFAOYSA-N pyrazolo[1,5-a]pyridine Chemical compound C1=CC=CN2N=CC=C21 DVUBDHRTVYLIPA-UHFFFAOYSA-N 0.000 description 1
- LDIJKUBTLZTFRG-UHFFFAOYSA-N pyrazolo[1,5-a]pyrimidine Chemical compound N1=CC=CN2N=CC=C21 LDIJKUBTLZTFRG-UHFFFAOYSA-N 0.000 description 1
- 125000005576 pyrimidinylene group Chemical group 0.000 description 1
- NPWMTBZSRRLQNJ-UHFFFAOYSA-N pyroglutamine Chemical compound NC1CCC(=O)NC1=O NPWMTBZSRRLQNJ-UHFFFAOYSA-N 0.000 description 1
- MOVFAUAADQBPRE-UHFFFAOYSA-N pyrrolo[2,1-b][1,3]thiazole Chemical compound S1C=CN2C=CC=C21 MOVFAUAADQBPRE-UHFFFAOYSA-N 0.000 description 1
- 238000010833 quantitative mass spectrometry Methods 0.000 description 1
- RONWGALEIBILOG-VMJVVOMYSA-N quinine sulfate Chemical compound [H+].[H+].[O-]S([O-])(=O)=O.C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21.C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 RONWGALEIBILOG-VMJVVOMYSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- XIIOFHFUYBLOLW-UHFFFAOYSA-N selpercatinib Chemical compound OC(COC=1C=C(C=2N(C=1)N=CC=2C#N)C=1C=NC(=CC=1)N1CC2N(C(C1)C2)CC=1C=NC(=CC=1)OC)(C)C XIIOFHFUYBLOLW-UHFFFAOYSA-N 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- HYHCSLBZRBJJCH-UHFFFAOYSA-M sodium hydrosulfide Chemical compound [Na+].[SH-] HYHCSLBZRBJJCH-UHFFFAOYSA-M 0.000 description 1
- PODWXQQNRWNDGD-UHFFFAOYSA-L sodium thiosulfate pentahydrate Chemical compound O.O.O.O.O.[Na+].[Na+].[O-]S([S-])(=O)=O PODWXQQNRWNDGD-UHFFFAOYSA-L 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- LZCVVMQABORALM-UHFFFAOYSA-N spiro[2.5]octyl Chemical group [CH]1CC11CCCCC1 LZCVVMQABORALM-UHFFFAOYSA-N 0.000 description 1
- CTDQAGUNKPRERK-UHFFFAOYSA-N spirodecane Chemical compound C1CCCC21CCCCC2 CTDQAGUNKPRERK-UHFFFAOYSA-N 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 125000003375 sulfoxide group Chemical group 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- OHUJQWJCNMMZFM-UHFFFAOYSA-N tert-butyl n-(5-bromopentyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCCCCBr OHUJQWJCNMMZFM-UHFFFAOYSA-N 0.000 description 1
- XBDSVMQPKSQVMH-UHFFFAOYSA-N tert-butyl n-(8-bromooctyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCCCCCCCBr XBDSVMQPKSQVMH-UHFFFAOYSA-N 0.000 description 1
- IOGXOCVLYRDXLW-UHFFFAOYSA-N tert-butyl nitrite Chemical compound CC(C)(C)ON=O IOGXOCVLYRDXLW-UHFFFAOYSA-N 0.000 description 1
- 239000012414 tert-butyl nitrite Substances 0.000 description 1
- 150000003512 tertiary amines Chemical group 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- ZDLBWMYNYNATIW-UHFFFAOYSA-N tetracos-1-ene Chemical compound CCCCCCCCCCCCCCCCCCCCCCC=C ZDLBWMYNYNATIW-UHFFFAOYSA-N 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000005556 thienylene group Chemical group 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 108010072897 transcription factor Brn-2 Proteins 0.000 description 1
- PCFIPYFVXDCWBW-UHFFFAOYSA-N tricyclo[3.3.1.03,7]nonane Chemical compound C1C(C2)C3CC2CC1C3 PCFIPYFVXDCWBW-UHFFFAOYSA-N 0.000 description 1
- KIFOXEQDAPALIF-UHFFFAOYSA-N trifluoromethyl methanesulfonate Chemical compound CS(=O)(=O)OC(F)(F)F KIFOXEQDAPALIF-UHFFFAOYSA-N 0.000 description 1
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
- PXXNTAGJWPJAGM-UHFFFAOYSA-N vertaline Natural products C1C2C=3C=C(OC)C(OC)=CC=3OC(C=C3)=CC=C3CCC(=O)OC1CC1N2CCCC1 PXXNTAGJWPJAGM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
Definitions
- the present disclosure generally relates to compounds represented by general formula (I) or their salts, solvates, isotopically enriched analogs, tautomers, polymorphs, stereoisomers (including enantiomers) Isomers), or mixtures of stereoisomers, and their application in the treatment of tumors.
- Multiple myeloma is a malignant hematological cancer, accounting for about all tumors
- Thalidomide is the first generation of immunomodulatory drugs. It was used to treat morning sickness in pregnant women in the 1950s and 1960s, but it was forbidden to use it because it would cause malformed fetuses.
- Singhal et al. used thalidomide as a single agent for the treatment of refractory multiple myeloma patients for the first time, it showed good clinical effectiveness; subsequently, a large number of studies on thalidomide as a single agent or combined with dexamethasone A clinical trial of Metsone in the treatment of refractory or relapsed multiple myeloma.
- Thalidomide's immunomodulatory and anti-tumor activities have been discovered, and these drugs have attracted widespread attention.
- scientists have synthesized a series of phthalimide-replaced derivatives Pomalidomide and Lena with thalidomide as the lead compound.
- Degree amine Limalidomide
- Lenalidomide is a derivative with lower toxicity but higher activity. In 2006, it was approved by the FDA in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma.
- the third-generation immunomodulatory drug pomalidomide was approved for at least two drugs including lenalidomide and bortezomib Patients with relapsed/refractory multiple myeloma included in treatment.
- the detailed mechanism of action has not been clear until a study in 2010 used biochemical methods to affinity purify proteins that interact with thalidomide and identify the main targets of thalidomide and its analogs The point is Cereblon, and research in related fields is becoming increasingly active.
- immunomodulatory drugs can bind to the CRBN protein in cells, so that CRL4A eRBN ubiquitin ligase ubiquitinates and degrades the transcription factors IKZF1 and IKZF3. These two transcription factors are essential in the development and survival of B cells.
- Professor Harper discovered five endogenous ligase substrates through the ubiquitination analysis of the protein chip: GRINL1A, MBOAT7, OTUD7B, C6orfl41 and MEIS2.
- MEIS2 as a transcription factor, plays an important role in the normal development of the human body.
- MEIS2 myelodysplastic syndrome
- SILAC cell culture
- thalidomide drugs and their derivatives play a vital role in the treatment of multiple myeloma and other related malignant tumors, but the current reports of such compounds substituted by heteroatoms The biological activity needs to be further improved. Therefore, it is urgent to design and synthesize a series of thalidomide drugs with high activity in order to achieve better curative effect. Summary of the invention
- the present invention provides a compound of formula (I) or a salt, solvate, isotope-enriched analog, tautomer, polymorph, stereoisomer (including enantiomers) Isomer), or a mixture of stereoisomers:
- B, U, V, W are the same or different and each independently represents CH or N, where B, U, V, and W are not N at the same time;
- Y represents O or S;
- R represents SH, and L and Xi f exist;
- R represents S, L represents an optionally substituted linear or branched alkyl group, and ⁇ does not exist;
- R represents S(O) or S(0) 2
- L represents an optionally substituted linear or branched alkyl group or amino group, and Xi f is present;
- R represents S, S(O) or S(0) 2 ,
- L represents an optionally substituted linear or branched alkylene group, wherein the linear or branched alkylene group is optionally interrupted one or more times by one or more groups selected from: 0, C(O), S, S(O), S(0) 2 , C(0)N(Ri), N(R 2 )C(0), N(R 3 ), N(R 4 )C( 0) N(R 5 ), optionally substituted cycloalkylene, optionally substituted arylene, optionally substituted heterocyclylene, optionally substituted heteroarylene, or any combination thereof, wherein Ri , R 2, R 3, R 4 and 115 each independently represent H or Ci_ 3 ware group;
- Xi represents NReR ?, C(0)NR e R f , NHC(0)R 8 , NHC(0)NR 9 R IO ⁇ quaternary ammonium salt group, OR h , SH, optional substitution (especially optionally A straight or branched chain alkyl group substituted by one or more fluorines, an optionally substituted cycloalkyl group, an optionally substituted aryl group, an optionally substituted heterocyclic group or an optionally substituted heteroaryl group, wherein, Re, R 7 , R e , R f , R h , R 9 and R 10 each independently represent H, an optionally substituted linear or branched alkyl group, an optionally substituted cycloalkyl group, an optionally substituted aryl group Group, an optionally substituted heterocyclic group or an optionally substituted heteroaryl group, provided that R 6 and R 7 are not H at the same time, and which represents a linear or branched alkyl group, an aryl group,
- Xi represents a group of the formula (Gi):
- B L U I , V I , ⁇ are the same or different and independently represent CH or N, where Bp Up Vi Wi is not N at the same time;
- Z represents S, S(O) or S(0) 2;
- Another object of the present invention is to provide a compound of formula (r) or a salt, solvate, isotope-enriched analog, tautomer, polymorph, stereoisomer (including enantiomers) Structure), or a mixture of stereoisomers:
- A, B, U, V, W, Y are as defined in formula (I) herein;
- R represents S, S(O) or S(0) 2;
- L represents an optionally substituted linear or branched alkylene group, wherein the linear or branched alkylene group is optionally interrupted one or more times by one or more groups selected from: 0, C(O), S, S(O), S(0) 2 , S(0) 2 N(R I ), N(R 2 )S(O) 2 , C(0)N(Ri), N (R 2 )C(0), N(R 3 ), N(R 4 )C(0)N(R 5) , optionally substituted cycloalkylene, optionally substituted arylene, optionally substituted heterocyclylene, optionally substituted heteroarylene group, or any combination thereof, wherein Ri, R 2, R 3, R 4 and 115 each independently represent H or C M alkyl; and
- X ! represents NHC O)! ⁇ or SR j , where and each independently represent optionally selected from ( ⁇ _ 6 alkyl, oxo, halogen, cyano, trifluoromethyl, amino , Hydroxy, Ci_ 3 alkoxy, halo Ci_ 3 alkoxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy or cycloalkyl substituted with any combination of substituents, Or Xi means optionally selected from Ci_ 6 alkyl, oxo, halogen, cyano, trifluoromethyl, amino, hydroxy, Ci_ 3 alkoxy, halogenated Ci_ 3 alkoxy, methanesulfonyloxy , Cycloalkyl substituted with trifluoromethanesulfonyloxy, p-toluenesulfonyloxy or any combination thereof; or
- NReRy represents H or Cw alkyl
- R 7 represents optionally selected from the group consisting of ⁇ _ 6 alkyl, oxo, halogen, cyano, trifluoromethyl, amino, hydroxy, Ci_ 3 alkoxy, halogen Substitute Ci_ 3 alkoxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy or any combination of substituents substituted cycloalkyl; or
- the present invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising the compound of formula (I), compound of formula (r), or a pharmaceutically acceptable salt, solvate, or isotope thereof Enrichment of analogs, tautomers, polymorphs, stereoisomers (including enantiomers), or mixtures of stereoisomers, and at least one pharmaceutically acceptable carrier.
- the present invention also provides a kit or a kit, which comprises the compound of formula (I), compound of formula (r), or a pharmaceutically acceptable salt thereof, Solvates, isotopically enriched analogs, tautomers, polymorphs, stereoisomers (including enantiomers), or mixtures of stereoisomers, or the pharmaceutical composition of the present invention .
- the present invention also provides a compound of formula (I), or a compound of formula (r), or a pharmaceutically acceptable salt, solvate, isotope-enriched analog, Tautomers, polymorphs, stereoisomers (including enantiomers), or mixtures of stereoisomers, which are used as pharmaceuticals.
- the compound of formula (I), or compound of formula (r) according to the present invention or a pharmaceutically acceptable salt, solvate, isotope-enriched analog, or tautomer Forms, polymorphs, stereoisomers (including enantiomers), or mixtures of stereoisomers or the pharmaceutical composition of the present invention are used to treat cancer or tumors.
- the present invention also provides a compound of formula (I), compound of formula (r), or a pharmaceutically acceptable salt, solvate, isotope-enriched analog, and mutual Tautomers, polymorphs, stereoisomers (including enantiomers), or mixtures of stereoisomers or the use of the pharmaceutical composition of the present invention, which are used to prepare for treatment Cancer or tumor medicine.
- the present invention also provides a method of treating cancer or tumor, which comprises administering to a subject a therapeutically effective amount of the compound of formula (I) or the compound of formula (r), or Its pharmaceutically acceptable salts, solvates, isotopically enriched analogs, tautomers, polymorphs, stereoisomers (including enantiomers), or mixtures of stereoisomers, Or said pharmaceutical composition.
- Figure 1 shows the reported target proteins of small immunomodulatory molecules and their indications.
- Figure 2 is a study on the degradation of IKZF1 and IKZF3 proteins in MM1S cells by the compounds of the present invention. detailed description
- Embodiment 1 a compound of formula (I) or a salt, solvate, isotope-enriched analog, tautomer, polymorph, or stereoisomer thereof Isomers (including enantiomers), or stereoisomers Body mixture:
- B, U, V, and W are the same or different and independently represent CH or N, where B, U, V, and W are not N at the same time;
- Y means 0 or S
- R represents SH, and L and Xi f exist;
- R represents S, L represents an optionally substituted linear or branched alkyl group, and ⁇ does not exist;
- R represents S(O) or S(0) 2
- L represents an optionally substituted linear or branched alkyl group or amino group, and Xi f is present;
- R represents S, S(O) or S(0) 2 ,
- L represents an optionally substituted linear or branched alkylene group, wherein the linear or branched alkylene group is optionally interrupted one or more times by one or more groups selected from: 0, C(O), S, S(O), S(0) 2 , C(0)N(Ri), N(R 2 )C(0), N(R 3 ), N(R 4 )C( 0) N(R 5 ), optionally substituted cycloalkylene, optionally substituted arylene, optionally substituted heterocyclylene, optionally substituted heteroarylene or any combination thereof, wherein, R 2, R 3, R 4 and 115 each independently represent H or a group firing (firing preferably Ci_ 3-yl); and
- X ! represents NRgRy ⁇ C(0)NR e R f , NHC(0)R 8 , NHC(0)NR 9 Rio ⁇ quaternary ammonium salt group, OR h , SH, optional substitution (especially optionally substituted by One or more fluorine-substituted linear or branched alkyl groups, optionally substituted cycloalkyl groups, optionally substituted aryl groups, optionally substituted heterocyclic groups or optionally substituted heteroaryl groups, wherein, R 7 , R e , R f , R h , and R 1Q each independently represent H, an optionally substituted linear or branched alkyl group, an optionally substituted cycloalkyl group, an optionally substituted aryl group, an optional A substituted heterocyclic group or an optionally substituted heteroaryl group, provided that R 6 is not H at the same time, and 11 8 represents a linear or branched alkyl group, an aryl group, a heteroaryl group or
- Xi represents a group of the formula (Gi): Formula (GO
- Bi, Ui, Vi, ⁇ are the same or different and independently represent CH or N, where, Ui,: and Wi are not N at the same time;
- Z represents S, S(O) or S(0) 2;
- Embodiment 2 It relates to the compound of formula (I) or its salt, solvate, isotope enriched analogue, tautomer, polymorph, stereoisomer as described in embodiment 1) ,, Or a mixture of stereoisomers, wherein the ring atoms B, U, V, and W in formula (I) are the same, and all are CH.
- Embodiment 3 It relates to the compound of formula (I) or its salt, solvate, isotope-enriched analogue, tautomer, polymorph, stereoisomer as described in embodiment 1) ,, Or a mixture of stereoisomers, wherein one of the ring atoms B, U, V, and W in formula (I) is N, and the rest are CH.
- Embodiment 4 It relates to the compound of formula (I) or its salt, solvate, isotope enriched analog, tautomer, polymorph, stereoisomer as described in embodiment 1) ,, Or a mixture of stereoisomers, wherein two of the ring atoms B, U, V, and W in formula (I) are N, and the rest are CH.
- Embodiment 5 It relates to the compound of formula (I) or its salt, solvate, isotope-enriched analogue, tautomer, polymorph, stereoisomer as described in embodiment 1) ,, Or a mixture of stereoisomers, wherein three of the ring atoms B, U, V, and W in formula (I) are N, and the rest are CH.
- Embodiment 6) It relates to the compound of formula (I) or its salt, solvate, isotope-enriched analog, tautomer, polymorph, stereoisomer as described in embodiment 1) ,, Or a mixture of stereoisomers, which are also compounds of formula (la):
- Embodiment 7 It relates to the compound of formula (I) or its salt, solvate, isotope enriched analog, tautomer, polymorph, stereoisomer as described in embodiment 1) ,, Or a mixture of stereoisomers, which are also compounds of formula Ob):
- Embodiment 8 It relates to the compound of formula (I) or its salt, solvate, isotope enriched analog, tautomer, polymorph, stereoisomer as described in embodiment 1) ,, Or a mixture of stereoisomers, which are also compounds of formula (Ic):
- Embodiment 9 It relates to the compound of formula (I) or its salt, solvate, isotope enriched analogue, tautomer, polymorph, stereoisomer as described in embodiment 1) ,, Or a mixture of stereoisomers, which are also compounds of formula (Id): Formula (Id)
- Embodiment 10 It relates to the compound of formula (I) or its salt, solvate, isotope enriched analogue, tautomer, polymorph, stereoisomer as described in embodiment 1) ,, Or a mixture of stereoisomers, which are also compounds of formula (Ie):
- Embodiment 11 It relates to the compound of formula (I) or its salt, solvate, isotope-enriched analogue, tautomer, and polymorph as described in any one of embodiments 1)-10) Forms, stereoisomers, or mixtures of stereoisomers, where Y represents 0.
- Embodiment 12 It relates to the compound of formula (I) or its salt, solvate, isotope-enriched analogue, tautomer, and polymorph as described in any one of embodiments 1)-10) Forms, stereoisomers, or mixtures of stereoisomers, wherein Y in formula (I) represents S.
- Embodiment 13 It relates to the compound of formula (I) or its salt, solvate, isotope-enriched analogue, tautomer, polymorph as described in any one of embodiments 1)-11) Forms, stereoisomers, or mixtures of stereoisomers, where A in formula (I) represents cco).
- Embodiment 14 It relates to the compound of formula (I) or its salt, solvate, isotope-enriched analogue, tautomer, and polymorph as described in any one of embodiments 1)-11) Forms, stereoisomers, or mixtures of stereoisomers, where A in formula (I) represents CH 2 .
- Embodiment 15 It relates to the compound of formula (I) or its salt, solvate, isotope-enriched analogue, tautomer, and polymorph as described in any one of embodiments 1)-14) Forms, stereoisomers, or mixtures of stereoisomers, wherein R in formula (I) represents S, L represents an optionally substituted linear or branched alkyl group, and XiF is present. In a sub-embodiment, R represents S, and L represents an optionally substituted linear or branched C MO alkyl (especially ( ⁇ alkane) ⁇ ), and does not exist.
- R represents S
- L represents methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, Neopentyl, tertpentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl, or pentadecyl, and Xi f exists.
- Embodiment 16 It relates to the compound of formula (I) or its salt, solvate, isotope-enriched analogue, tautomer, and polymorph as described in any one of embodiments 1)-14) Form, stereoisomer, or mixture of stereoisomers, wherein R in formula (I) represents S(O) or S(0) 2 , and L represents an optionally substituted linear or branched alkyl group Or amino, and Xi F is present. In a sub-embodiment, R represents S(O) or S(0) 2 , L represents an optionally substituted linear or branched C MO alkyl (especially C MO alkyl) or amino group, and does not exist.
- R represents S(O) or S(0) 2
- L represents methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert Butyl, pentyl, isopentyl, neopentyl, p-pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl Group, pentadecyl group or amino group, and Xi does not exist.
- Embodiment 17 It relates to the compound of formula (I) or its salt, solvate, isotope-enriched analogue, tautomer, and polymorph as described in any one of Embodiments 1)-14) Forms, stereoisomers, or mixtures of stereoisomers, where R represents SH, and L and Xi f are present.
- Embodiment 18 It relates to the compound of formula (I) or its salt, solvate, isotope-enriched analogue, tautomer, polymorph as described in any one of the embodiments 1)-14) Forms, stereoisomers, or mixtures of stereoisomers, where
- R represents S, S(O) or S(0) 2;
- L represents an optionally substituted linear or branched C MO alkylene group, wherein the linear or branched C MO alkylene group is optionally interrupted by one or more groups selected from Times: 0, C(0), S, S(0), S(0) 2 , C(0)N(Ri), N(R 2 )C(0), N(R 3 ), N(R 4 ) C(0)N(R5 ) , optionally substituted cycloalkylene, optionally substituted arylene, optionally substituted heterocyclylene, optionally substituted heteroarylene or any of them A combination, wherein Ri, R 2 , R 3 , R 4 and R 5 each independently represent an H or Ci- 3 alkyl group; and
- X ! represents NRgRy ⁇ C(0)NR e R f , NHC(0)R 8 , NHC(0)NR 9 Rio ⁇ 0R h , SH, quaternary ammonium salt group, optional substitution (especially optionally substituted by One or more fluorine-substituted linear or branched Cwo alkyl groups, optionally substituted cycloalkyl groups, selected substituted aryl groups, selected substituted heterocyclic groups or selected substituted heteroaryl groups ,
- R 6 , R 7 , Re, R f , R h , R 9 and R 1Q each independently represent H, optionally substituted linear or branched Cwo alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl or optionally substituted heteroaryl, wherein with the proviso that, 117 are not simultaneously H, and wherein R 8 represents a linear or branched ⁇ _ 8 alkyl group, Aryl,
- Xi represents a group of the formula (Gi): Formula (GO
- Bi, Ui, Vi, ⁇ are the same or different and independently represent CH or N, where, Ui,: and Wi are not N at the same time;
- Z represents S, S(O) or S(0) 2 .
- Embodiment 19 It relates to the compound of formula (I) or its salt, solvate, isotope-enriched analogue, tautomer, and polymorph as described in any one of embodiments 1)-14) Forms, stereoisomers, or mixtures of stereoisomers, where
- R represents S, S(O) or S(0) 2;
- L represents an optionally substituted linear or branched C MO alkylene group, wherein the linear or branched C MO alkylene group is optionally interrupted by one or more groups selected from Times: 0, C(O), S, S(O), S(0) 2 , C(0)N(Ri), N(R 2 )C(0), N(R 3 ), N(R 4) C (0) N ( R 5), optionally substituted with substituents selected from halogen, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy group or Ci_ 5 alkyl substituents arylene, optionally substituted with substituents selected from halogen, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy group, oxo group or Ci_ 5 alkyl substituents heterocyclylene , optionally substituted with halo, methan
- Xi represents NRgRy, C(0)NR e R f , NHC(0)R 8 , NHC(0)NR 9 Rio, OR h , SH, a quaternary ammonium salt group, optionally substituted by one or more fluorine Straight or branched Cwo alkyl, optionally selected from halogen, oxo, cyano, trifluoromethyl, amino, hydroxy, Ci_ 3 alkoxy, halo Ci_ 3 alkoxy, methanesulfonyl Cycloalkyl substituted with substituents of oxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, Ci_ 6 alkyl or any combination thereof, optionally selected from halogen, oxo, cyano, Trifluoromethyl, amino, hydroxy, Ci_ 3 alkoxy, halogenated Ci_ 3 alkoxy, methanesulfonyloxy, trifluoromethanesulfony
- Ci_ 6 alkyl optionally substituted 6-membered aryl, optionally substituted 5- or 6-membered heterocyclyl, optionally substituted 5- or 6-membered heteroaryl or any combination of substituents substituted hetero
- R 6 , R 7 , R e , R f , R h , R 9 and R 1Q each independently represent H, an optionally substituted linear or branched chain
- Embodiment 20 It relates to the compound of formula (I) or its salt, solvate, isotope-enriched analogue, tautomer, polymorph, and stereo as described in embodiment 1) or 19) Isomers, or mixtures of stereoisomers, where L represents the following optionally substituted (for example, optionally selected from halogen, C alkyl, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluene Sulfonyloxy or any combination of substituents substituted) group: straight or branched CVC 40 alkylene, *-((CH 2 ) nl O) ml -(CH 2 ) n2 -, *- ((CH 2) nl 0) ml - (CH 2) n2 -0- (CH 2) n3 -, * - (CH 2) nl -0- (CH 2) n2 -, * - ((CRiiR)
- R 21 , R 22 , R 23 , R 24 , R 25 and R 26 are each independently selected from 11 and C M alkyl groups;
- R11, R12, Rl3, Rl4, Rl5, Rl6, Rl7, Rl8, Rl9 and R2 Q each independently represent H, linear or branched CrCn ) alkyl or C 3 -C 1 () cycloalkyl, wherein When in the same group L, R n , R 12 , R 13 , R 14 , or R 15 , R 16 , R 17 , R 18 , R 19 , R 2Q are not H at the same time; and nl, n2, n3, ml independently represent 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or An integer of 20.
- Embodiment 21 It relates to a compound of formula (I) or a salt, solvate, isotope-enriched analog, tautomer, polymorph, or stereoisomer as described in embodiment 20) , Or a mixture of stereoisomers, where L represents an optionally substituted linear or branched CrC % alkylene group.
- L represents optionally substituted with a substituent selected from halogen, Cw alkyl, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy or any combination thereof
- Embodiment 22 It relates to the compound of formula (I) or its salt, solvate, isotope-enriched analogue, tautomer, polymorph, and stereo as described in embodiment 20) or 21) Isomers, or mixtures of stereoisomers, where L represents the following optionally selected from halogen, Cw alkyl, methanesulfonyloxy, trifluoromethanesulfonyloxy, or p-toluenesulfonyloxy or any combination group substituents: -CH 2-; - (CH 2 ) 2-; - (CH 2) 3-; - (CH 2) 4 - ;-( CH 2) 5-; - (CH 2 ) 6 -; -(CH 2 ) 7 -; -(CH 2 ) 8 -; -(CH 2 ) 9 -; -(CH 2 )i0-; -(CH 2 )n-; -(CH 2 ) i 2 - ;
- L represents -CH 2-; - (CH 2) 2 - ;-( CH 2) 3 - ;-( CH 2) 4 - ;-( CH 2) 5 - ;-( CH 2 ) 6 -;-(CH 2 ) 7 -;-(CH 2 ) 8 -;-(CH 2 ) 9 -;-(CH 2 )IO-; -(CH 2 )H-;- (CH2)12 -;-(CH2)13-;-(CH2)14-;-(CH2)15-;-(CH2)16-;-(CH2)17-;-(CH2)18-;-(CH2)19_; -(CH2)20-.
- Embodiment 23 It relates to the compound of formula (I) or its salt, solvate, isotope enriched analogue, tautomer, polymorph, stereoisomer as described in embodiment 20) , Or a mixture of stereoisomers, where L represents the following optionally substituted (for example, optionally selected from halogen, Cw alkyl, methanesulfonyloxy, trifluoromethanesulfonyloxy or p-toluenesulfonyloxy ((CH 2 ) nl O) ml -(CH 2 ) n2 -, *- ((CH 2 ) nl 0) ml -(CH 2 ) n2 -0-(CH 2 ) n3 -, *-(CH 2 ) nl -0-(CH 2 ) n2 -, *-((CRnRi 2 ) ni O) mi -(CRi3Ri4)
- Embodiment 24 It relates to the compound of formula (I) or a salt, solvate, isotope-enriched analog, tautomer, polymorph, or stereo as described in embodiment 20) or 23) Isomers, or mixtures of stereoisomers, where L represents the following optionally substituted (for example, optionally selected from halogen, C alkyl, methanesulfonyloxy, trifluoromethanesulfonyloxy or p-toluene Sulfonyloxy or any combination of substituents substituted) group:
- Embodiment 25 It relates to the compound of formula (I) or its salt, solvate, isotope-enriched analog, tautomer, polymorph, stereoisomer as described in embodiment 20) , Or a mixture of stereoisomers, where L represents the following optionally substituted (for example, optionally selected from halogen, Ci_ 5 alkyl, methanesulfonyloxy, trifluoromethanesulfonyloxy or p-toluenesulfonyl Oxy or any combination of substituents) *-(CH 2 ) nl -N(R 2i )-(CH 2 ) n2 -, where * represents the point of attachment to the group R; R 21 is selected from H and Ci_ 3 alkyl; nl and n2 each independently represent 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or An integer of 20.
- L represents the following optionally substituted (for example, optionally selected from halogen, Ci
- Embodiment 26 It relates to the compound of formula (I) or its salt, solvate, isotope-enriched analogue, tautomer, polymorph, and stereo as described in embodiment 20) or 25) Isomers, or mixtures of stereoisomers, where L represents the following optionally substituted (for example, optionally selected from halogen, C alkyl, methanesulfonyloxy, trifluoromethanesulfonyloxy or p-toluene Sulfonyloxy or any combination of substituents substituted) groups: ⁇ (CHA-NH- CHA-, *- (CH 2 ) 2 -NH-(CH 2 ) I -, *-(CH 2 ) 2 -NH-(CH 2 ) 2 -, *-(CH 2 ) 2 -NH-(CH 2 ) 3 -, *-(CH 2 ) 2 -NH-(CH 2 ) 4 -, *- (CH 2 ) 2 -
- Embodiment 27 It relates to the compound of formula (I) or its salt, solvate, isotope-enriched analogue, tautomer, polymorph, stereoisomer as described in embodiment 20) , Or a mixture of stereoisomers, where L represents the following optionally substituted (for example, optionally selected from halogen, Ci_ 5 alkyl, methanesulfonyloxy, trifluoromethanesulfonyloxy or p-toluenesulfonyl Oxy or any combination of substituents) *-(CH 2 ) nl -N(R 22 )C(0)-(CH 2 ) n2 -, where * represents the point of attachment to the group R; R 22 Selected from H and Ci_ 3 alkyl; nl and n2 each independently represent 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, An integer of 18, 19, or 20.
- L represents the following optionally substituted (for example, optionally selected from hal
- Embodiment 28 It relates to the compound of formula (I) or a salt, solvate, isotope-enriched analog, tautomer, polymorph, or stereo as described in embodiment 20) or 27).
- Embodiment 29 It relates to the compound of formula (I) or its salt, solvate, isotope-enriched analogue, tautomer, polymorph, stereoisomer as described in embodiment 20) , Or a mixture of stereoisomers, where L represents the following optionally substituted (for example, optionally selected from halogen, Cw alkyl, methanesulfonyloxy, trifluoromethanesulfonyloxy or p-toluenesulfonyloxy Group or any combination of substituents) group *-(CH 2 ) nl -C(0)N(R 23 )-(CH 2 ) n2 -, where * represents the point of attachment to the group R; R 23 is selected from H and Ci_ 3 alkyl; nl and n2 each independently represent
- Embodiment 30 It relates to the compound of formula (I) or its salt, solvate, isotope-enriched analogue, tautomer, polymorph, or stereo as described in embodiment 20) or 29) Isomers, or mixtures of stereoisomers, where L represents the following optionally substituted (for example, optionally selected from halogen, C alkyl, methanesulfonyloxy, trifluoromethanesulfonyloxy or p-toluene Substituted by a sulfonyloxy group or any combination thereof) group: *-(CH 2 ) 2 -C(0)NH-CH 2 -,
- Embodiment 31 It relates to the compound of formula (I) or its salt, solvate, isotope enriched analogue, tautomer, polymorph, stereoisomer as described in embodiment 20) , Or a mixture of stereoisomers, where L represents the following optionally substituted (for example, optionally selected from halogen, Ci_ 5 alkyl, methanesulfonyloxy, trifluoromethanesulfonyloxy or Substituted by p-toluenesulfonyloxy or any combination of substituents) *-(CH 2 ) nl -N(R 24 )C(0)N(R 25 )-(CH 2)n2 -, where * means and The point of attachment of the group R; R 24 and R 25 are each independently selected from H and C M alkyl; nl, n2 each independently represent 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 , 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20.
- L represents the following optionally
- Embodiment 32 It relates to the compound of formula (I) or its salt, solvate, isotope-enriched analogue, tautomer, polymorph, or stereo as described in embodiment 20) or 31).
- Embodiment 33 It relates to the compound of formula (I) or its salt, solvate, isotope-enriched analog, tautomer, polymorph, stereoisomer as described in embodiment 20) , Or a mixture of stereoisomers, where L represents *-(012)...1-piperidanylene-(CH2) n2 -, where * denotes the point of attachment to the group R; the piperidylene is optional Ground through halogen, methanesulfonyloxy, trifluoromethanesulfonyloxy or p-toluenesulfonyloxy or Cw alkyl (especially methyl, ethyl, propyl, isopropyl, butyl, sec-butyl Or tert-butyl) or any combination of substituents; nl and n2 each independently represent 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 , 16, 17, 18, 19, or 20.
- Embodiment 34 It relates to the compound of formula (I) or a salt, solvate, isotope-enriched analog, tautomer, polymorph, or stereo as described in embodiment 20) or 33). Isomers, or mixtures of stereoisomers, where L represents *-CH 2 -piperazinylene-CH 2 -, *-(CH 2 ) 2 -piperazinylene-(CH 2 ) 2 -, * -(CH 2 ) 2 -piperazinylidene-(CH 2 ) 3- , *-(CH 2 ) 2 -piperazinylidene-(CH 2 ) 4 -, *-(CH 2 ) 2 -piperazinide -(CH 2 ) 5 -, *-(CH 2 ) 3 -piperazinylidene-CH 2 -, *- (CH 2 ) 3 -piperazinylidene-(CH 2 ) 2 -, *- (CH 2 ) 3 -piperazinylid
- L represents *-CH 2 -piperazinyl-CH 2 -, *-(CH 2 ) 2 -piperazinyl-(CH 2 ) 2 -, *-(CH 2 ) 2 -piperazinyl-( CH 2 ) 3 -, *- (CH 2 ) 2 -piperazinylidene-(CH 2 ) 4 -, *-(CH 2 ) 2 -piperazinylidene-(CH 2 ) 5 -, *-(CH 2 ) 3 -piperazinylidene -CH 2 -, *-(CH 2 ) 3 -Piperazinylidene-(CH 2 ) 2 -, *-(CH 2 ) 3 -Piperazinylidene-(CH 2 ) 3 -, *-(CH 2 ) 4 -piperazinyl-CH 2 -, *-(CH 2 ) 4 -piperazinyl-CH 2 -, *-(CH 2 )
- Embodiment 35 It relates to the compound of formula (I) or its salt, solvate, isotope enriched analogue, tautomer, polymorph, stereoisomer as described in embodiment 20) , Or a mixture of stereoisomers, where L represents *-(CH 2 ) nl -phenylene-(CH 2 ) n2 -, where * represents the point of attachment to the group R; the phenylene group is optionally halogen, methanesulfonyloxy, trifluoromethanesulfonyloxy or p-toluenesulfonyloxy group or a Ci_ 5 alkyl (especially methyl, ethyl, propyl, isopropyl, butyl, sec-butyl Or tert-butyl) or any combination of substituents; nl and n2 each independently represent 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 , 16, 17, 18, 19, or 20
- Embodiment 36 It relates to a compound of formula (I) or a salt, solvate, isotope-enriched analog, tautomer, polymorph, or stereo as described in embodiment 20) or 35).
- Isomers, or mixtures of stereoisomers where L represents *-CH 2 -phenylene-CH 2 -, *-(CH 2 ) 2 -phenylene-(CH 2 ) 2 -, *-( CH 2 ) 2 -phenylene-(CH 2 ) 3 -, *- (CH 2 ) 2 -phenylene-(CH 2 ) 4 -, *-(CH 2 ) 2 -phenylene-(CH 2 ) 5 -, *-(CH 2 ) 3 -phenylene-CH 2 -, *-(CH 2 ) 3 -phenylene- (CH 2 ) 2 -, *-(CH 2 ) 3 -phenylene- (CH 2 ) 2 -, *-(CH 2 ) 3 -pheny
- L represents *-CH 2 -phenylene-CH 2 -, *-(CH 2 ) 2 -phenylene-(CH 2 ) 2 -, *-(CH 2 ) 2- Phenyl- (CH 2 ) 3 -, *-(CH 2 ) 2 -Phenyl-(CH 2 ) 4 -, *-(CH 2 ) 2 -Phenyl-(CH 2 ) 5 -, *- (CH 2 ) 3 -phenylene-CH 2 -, *- (CH 2 ) 3 -phenylene-(CH 2 ) 2 -, *-(CH 2 ) 3 -phenylene-(CH 2 ) 3 -, *-(CH 2 ) 4 -phenylene-CH 2 -, *-(CH 2 ) 4 -phenylene- (CH 2 ) 2 -, *-(CH 2 ) 4 -phenylene- (CH 2 ) 2 -, *-(CH 2 ) 4 -phenylene-
- Embodiment 37 It relates to the compound of formula (I) or its salt, solvate, isotope-enriched analog, tautomer, polymorph, stereoisomer as described in embodiment 20) , Or a mixture of stereoisomers, where L represents the following optionally substituted (for example, optionally selected from halogen, Ci_ 5 alkyl, methanesulfonyloxy, trifluoromethanesulfonyloxy or p-toluenesulfonyl Oxy or any combination of substituents substituted) group *-(CH 2 ) nl -S-(CH 2 ) n2 -, where * represents the point of connection with the group R; nl and n2 each independently represent 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20.
- L represents the following optionally substituted (for example, optionally selected from halogen, Ci_ 5 alkyl, methanesulfonyloxy, tri
- Embodiment 38 It relates to the compound of formula (I) or a salt, solvate, isotope-enriched analog, tautomer, polymorph, or stereo as described in embodiment 20) or 37).
- L represents the following optionally substituted (for example, optionally selected from halogen, C alkyl, methanesulfonyloxy, trifluoromethanesulfonyloxy or p-toluene Sulfonyloxy or any combination of substituents substituted) groups: *-(CH 2 ) I S(CH 2 ) I- , *- (CH 2 ) 2 S(CH 2 ) 2 -, *-( CH 2 ) 2 S(CH 2 ) I- , *-(CH 2 ) I S(CH 2 ) 2- , *-(CH 2 ) I S(CH 2 ) 3- , *-(CH 2 ) I S (CH 2 ) 4- , *-(CH 2 ) I S(CH 2 ) 4- , *
- Embodiment 39 It relates to the compound of formula (I) or its salt, solvate, isotope enriched analogue, tautomer, polymorph, stereoisomer as described in embodiment 20) , Or a mixture of stereoisomers, where L represents the following optionally substituted (for example, optionally selected from halogen, Cw alkyl, methanesulfonyloxy, trifluoromethanesulfonyloxy or p-toluenesulfonyloxy Group or any combination of substituents) group *-(CH 2 ) nl -S(0)-(CH 2 ) n2 -, where * represents the point of connection with the group R; nl and n2 are each independently Represents an integer of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20.
- L represents the following optionally substituted (for example, optionally selected from halogen, Cw alkyl, methanesulfonyl
- Embodiment 40 It relates to the compound of formula (I) or its salt, solvate, isotope-enriched analogue, tautomer, polymorph, or stereo as described in embodiment 20) or 39) Isomers, or mixtures of stereoisomers, where L represents the following optionally substituted (for example, optionally selected from halogen, C alkyl, methanesulfonyloxy, trifluoromethanesulfonyloxy or p-toluene Sulfonyloxy or any combination of substituents substituted) groups: *-(CH 2 ) I S(0)(CH 2 ) I- , *- (CH 2 ) 2 S(0)(CH 2 ) 2 -, *-(CH 2 ) 2 S(0)(CH 2 ) r , (9) -, *-(CH 2 ) 1 S(0)(CH 2 ) 3- , *- (CH 2 ) !
- Embodiment 41 It relates to the compound of formula (I) or its salt, solvate, isotope enriched analogue, tautomer, polymorph, stereoisomer as described in embodiment 20) , Or a mixture of stereoisomers, where L represents the following optionally substituted (for example, optionally selected from halogen, Ci_ 5 alkyl, methanesulfonyloxy, trifluoromethanesulfonyloxy or p-toluenesulfonyl Oxy or any combination of substituents) group *-(CH 2 ) nl -S(0) 2 -(CH 2 ) n2 -, where * represents the point of connection with the group R; nl and n2 respectively It independently represents an integer of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20.
- L represents the following optionally substituted (for example, optionally selected from halogen, Ci_ 5 alkyl, methanesulfon
- Embodiment 42 It relates to the compound of formula (I) or a salt, solvate, isotope-enriched analog, tautomer, polymorph, or stereo as described in embodiment 20) or 41).
- Embodiment 44 It relates to the compound of formula (I) or its salt, solvate, isotope-enriched analogue, tautomer, polymorph, stereoisomer as described in embodiment 20) , Or a mixture of stereoisomers, where L represents not substituted with a choice (for example, optionally selected from halogen, Ci_ 5 alkyl, methanesulfonyloxy, trifluoromethanesulfonyloxy or p-toluenesulfonyl Oxy or any combination of substituents substituted) group:
- a choice for example, optionally selected from halogen, Ci_ 5 alkyl, methanesulfonyloxy, trifluoromethanesulfonyloxy or p-toluenesulfonyl Oxy or any combination of substituents substituted
- Embodiment 45 It relates to the compound of formula (I) or its salt, solvate, isotope enriched analogue, tautomer, polymorph, stereoisomer as described in embodiment 20) , Or a mixture of stereoisomers, where L represents the following optionally substituted (for example, optionally selected from halogen, Cw alkyl, methanesulfonyloxy, trifluoromethanesulfonyloxy or p-toluenesulfonyloxy Group or any combination of substituents substituted) group:
- Embodiment 46 It relates to the compound of formula (I) or its salt, solvate, isotope-enriched analogue, tautomer, and polymorph as described in any one of embodiments 18) to 45) Form, stereoisomer, or mixture of stereoisomers, where Xi represents C(0)NH 2 , piperidine-1-carbonyl, N,N-diisopropylcarbamoyl, NHC(0)CH 3 , SH, adamantyl-0- (especially adamantane-1-yl-0- or adamantane-2-yl-0-), norbornyl-0-, 1,7,7 -trimethyl Base-bicyclo[2.2.1]heptyl-0- (especially (1 S,2R,4S)-1,7,7 -trimethylbicyclo[2.2.1]heptane-2-yl-0 -) Or OH.
- Xi represents C(0)NH 2 , piperidine-1-carbonyl, N,N-di
- Embodiment 47 It relates to the compound of formula (I) or its salt, solvate, isotope-enriched analogue, tautomer, and polymorph as described in any one of embodiments 18) to 45) Forms, stereoisomers, or mixtures of stereoisomers, where Xi represents cyclohexyl-0- (for example, 2-isopropyl-5-methylcyclohexyl-0-), adamantine-1 -Base-0-, adamantane-2-yl-0-, adamantyl-NHC(O)-, 3,5-dimethyladamantan-1-yl-cis ( : (0)-, adamantane -2-yl-NHC(O)-, or NHC(0)CH 3 .
- Xi represents cyclohexyl-0- (for example, 2-isopropyl-5-methylcyclohexyl-0-), adamantine-1 -Base-0-, adamantane
- Embodiment 48 It relates to the compound of formula (I) or its salt, solvate, isotope-enriched analogue, tautomer, and polymorph as described in any one of embodiments 18) to 45) Forms, stereoisomers, or mixtures of stereoisomers, where ⁇ represents a linear or branched Cwo alkyl group optionally substituted with one or more fluorines.
- Embodiment 49 It relates to the compound of formula (I) or its salt, solvate, isotope-enriched analog, tautomer, polymorph, stereoisomer as described in embodiment 48) ,, Or a mixture of stereoisomers, where it means 0? 2 0? 3 or 0? 3 .
- Embodiment 50 It relates to the compound of formula (I) or its salt, solvate, isotope-enriched analogue, tautomer, and polymorph as described in any one of embodiments 18) to 45) Forms, stereoisomers, or mixtures of stereoisomers, where ⁇ means optionally selected from halogen, cyano, Ci_ 3 alkyl, Ci_ 3 alkoxy, trifluoromethyl, methanesulfonyloxy , Trifluoromethanesulfonyloxy or p-toluenesulfonyloxy or Cw alkyl or any combination of substituents substituted cycloalkyl.
- Embodiment 51 It relates to the compound of formula (I) or its salt, solvate, isotope enriched analogue, tautomer, polymorph, stereoisomer as described in embodiment 50) , Or a mixture of stereoisomers, which represents cyclobutyl, 3,3-difluorocyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, bicyclo[2.2.1]heptane-2-yl or Adamantyl.
- Embodiment 52 It relates to the compound of formula (I) or its salt, solvate, isotope-enriched analogue, tautomer, polymorph, stereoisomer as described in embodiment 50) , Or a mixture of stereoisomers, which represents cyclopropyl, 2,3-dihydro-111-indenyl, or 4-cyano-2,3-dihydro-1H-indenyl.
- Embodiment 53 It relates to the compound of formula (I) or its salt, solvate, isotope enriched analogue, tautomer, polymorph, stereoisomer as described in embodiment 50) , Or a mixture of stereoisomers, wherein it represents adamantyl-1-yl, adamantyl-2-yl, 3,5-dimethyladamantan-1-yl or (1 S, 2R, 4S)-1 ,7,7-Methylbicyclo[2.2.1]heptan-2-yl.
- Embodiment 54 It relates to the compound of formula (I) or its salt, solvate, isotope-enriched analogue, tautomer, and polymorph as described in any one of embodiments 18) to 45) Forms, stereoisomers, or mixtures of stereoisomers, wherein Xi represents a quaternary ammonium salt group of formula N + RJl b R c X, wherein R a , R b , and each independently represent Ci.
- X_ represents F, Cl ⁇ Br_, or 1_; or where R b and the N atom to which they are connected together form a five- to eight-membered heterocyclic group, and the ring atoms of the five- to eight-membered heterocyclic group may Optionally, it further includes a heteroatom selected from oxygen, nitrogen, and sulfur, R c represents a C UQ alkyl group, and X—represents F, Cl—, Br ⁇ or r.
- Embodiment 55 It relates to the compound of formula (I) or its salt, solvate, isotope enriched analogue, tautomer, polymorph, stereoisomer as described in embodiment 54) or a mixture of stereoisomers, wherein R a, R b, R c each independently represent C I-IQ not firing group (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, Base, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, ter-pentyl, hexyl, heptyl, octyl, nonyl, or decyl).
- C I-IQ not firing group e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, Base, sec-buty
- Embodiment 56 It relates to the compound of formula (I) or its salt, solvate, isotope-enriched analogue, tautomer, polymorph, stereoisomer as described in embodiment 54) or a mixture of stereoisomers, wherein R a, Rb each independently represent not methyl, ethyl, propyl, isopropyl or butyl, Rc of the table is not ethyl, and X _ table is not cr.
- Embodiment 57 It relates to the compound of formula (I) or its salt, solvate, isotope-enriched analog, tautomer, polymorph, stereoisomer as described in embodiment 54) or a mixture of stereoisomers, wherein R a, R b, R c each represents an ethyl group, and X represents _ Cr; or wherein R a, R b, R c each represents a methyl group, and X represents _ cr.
- Embodiment 58 It relates to the compound of formula (I) or its salt, solvate, isotope-enriched analogue, tautomer, and polymorph as described in any one of embodiments 18) to 45) Forms, stereoisomers, or mixtures of stereoisomers, where Xi represents a quaternary ammonium salt group of formula N + R a R b R ⁇ X_W, wherein R b and the N atom to which they are connected together form a five-membered to An eight-membered heterocyclic group, wherein the ring atoms of the five- to eight-membered heterocyclic group optionally further include heteroatoms selected from oxygen, nitrogen and sulfur, And X—represents F, cr, Br ⁇ or 1_.
- Embodiment 59 It relates to the compound of formula (I) or its salt, solvate, isotope-enriched analog, tautomer, polymorph, stereoisomer as described in embodiment 58) ,, Or a mixture of stereoisomers, where
- Embodiment 60 It relates to the compound of formula (I) or its salt, solvate, isotope-enriched analogue, tautomer, and polymorph as described in any one of embodiments 18) to 45) Forms, stereoisomers, or mixtures of stereoisomers, where it represents an optional selected from halogen, halogenated Ci_ 3 alkyl, methanesulfonyloxy, trifluoromethanesulfonyloxy, and p-toluenesulfonyl An aryl group substituted with a substituent of an oxy group, a Cw alkyl group, or any combination thereof.
- Embodiment 61 It relates to the compound of formula (I) or a salt, solvate, or isoposition thereof as described in embodiment 58) A prime-enriched analog, tautomer, polymorph, stereoisomer, or mixture of stereoisomers, which represents an optionally substituted phenyl or zeyl group.
- Embodiment 62 It relates to the compound of formula (I) or its salt, solvate, isotope-enriched analogue, tautomer, polymorph, or stereoisomer as described in embodiment 58) , Or a mixture of stereoisomers, which represents phenyl, 4-fluorophenyl, 4-chlorophenyl, 3,5-difluorophenyl, 4-(bromomethyl)-2-fluorophenyl, or 3, 4, 5-Trifluorophenyl.
- Embodiment 63 It relates to the compound of formula (I) or its salt, solvate, isotope-enriched analogue, tautomer, and polymorph as described in any one of embodiments 18) to 45) Type, stereoisomer, or mixture of stereoisomers, which represents an optionally substituted heterocyclic group or an optionally substituted heteroaryl group, wherein the substituent of the optionally substituted heterocyclic group is selected from: Ci_ 6 firing group (e.g.
- Ci_ 3-yl Su, oxo, chloro, amino, light group, Ci_ 3 firing group, on behalf of C l-3 alkoxy firing, firing substituting C l-3-yl ,
- the 5- or 6-membered heteroaryl group, or any combination thereof, and the substituent of the optionally substituted heteroaryl group are selected from: Ci_ 6 alkyl (such as Q_ 3 alkyl), halogen, cyano, amino, Hydroxyl, Ci_ 3 alkoxy, halogenated Ci_ 3 alkoxy, Alkyl;) phosphono, Ci_ 6 alkylsulfonyl, optionally substituted 6-membered aryl, optionally substituted 5- or 6-membered heterocyclic group, or optionally substituted 5- or 6-membered
- Embodiment 64 It relates to the compound of formula (I) or its salt, solvate, isotope-enriched analogue, tautomer, polymorph, stereoisomer, Or a mixture of stereoisomers, wherein the substituent of the optionally substituted 5- or 6-membered heterocyclic group is selected from the group consisting of Cw alkyl (for example, Q_ 3 alkyl), cyano, halogenated Q_ 3 alkyl, and amino , Hydroxy, or halogen or any combination thereof, the substituent of the optionally substituted 6-membered aryl group is selected from Ci_ 6 alkyl (for example, Ci_ 3 alkyl), halogenated Ci_ 3 alkyl, amino, hydroxy, or halogen or any combination thereof, and optionally substituted in the 5 - substituents selected from Q_ 6 alkyl group (e.g. Ci_ 3 alkyl), or 6-membered heteroaryl group, a halogenated Cg alkyl
- Embodiment 65 It relates to the compound of formula (I) or a salt, solvate, isotope-enriched analog, tautomer, polymorph, or stereoisomer as described in embodiment 63) or 64).
- Ci_ 3 alkyl halogen, oxo, cyano, amino, hydroxy, Q_ 3 alkoxy, halo Q_ 3 Alkoxy, Alkyl) phosphono, Ci_ 6 alkylsulfonyl, optionally substituted 6-membered aryl, optionally substituted 5- or 6-membered heterocyclic group, or optionally substituted 5- or 6-membered heteroaryl or Substituted in any combination) piperidinyl, optionally substituted (for example by Q_ 6 alkyl (for example 1-3 firing yl), Su, oxo, chloro, amino, light group, (1-3 ⁇ alkoxy burning, generation (firing ⁇ 1-3 alkoxy, C l-3 alkyl substituting, bis ( Ci_ 6 alkyl) phosphono, Ci_ 6 alkylsulfonyl, optionally substituted 6-membered aryl, optionally substituted 5- or 6-membered heterocyclic group, or optionally substituted 5- or 6-membere
- Ci_ 6 alkyl e.g. Ci_ 3 alkyl
- halogen, oxo, cyano amino, hydroxy, Ci_ 3 alkoxy, halogenated Ci_ 3 alkoxy , Alkyl
- phosphono Ci_ 6 alkylsulfonyl, optionally substituted 6-membered aryl, optionally substituted 5- or 6-membered heterocyclic group, or optionally substituted 5- or 6-membered heteroaryl or Substituted by any combination thereof) 3, 8-diazabicyclo[3.2.1] octane-3-yl, optionally substituted (for example, by Ci_ 6 alkyl (for example, C 1-3 alkyl), prime, oxygen substituents, chloro group, amino group, light group, a C l-3 alkoxy firing, firing substituting C l-3 alkoxy, C l-3 Generation firing group, di (C l-6-yl firing) wins cool group, C 1-6 alkylcarbonyl, optionally substitute
- Ci_ 6 alkyl e.g. Ci_ 3 alkyl
- halogen cyano, amino, hydroxy, Ci_ 3 Alkoxy, halogenated Ci_ 3 alkoxy, Alkyl
- phosphono Ci_ 6 alkylsulfonyl, optionally substituted 6-membered aryl, optionally substituted 5- or 6-membered heterocyclic group, or optionally substituted 5- or 6-membered heteroaryl or Any combination thereof (substituted) pyrrolidinyl, optionally substituted (for example, Ci_ 6 alkyl (e.g., Ci_ 3 alkyl), halogen, chloro, amino, hydroxyl, C 1-3 alkoxy, substituted C 1 firing -3 alkoxy, C l-3 Generation firing group, di (C l-6-yl firing) wins cool group, Q_ 6 alkylsulfonyl group, an optionally substituted 6 membered aryl, optionally substituted 5 - or 6-membered heterocycly
- Embodiment 66 It relates to the compound of formula (I) as described in embodiment 63) or 64) or a salt, solvate, isotope enriched analog, tautomer, polymorph, and stereoisomer A structure, or a mixture of stereoisomers, which represents the following optionally substituted groups: 2-azabicyclo[3.2.1] octyl, 1,4-diazabicyclo[3.2.1] Octyl, tetrahydro-2H-pyranyl, azepanyl, azepanyl, isoindolyl, thiomorpholino, 5-azaspiro[2.4]heptyl, 6 -Azaspiro[2.5]octyl, 2-oxa-7-azaspiro[3.5]nonyl, 3-azabicyclo[3.1.0]hexyl, 3-azabicyclo [4.1.0] Heptyl, 5,7-dihydro-611-pyrrolo [3,4] pyr
- Embodiment 67 It relates to the compound of formula (I) or its salt, solvate, isotope enriched analog, tautomer, polymorph, stereoisomer, Or a mixture of stereoisomers, where Xi represents morpholinyl, piperidinyl, piperazinyl, N-methylpiperazinyl, (N-methylpiperazinyl)piperidinyl, 3,5-dimethyl Piperazinyl, 1,4-diazepan-1-yl, 4-methyl-1,4-diazepan-1-yl, 1-methyl-1,4-diazepine Heptane-1-yl, 8-methyl-3,8-diazabicyclo [3.2.1] octane-3-yl, 5-methyl-2,5-diazabicyclo [2.2.
- Embodiment 68 It relates to the compound of formula (I) as described in embodiment 65) or 66) or its salt, solvate, isotope enriched analogue, tautomer, polymorph, stereoisomer A structure, or a mixture of stereoisomers, where X !
- Embodiment 69 It relates to the compound of formula (I) or its salt, solvate, isotope enriched analogue, tautomer, and polymorph as described in any one of embodiments 18) to 45) Wherein represents an optionally substituted cycloalkyl or an optionally substituted aryl group, wherein the substituent of the optionally substituted cycloalkyl group is selected from : Ci_ 6 alkyl group, halogen, Ci_ 3 alkoxycarbonyl group or any combination thereof, wherein the substituent of the optionally substituted aryl group is selected from the group consisting of: substituted C2_4 alkenyl, halogen or any combination thereof.
- Embodiment 70 It relates to the compound of formula (I) or its salt, solvate, isotope-enriched analogue, tautomer, polymorph, stereoisomer, Or a mixture of stereoisomers, where Xi
- Embodiment 71 It relates to the compound of formula (I) or its salt, solvate, isotope-enriched analogue, tautomer, and polymorph as described in any one of embodiments 18) to 45) Compounds, stereoisomers, or mixtures of stereoisomers, where X: represents NR 6 R 7 , where Re and R 7 each independently represent H or optionally substituted linear or branched Ci_ 1() alkane The condition is that Re and R 7 are not H at the same time.
- Embodiment 72 It relates to the compound of formula (I) or its salt, solvate, isotope-enriched analog, tautomer, polymorph, stereoisomer, Or a mixture of stereoisomers, where Xi represents NHCH 3 , N(CH 3 ) 2 , N(CH 2 CH 3 ) 2 , or N(CH(CH 3 ) 2 ) 2 .
- Embodiment 73 It relates to the compound of formula (I) or its salt, solvate, isotope-enriched analogue, tautomer, and polymorph as described in any one of embodiments 18) to 45) Compounds, stereoisomers, or mixtures of stereoisomers, where X: represents NR 6 R 7 , where Re represents H, and R 7 represents substituted ethyl, where the substituent is 2,6-dichloro- 3-fluorophenyl.
- Embodiment 74 It relates to the compound of formula (I) or its salt, solvate, isotope-enriched analogue, tautomer, polymorph as described in any one of embodiments 18) to 45) Compound, stereoisomer, or mixture of stereoisomers, where represents NR 6 R 7 , wherein R 6 represents H or methyl, and R 7 represents optionally substituted cycloalkyl, optionally A substituted aryl group, an optionally substituted heterocyclic group, or an optionally substituted heteroaryl group, wherein the substituent of the group represented by R 7 is optionally selected from the group consisting of: prime, Ci_ 5 alkyl, di(Ci_ 6 alkyl) saccharyl group, Ci_ 6 alkylcarbayl group, oxo group, optionally substituted 6-membered aryl group, optionally substituted 5- or 6-membered heterocyclic group, optionally substituted 5- or 6-membered Membered heteroaryl group, or cyano
- Embodiment 75 It relates to the compound of formula (I) or its salt, solvate, isotopic enrichment analogue, tautomer, polymorph, stereoisomer, Or a mixture of stereoisomers, where Xi represents NR 6 R 7 , where R 6 represents H or methyl, and R 7 represents pyrimidinyl, pyrrolidinyl (especially pyrrolidin-1-yl), pyridyl, Quinazolinyl, 6, 7-difluoroquinazolin-4-yl, phenyl, 3-chloro-4-methylphenyl, 4-fluorophenyl, 3,5-difluorophenyl, 3, 4, 5 -Trifluorophenyl, 2-(dimethylphosphono)phenyl, 2-(isopropylsulfonyl)phenyl, 4-(pyrimidin-3-yl)pyrimidin-2-yl, indole Dolyl, 1-methyl-1H-in
- Embodiment 76 It relates to the compound of formula (I) or its salt, solvate, isotope enriched analogue, tautomer, polymorph as described in any one of embodiments 18) to 45) Compounds, stereoisomers, or mixtures of stereoisomers, where X: represents NR 6 R 7 , where Re represents H, methyl, ethyl, isopropyl or cyclohexyl, and R 7 represents optional substitution The following groups:
- Embodiment 77 It relates to the compound of formula (I) or its salt, solvate, isotopic enrichment analogue, tautomer, polymorph, stereoisomer, Or a mixture of stereoisomers, where R 7 represents
- Embodiment 78 It relates to the compound of formula (I) or its salt, solvate, isotope-enriched analogue, tautomer, and polymorph as described in any one of embodiments 18) to 45)
- X represents NR 6 R 7 , wherein Re represents H, and R 7 represents a substituted thiazolyl group, wherein the substituent has the structural formula C(0)NHR A group of d , where R d represents a Cw alkyl group or 2-chloro-6-methylphenyl group.
- Embodiment 79 It relates to the compound of formula (I) or its salt, solvate, isotope-enriched analogue, tautomer, and polymorph as described in any one of embodiments 18) to 45) Forms, stereoisomers, or mixtures of stereoisomers, where Xi represents NReR 7 , where Rg represents H, and R 7 represents pyrimidin-4-yl, pyridin-4-yl or quinazolin-4-yl ; Or where 1 represents NR 6 R 7 , where and represents a phenyl group.
- Embodiment 80 It relates to the compound of formula (I) or its salt, solvate, isotope-enriched analogue, tautomer, and polymorph as described in any one of embodiments 18) to 45) Forms, stereoisomers, or mixtures of stereoisomers, where Xi represents Xi represents NHC(0)NR 9 R 1() , where R 9 represents H, and R 1() represents adamantyl, adamantine -1-yl, adamantan-2-yl, 3,5-dimethyladamantan-1-yl, phenyl, or 3-chloro-4-methylphenyl. .
- Embodiment 81 It relates to the compound of formula (I) or its salt, solvate, isotope-enriched analogue, tautomer, and polymorph as described in any one of embodiments 18) to 45) Forms, stereoisomers, or mixtures of stereoisomers, where Xi represents C(0)NH 2 , piperidine-1-carbonyl, N,N-diisopropylcarbamoyl.
- Embodiment 82 It relates to the compound of formula (I) or its salt, solvate, isotope-enriched analogue, tautomer, and polymorph as described in any one of embodiments 18) to 45) Forms, stereoisomers, or mixtures of stereoisomers, where Xi represents OH, adamantyl-0-, norbornyl-0-, or 1,7,7-trimethyl-bicyclo [2.2 .1] Heptyl-0- (for example, (1 S,2R,4S)-1,7,7-trimethyl-bicyclo[2.2.1]heptyl-0-).
- Embodiment 83 It relates to the compound of formula (I) or its salt, solvate, isotope-enriched analogue, tautomer, and polymorph as described in any one of embodiments 18) to 45) Forms, stereoisomers, or mixtures of stereoisomers, which represent optionally substituted (for example, substituted by one or more fluorine) linear or branched Cwo alkyl groups.
- Xi table is not methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl , P-pentyl, hexyl, heptyl, octyl, nonyl, decyl, CF 2 CF 3 or CF 3 .
- Embodiment 84 It relates to the compound of formula (I) or its salt, solvate, isotope-enriched analogue, tautomer, and polymorph as described in any one of embodiments 18) to 45) Form, stereoisomer, or mixture of stereoisomers, where Xi represents NHC(0)R 8 , where Represents a straight-chain or branched C alkyl group, aryl group, heteroaryl group or heterocyclic group. In a sub-embodiment, Xi represents NHC(0)CH 3 .
- Embodiment 85 It relates to the compound of formula (I) or its salt, solvate, isotope-enriched analogue, tautomer, and polymorph as described in any one of embodiments 18) to 45) Form, stereoisomer, or mixture of stereoisomers, where Xi represents NHC(0)NR 9 R 1Q , where and R 1Q each independently represent H, optionally substituted linear or branched Cwo alkane Group, optionally substituted cycloalkyl group, optionally substituted aryl group, optionally substituted heterocyclic group or optionally substituted heteroaryl group, wherein R C ⁇ PR 1Q is optionally not H at the same time.
- Embodiment 86 It relates to the compound of formula (I) or its salt, solvate, isotope-enriched analogue, tautomer as described in any one of embodiments 18) to 45) or 85) , Polymorphs, stereoisomers, or mixtures of stereoisomers, wherein Xi represents NHC(0)NR 9 R IO , wherein R 9 and Rio each independently represent H or the following optionally substituted groups: Methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, ter-pentyl, hexyl, heptyl, octyl Base, nonyl, decyl, phenyl, naphthyl, pyrimidinyl, pyridyl, quinazolinyl, quin
- Embodiment 87 It relates to the compound of formula (I) or its salt, solvate, isotope-enriched analogue, and interconversion as described in any one of the embodiments 18) to 45), 85) or 86) Isomers, polymorphs, stereoisomers, or mixtures of stereoisomers, where Xi represents NHC(O)NR 9 R I0> where R 9 represents H, and R 1Q represents adamantyl, adamantyl -1-yl, adamantan-2-yl, 3,5-dimethyladamantan-1-yl, phenyl, or 3-chloro-4-methylphenyl.
- Embodiment 88 It relates to the compound of formula (I) or its salt, solvate, isotope-enriched analogue, tautomer, and polymorph as described in any one of embodiments 18) to 45) Forms, stereoisomers, or mixtures of stereoisomers, where ⁇ represents an optionally substituted cycloalkyl (for example, (: 3 -(: 12 cycloalkyl or C 3 -C 1Q cycloalkyl)).
- ⁇ represents an optionally substituted cycloalkyl (for example, (: 3 -(: 12 cycloalkyl or C 3 -C 1Q cycloalkyl)).
- the cycloalkyl group is selected from halogen, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, oxo, Ci_ 3 alkyl, and Ci_ 3 alkane. Oxy, cyano, or trifluoromethyl substitution.
- Xi represents cyclobutyl, 3,3-difluorocyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, bicyclo [ 2.2.1] heptane-2 - group or an adamantyl group in a 'sub-described embodiment, the table is not Xi firing adamantan-1-yl, adamantyl firing - 2 - yl, 3, 5 - dimethyladamantane firing - 1-yl or (1 S,2R,4S)-1,7,7-trimethylbicyclo[2.2.1]heptane-2-yl.
- Embodiment 89 It relates to the compound of formula (I) or a salt thereof as described in any one of embodiments 18) to 45), Solvates, isotopically enriched analogs, tautomers, polymorphs, stereoisomers, or mixtures of stereoisomers, where Xi represents an optionally substituted aryl group (for example, 5 to 14 yuan) Aryl) .
- the aryl group optionally substituted with halo, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, or Ci_ 3 alkyl.
- Xi represents phenyl, 4-fluorophenyl, 3,5-difluorophenyl, or 3,4,5-trifluorophenyl.
- Embodiment 90 It relates to the compound of formula (I) or its salt, solvate, isotope-enriched analogue, tautomer, and polymorph as described in any one of embodiments 18) to 45) Forms, stereoisomers, or mixtures of stereoisomers, where represents an optionally substituted heterocyclic group (for example, a 3-membered-12-membered heterocyclic group).
- the heterocyclic group is optionally substituted with a Ci- 6 alkyl group, an oxo group, a di(Ci- 6 alkyl)phosphono group, a Ci- 6 alkylsulfonyl group, an optionally substituted 5- or 6- Member heteroaryl, halogen, methanesulfonyloxy, trifluoromethanesulfonyloxy or p-toluenesulfonyloxy, oxo, Ci_ 3 alkoxy, cyano, trifluoromethyl, optionally substituted Aryl (for example, an optionally substituted 6-membered aryl group, such as phenyl or 4-fluorophenyl), an optionally substituted heterocyclic group (for example, an optionally substituted 5- or 6-membered heterocyclic group, such as piper Azinyl, N-methylpiperazinyl), amino or hydroxyl substitution.
- aryl for example, an optionally substituted 6-membered aryl
- the substituent of the optionally substituted 5- or 6-membered heterocyclic group is selected from C 1-6 alkyl or halogen
- the substituent of the optionally substituted 6-membered aryl group is selected from The C 1-6 alkyl group or element
- the substituent of the optionally substituted 5- or 6-membered heteroaryl group is selected from Ci- 6 alkyl or halogen.
- Xi represents the following optionally substituted heterocyclyl: azetidinyl, oxetanyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, pyridinyl, and triazole Group, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothienyl, tetrahydrothiopyranyl, oxazolidinyl, thiazolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, two Oxanyl, 1,4-diazepan-1-yl, 3,8-diazabicyclo[3.2.1]octane-3-yl or 2,5-diazabicyclo[2.2 .2] Octane-2-yl, wherein the substituent can be selected from: halogen, methanesulfonyloxy,
- Embodiment 91 It relates to the compound of formula (I) or its salt, solvate, isotope-enriched analogue, tautomer, and polymorph as described in any one of embodiments 18) to 45) Forms, stereoisomers, or mixtures of stereoisomers, where Xi represents an optionally substituted heteroaryl group (for example, a 5- to 10-membered heteroaryl group).
- the heteroaryl group is optionally substituted with a Ci- 6 alkyl group, an oxo group, a di(Ci- 6 alkyl)phosphono group, a Ci- 6 alkylsulfonyl group, an optionally substituted 6-membered aryl group , Optionally substituted 5- or 6-membered heterocyclic group, or optionally substituted 5- or 6-membered heteroaryl, halogen, methanesulfonyl Oxy, trifluoromethanesulfonyloxy or p-toluenesulfonyloxy, oxo, Ci_ 3 alkoxy, cyano, or trifluoromethyl substituted.
- the substituent of the optionally substituted 5- or 6-membered heterocyclic group is selected from Ci- 6 alkyl or halogen
- the substituent of the optionally substituted 6-membered aryl group is selected from Ci- 6
- the alkyl group or halogen, and the substituent of the optionally substituted 5- or 6-membered heteroaryl group is selected from Ci- 6 alkyl group or halogen.
- Xi represents an optionally substituted quinazolinyl, an optionally substituted pyridinyl, an optionally substituted pyrimidinyl, an optionally substituted thiazolyl, an optionally substituted quinolinyl, an optionally substituted The indolyl group, the optionally substituted benzothienyl group, or the optionally substituted benzofuranyl group, wherein the substituents are as defined above.
- Xi represents pyridyl, pyrimidinyl, thiazolyl, quinolinyl, 6, 7-difluoroquinazolin-4-yl, 3-cyano-quinolinyl, indolyl, 1 -Methyl-1H-indol-7-yl, benzothienyl, benzofuranyl, quinazolinyl, 6,7-difluoroquinazolin-4-yl, or 4-(pyridine-3- Base) pyrimidine-2-base.
- Embodiment 92 It relates to the compound of formula (I) or its salt, solvate, isotope-enriched analogue, tautomer, and polymorph as described in any one of embodiments 18) to 45) Form, stereoisomer, or mixture of stereoisomers, where Xi represents a group of formula (G0:
- a t represents (: 112 or (:(; 0;);
- the ring atoms,, Vi, Wi are the same, all are CH; or
- Ring atom One of them is N, the others are CH; or
- Ring atom Two of them are N and the rest are CH; or
- Z represents S, S(O) or S(0) 2 .
- Embodiment 93 It relates to the compound of formula (I) or its salt, solvate, isotope-enriched analogue, tautomer as described in any one of embodiments 18) to 45) or 92) , Polymorphs, stereoisomers, or mixtures of stereoisomers, where Xi represents a group of formula (G 2 ): Formula (G 2 )
- Ai represents CH 2 or C(O)
- Yi represents O or S
- Z represents S, S(O) or S(0) 2 .
- Embodiment 94 It relates to the compound of formula (I) or its salt, solvate, isotope-enriched analogue, tautomer as described in any one of embodiments 18) to 45) or 92) , Polymorphs, stereoisomers, or mixtures of stereoisomers, where Xi represents a group of formula (G 3 ):
- a t represents (: 112 or (: (0), Yi represents 0 or S, and Z represents S, S (O) or S (0) 2.
- Embodiment 95 It relates to the compound of formula (I) or its salt, solvate, isotope-enriched analogue, tautomer as described in any one of embodiments 18) to 45) or 92) , Polymorphs, stereoisomers, or mixtures of stereoisomers, where Xi represents a group of formula (G 4 ):
- a ! represents CH 2 or C(O)
- Yi represents 0 or S
- Z represents S, SO) or S(0; h.
- Embodiment 96 It relates to the compound of formula (I) or its salt, solvate, isotope-enriched analogue, tautomer as described in any one of embodiments 18) to 45) or 92) , Polymorphs, stereoisomers, or mixtures of stereoisomers, where Xi represents a group of formula (G 5 ): Formula (G 5 )
- Ai represents ( : 11 2 or ( : (0), Yi represents O or S, and Z represents S, S(O) or S(0) 2 .
- Embodiment 97 It relates to the compound of formula (I) or its salt, solvate, isotope-enriched analogue, tautomer as described in any one of embodiments 18) to 45) or 92) , Polymorphs, stereoisomers, or mixtures of stereoisomers, where Xi represents a group of formula (G 6 ):
- A represents CH 2 or C(O)
- Yi represents 0 or S
- Z represents S, S(O) or S(0) 2 .
- Embodiment 98 It relates to the compound of formula (I) or its salt, solvate, isotope-enriched analogue, tautomer, and polymorph as described in any one of embodiments 92) to 97) the mixture type thereof, a stereoisomer thereof, or a stereoisomer thereof, wherein a t represents (: 112 or (:(; 0), Yi represents 0, and Z represents S.
- the present invention provides an embodiment A1): a compound of formula (I') or a salt, solvate, isotope-enriched analog, tautomer, polymorph, stereoisomer Isomers (including enantiomers), or mixtures of stereoisomers:
- A, B, U, V, W, Y are as defined in any one of the implementation schemes 1)-14);
- R means S, S(O) or S(0) 2;
- L represents an optionally substituted linear or branched alkylene group, wherein the linear or branched alkylene group is optionally interrupted one or more times by one or more groups selected from: 0, C(O), S, S(O), S(0) 2 , S(0) 2 N(R I ), N(R 2 )S(O) 2 , C(0)N(Ri), N (R 2 )C(0), N(R 3 ), N(R 4 )C(0)N(R 5 ), optionally substituted cycloalkylene, optionally substituted arylene, optionally substituted The heterocyclylene, optionally substituted heteroarylene or any combination thereof, wherein Ri, R 2 , R 3 ,
- R 4 and 115 each independently represent H or Ci_ 3 alkyl
- X ! represents NHC O)! ⁇ or SR j , where and each independently represent optionally selected from ( ⁇ _ 6 alkyl, oxo, halogen, cyano, trifluoromethyl, amino , Hydroxy, Ci_ 3 alkoxy, halo Ci_ 3 alkoxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy or cycloalkyl substituted with any combination of substituents, Or Xi means optionally selected from Ci_ 6 alkyl, oxo, halogen, cyano, trifluoromethyl, amino, hydroxy, Ci_ 3 alkoxy, halogenated Ci_ 3 alkoxy, methanesulfonyloxy , Cycloalkyl substituted with trifluoromethanesulfonyloxy, p-toluenesulfonyloxy or any combination thereof; or
- R 6 represents H or Ci_ 6 alkyl
- R 7 represents optionally selected from Ci_ 6 alkyl, oxo, halogen, cyano, trifluoromethyl, amino, hydroxy, Ci_ 3 alkoxy, Cycloalkyl substituted with halogenated Ci_ 3 alkoxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy or any combination thereof; or
- Embodiment A2 It relates to the compound of formula (I') or its salt, solvate, isotope-enriched analogue, tautomer, polymorph, and stereoisomer as described in embodiment A1) Isomers, or mixtures of stereoisomers, where A represents CH 2 or C(O), and B, U, V, and W all represent CH.
- Embodiment A3 It relates to the compound of formula (1') or its salt, solvate, isotope enriched analogue, tautomer, polymorph, and stereoisomer as described in embodiment A1) Isomers, or a mixture of stereoisomers, where L represents an optionally substituted linear or branched C MO alkylene group, wherein the linear or branched C MO alkylene group is optionally substituted by one or more A group selected from the following interrupted one or more times: 0, C(O), S, S(O), S(0) 2 , S(0) 2 N(R I ), N(R 2 )S (0) 2 , C(0)N(R I ), N(R 2 )C(O), N(R 3 ), N(R 4 )C(O)N(R 5 ), optional from halogen, methanesulfonyloxy, trifluoromethanesulfonyloxy, 5 alkyl substituted arylene group or p-toluene
- Embodiment A4 It relates to the compound of formula (1') or its salt, solvate, isotope-enriched analogue, tautomer, polymorph, and stereoisomer as described in embodiment A1) Isomers, or mixtures of stereoisomers, where L represents the following optionally substituted groups: straight or branched CrQo alkylene, *-(CH 2 ) nl -N(R 22 )S(0) 2 -(CH 2 ) n2 -, *-(CH 2 ) nl -S(0) 2 N(R 23 )-(CH 2 ) n2 -, or *- ⁇ ! ⁇ ; ⁇ -phenylene-(CH 2 ) n2 -, where * represents the point of attachment to the group R, R 22 and R 23 are each independently selected from H and Ci_ 3 alkyl, nl, n2 each independently represent 1, 2, 3, 4, 5, 6 , 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20.
- Embodiment A5 It relates to the compound of formula (1') or its salt, solvate, isotope-enriched analogue, tautomer, polymorph, and stereoisomer as described in embodiment A1) Isomers, or a mixture of stereoisomers, where L represents the following optionally substituted group:
- Embodiment A6 It relates to the compound of formula (r) or its salt, solvate, isotope-enriched analogue, tautomer, polymorph, stereoisomer as described in embodiment A1) ,, Or a mixture of stereoisomers, where L represents the following optionally substituted group:
- Embodiment A7) It relates to the compound of formula (r) or its salt, solvate, isotope-enriched analogue, tautomer, polymorph as described in any one of the embodiments A1) to A6) Forms, stereoisomers, or mixtures of stereoisomers, in which:
- X ! represents the following optionally substituted groups:
- Adamantyl-C(0)NH-, adamantyl-S-, or norbornyl group wherein the substituent of the group is selected from Ci- 6 alkyl (for example, C 1-3 alkyl), oxo group, Su, chloro, methyl three gas, amino, light group, C l-3 alkoxy firing, generation of C l _ 3 alkoxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy Sulfonyloxy or any combination thereof.
- Embodiment A8 It relates to the compound of formula (r) or its salt, solvate, isotope-enriched analogue, tautomer, polymorph, stereoisomer as described in embodiment A7) , Or a mixture of stereoisomers, where Xi represents adamantane-1-yl-CCO)NH-, 3-hydroxyadamantyl-CCO)NH-, 3-hydroxyadamantan-1-yl-C(; 0)NH-,
- 3-chloroadamantan-1-yl-C(0)NH- 4-chloroadamantan-1-yl-C(0)NH-, 2-chloroadamantan-1-yl-C(0)NH- , King Kong Alk-2-yl-C(0)NH-, adamantane-1-yl-S-, 3-hydroxyadamantyl-S-, 3-hydroxyadamantan-1-yl-S-, 3-chloroadamantyl Alkyl-1-yl-S-, 4-chloroadamantane-1-yl-S-, 2-chloroadamantane-1-yl-S-, adamantane-2-yl-S-, bicyclic [2.2.
- Embodiment A9 It relates to the compound of formula (r) or its salt, solvate, isotope-enriched analogue, tautomer, and polymorph as described in any one of embodiments A1) to A6) Forms, stereoisomers, or mixtures of stereoisomers, where
- NReRy represents H or ( ⁇ _ 3 alkyl, R 7 represents the following optionally substituted groups:
- Embodiment A10) It relates to the compound of formula (r) or its salt, solvate, isotope-enriched analogue, tautomer, and polymorph as described in any one of embodiments A1) to A6) Types, stereoisomers, or mixtures of stereoisomers, wherein R7 represents ⁇ K adamantan-1-yl, 3-light fund pyrano-1-yl, 3-light fund pyrano-1-yl, 3- Chloroadamant-1-yl, 4-chloroadamantane-1-yl, 2-chloroadamantane-1-yl, adamantane-2-yl, bicyclo[2.2.1]heptane-2-yl, 1 ,7,7-trimethylbicyclo[2.2.1]heptane-2-yl, 7,7-dimethylbicyclo[2.2.1]heptane-1-yl, or 7,7-dimethyl Base-2 -oxobicyclo [2.2.1]
- Embodiment A11 It relates to the compound of formula (r) or its salt, solvate, isotope-enriched analogue, tautomer, and polymorphism as described in any one of embodiments A1) to A6).
- U represents ( ⁇ _ 3 alkyl, represents optionally substituted piperidinyl, wherein the substituted piperazine optionally substituted group given port
- the group is selected from: C 1-6 alkyl (for example, C 1-3 alkyl), element, oxo, chloro, amino, hydroxy, Ci_ 3 alkoxy, halogenated Ci_ 3 alkoxy, halogenated Ci_ 3 alkyl, di(C M alkyl) phosphono, Ci_ 6 alkylsulfonyl or any combination thereof.
- the compounds of formula (I), (la), Ob), (Ic), (Id), and formula (I') of the present invention can have a stereo configuration, and therefore can be different in more than one stereo
- the present invention also relates to compounds having a stereoconfiguration in a substantially pure isomeric form, such as greater than about 90% ee, such as about 95% ee or 97% ee, or greater than 99% ee, and mixtures thereof, including racemic mixtures.
- These isomers can be prepared by conventional methods in the art such as asymmetric synthesis (eg chiral intermediates) or chiral resolution.
- Another aspect of the present invention also provides a pharmaceutical composition, which comprises as an active ingredient the compound of formula (I) or the compound of formula (r) of the present invention, or a pharmaceutically acceptable compound thereof Salts, racemates, enantiomers, diastereomers, solvates or polymorphs, and pharmaceutically acceptable carriers.
- the pharmaceutical composition of the present invention further includes at least one additional drug for treating or preventing cancer or tumor.
- the cancer or tumor includes but is not limited to multiple myeloma, myelodysplastic syndrome (MDS), previously treated myelodysplastic syndrome, plasma cell myeloma, transplantation-related cancer , Myelofibrosis, plasma cell myeloma, bone marrow disease, neutropenia; leukemia, acute myeloid leukemia, anemia, chronic myeloid leukemia, B-cell chronic lymphocytic leukemia, acute myeloid leukemia (AML), CD20 positive ; Primary lymphoma, B-cell lymphoma, recurrent B-cell non-Hodgkin’s lymphoma, recurrent diffuse large B-cell lymphoma, recurrent primary mediastinal (thymus) large B-cell, recurrent transforming non-Hodgkin’s lymphoma Hodgkin's lymphoma, refractory B-cell non-Hodgkin’s lymphoma,
- MDS myel
- the pharmaceutical composition of the present invention containing the active ingredient can be administered according to a suitable route of administration (including but not limited to nasal cavity administration, inhalation administration, topical administration, oral administration, oral mucosal administration, Rectal, pleural, intraperitoneal, vaginal, intramuscular, subcutaneous, transdermal, epidural, intrathecal, and intravenous) are prepared into Suitable preparation forms such as spray preparations, patches, tablets, capsules, dragees, troches, powders, granules, powder injections, or liquid preparations (such as suspensions, solutions, emulsions or syrups).
- a suitable route of administration including but not limited to nasal cavity administration, inhalation administration, topical administration, oral administration, oral mucosal administration, Rectal, pleural, intraperitoneal, vaginal, intramuscular, subcutaneous, transdermal, epidural, intrathecal, and intravenous
- Suitable preparation forms such as spray preparations, patches, tablets, capsules, dragees, tro
- the compound of formula (I) of the present invention or a pharmaceutically acceptable salt, racemate, enantiomer, diastereomer, Solvates or polymorphs, which are used as medicaments.
- the compound of formula (I), or compound of formula (r), or a pharmaceutically acceptable salt, racemate, enantiomer, Diastereomers, solvates or polymorphs which are used to prevent and/or treat cancer or tumors.
- the cancer or tumor includes, but is not limited to, multiple myeloma, myelodysplastic syndrome (MDS), previously treated myelodysplastic syndrome, plasma cell myeloma, transplantation-related cancer, bone marrow fibers Myeloma, plasma cell myeloma, bone marrow disease, neutropenia; leukemia, acute myeloid leukemia, anemia, chronic myeloid leukemia, B-cell chronic lymphocytic leukemia, acute myeloid leukemia (AML), CD20 positive; primary Lymphoma, B-cell lymphoma, recurrent B-cell non-Hodgkin’s lymphoma, recurrent diffuse large B-cell lymphoma, recurrent primary mediastinal (thymus) large B-cell, recurrent transforming non-Hodgkin’s Lymphoma, refractory B-cell non-Hodgkin's lymphoma, refractory diffuse large B-cell
- Another aspect of the present invention provides a compound of formula (I), or a compound of formula (r), or a pharmaceutically acceptable salt, racemate, enantiomer, or non-
- enantiomers, solvates or polymorphs for the preparation of drugs for the prevention and/or treatment of cancer or tumors.
- the cancer or tumor includes, but is not limited to, multiple myeloma, myelodysplastic syndrome (MDS), previously treated myelodysplastic syndrome, plasma cell myeloma, transplantation-related cancer, and bone marrow fibers Myeloma, plasma cell myeloma, bone marrow disease, neutropenia; leukemia, acute myeloid leukemia, anemia, chronic myeloid leukemia, B-cell chronic lymphocytic leukemia, acute myeloid leukemia (AML), CD20 positive; primary Lymphoma, B-cell lymphoma, recurrent B-cell non-Hodgkin’s lymphoma, recurrent diffuse large B-cell lymphoma, recurrent primary mediastinal (thymus) large B-cell, recurrent transforming non-Hodgkin’s lymphoma Lymphoma, refractory B-cell non-Hodgkin's lymphoma, refractory
- Another aspect of the present invention also provides a method for treating or preventing cancer or tumor, which comprises administering to a subject a therapeutically effective amount of the compound of formula (I), or compound of formula (r), or Its pharmaceutically acceptable salts, racemates, enantiomers, diastereomers, solvates or polymorphs, or the pharmaceutical composition of the present invention.
- the cancer or tumor is selected from the group consisting of: multiple myeloma, myelodysplastic syndrome (MDS) , Previous treatment of myelodysplastic syndrome, plasma cell myeloma, transplant-related cancer, myelofibrosis, plasma cell myeloma, bone marrow disease, neutropenia; leukemia, acute myeloid leukemia, anemia, chronic granulocyte Leukemia, B-cell chronic lymphocytic leukemia, acute myeloid leukemia (AML), CD20 positive; primary lymphoma, B-cell lymphoma, recurrent B-cell non-Hodgkin’s lymphoma, recurrent diffuse large B-cell lymphoma Tumors, recurrent primary mediastinal (thymus) large B-cells, recurrent transforming non-Hodgkin’s lymphoma, refractory B-
- MDS myelodysplastic syndrome
- the compound of formula (I), or compound of formula (I'), or a pharmaceutically acceptable salt or external elimination thereof according to the present invention Rotate, enantiomer, diastereomer, solvate or polymorph, or said pharmaceutical composition, by at least one selected from nasal administration, inhalation administration, topical administration, Oral administration, oral mucosal administration, rectal administration, pleural cavity administration, peritoneal administration, vaginal administration, intramuscular administration, subcutaneous administration, percutaneous administration, epidural administration, intrathecal administration Drug and intravenous administration are administered to the subject.
- halogen atom or halogen used alone or in combination refer to fluorine, chlorine, bromine or iodine, and preferably F, C1 or Br.
- alkyl used alone or in combination refers to a straight or branched chain alkyl group.
- C x -C y alkyl or “C xy alkyl” (x and y are each an integer) refers to a straight or branched chain alkyl group containing x to y carbon atoms.
- Cy alkyl used alone or in combination in the present invention refers to a straight or branched chain alkyl group containing 1 to 10 carbon atoms.
- Cwo alkyl group preferably present invention is Ci_ 9 alkyl, more preferably Ci_ 8 alkyl group, further more preferably C 2-8 alkyl, more preferably Cw alkyl group, even more preferably an alkyl group Cw, Cw alkyl , Or ( ⁇ _ 4 alkyl.
- Representative examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, Neopentyl, tertpentyl, hexyl, heptyl, octyl, nonyl and decyl.
- Q_ 3 alkyl in the present invention refers to an alkyl group containing 1 to 3 carbon atoms, and representative examples thereof include Methyl, ethyl, n-propyl and isopropyl.
- the "alkyl” is optionally substituted, and the substituent is preferably one or more selected from halogen, cyano, Ci_ 3 Alkyl group, Ci_ 3 alkoxy group, trifluoromethyl group, heterocyclic group or a combination of substituents.
- alkylene (which is used interchangeably with “alkylene chain”), used alone or in combination, refers to a straight or branched bivalent chain composed of carbon and hydrogen atoms.
- C x -C y alkylene (X and y are each an integer) refers to a linear or branched alkylene group containing x to y carbon atoms.
- the CrC % alkylene group of the present invention is preferably C1-C29 alkylene group, C1-C28 alkylene group, C1-C27 alkylene group, C1-C26 alkylene group, C1-C25 alkylene group, C1-C24 alkylene group group, C1-C23 alkylene firing group, C1-C22 alkylene firing group, C1-C21 alkylene firing group, C1-C20 alkylene firing group, C1-C19 alkylene group firing, Ci_ C l8 firing alkylene group, C l -C l7 alkylene Alkylene group, C l -C l6 alkylene group, C l -C l5 alkylene group, C l -C l
- Representative examples include, but are not limited to, methylene, ethylene, propylene, isopropylidene, butylene, isobutylene, sec-butylene, tert-butylene, pentylene, isopentylene , Neopentylene, terpentylene, hexylene, heptylene, octylene, nonylene, decylene, undecylene, dodecylene, tridecylene, decylene Tetraalkyl, pentadecylene, hexadecylene, heptadecylene, octadecylene, nonadecylene, eicosylene, eicosylene, arachidylene Dialkyl, trichenylene, tetracosene, pentadecylene, hexadecylene, heptadecylene, octadecylene, and 29 Alkyl,
- the "alkylene” is optionally substituted, and the substituent is preferably one or more selected from halogen, cyano, Ci_ 3 alkyl, Ci_ 3 alkoxy, trifluoromethyl , Heterocyclic group or a combination of substituents.
- aryl used alone or in combination refers to an aromatic hydrocarbon group containing 5 to 14 carbon atoms and optionally one or more fused rings, such as phenyl and naphthyl. Or fluorenyl.
- the "aryl group” is an optionally substituted aryl group.
- a substituted aryl group refers to an aryl group substituted 1-3 times by a substituent, wherein the substituent is preferably selected from Ci_ 6 alkyl (for example, Ci_ 3 alkyl), halogenated alkenyl, halogenated Q_ 3 alkoxy, Cyano, Ci_ 3 alkoxy, halogenated Ci_ 3 alkyl (trifluoromethyl), heterocyclic, halogen, amino or hydroxyl.
- arylene used alone or in combination refers to a divalent aromatic hydrocarbon group containing 5 to 14 carbon atoms and optionally one or more fused rings, such as phenylene Group or naphthylene or fluorenylene.
- the "arylene group” is an optionally substituted arylene group.
- a substituted arylene group refers to an arylene group substituted 1-3 times by a substituent, wherein the substituent is selected from the group consisting of ⁇ _ 3 alkyl, halogenated alkenyl, halogenated Q_ 3 alkoxy, cyano, Q_ 3 Alkoxy, halogenated Ci_ 3 alkyl (trifluoromethyl), heterocyclic group, halogen, amino or hydroxyl.
- alkoxy used alone or in combination refers to a linear or branched alkoxy group, the structural formula of which is -O-alkyl.
- the alkyl moiety of the alkyloxy group may contain 1-10 carbon atoms.
- Representative examples of "alkyloxy” include, but are not limited to, methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, pentoxy, 2 -Pentyloxy, isopentyloxy, neopentyloxy, hexyloxy, 2-hexyloxy, 3-hexyloxy, 3-methylpentyloxy, etc.
- Ci_ 3 alkoxy refers to a straight or branched chain alkoxy group containing 1 to 3 carbon atoms.
- Representative examples of Ci_ 3 alkoxy include but are not limited to methoxy, ethoxy, n-propoxy and isopropoxy. Preferably methoxy and Ethoxy.
- cycloalkyl used alone or in combination refers to having 3 to 12 carbon atoms (for example, 3-12, 3-11, 3-10, 3-8, 3-7, 3-6 carbon atoms) saturated and partially unsaturated (that is, having one or more double bonds, but not fully conjugated) monocyclic or bicyclic or polycyclic cyclic hydrocarbon groups.
- C 3 -C 1Q cycloalkyl refers to a saturated and partially unsaturated (that is, one or more double bonds, but not fully conjugated) monocyclic or bicyclic or polycyclic rings with 3 to 10 carbon atoms Cycloalkyl.
- cycloalkyl includes monocyclic, bicyclic, or tricyclic alkyl groups, which have 3 to 12 carbon atoms.
- monocyclic cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, and cyclooctyl.
- Bicyclic and tricyclic cycloalkyls include bridged cycloalkyls, fused rings and spirocycloalkyls, such as but not limited to decalin, octahydrocyclopentadiene, octahydro-1H-indenyl, 2,3-di Hydrogen-111-indenyl, spirocyclic group, adamantyl group, noradamantyl group, norbornyl group (system named bicyclo[2.2.1]heptyl group).
- the "cycloalkyl” is optionally mono- or poly-substituted, for example, but not limited to, 2,2-, 2,3-, 2,4-, 2,5-, Or 2, 6-disubstituted cyclohexyl.
- the substituent of the substituted "cycloalkyl” is preferably one or more selected from halogen, cyano, ⁇ _ 3 alkyl, ⁇ _ 3 alkoxy, halo ⁇ _ 3 alkyl ( For example, trifluoromethyl), amino, hydroxyl, heterocyclic group or any combination of substituents.
- cycloalkylene used alone or in combination means having 3 to 12 carbon atoms (for example, 3-12, 3-11, 3-10, 3-8 , 3-7, 3-6 carbon atoms) saturated and partially unsaturated (that is, with one or more double bonds, but not fully conjugated) monocyclic or bicyclic or polycyclic cyclic hydrocarbon divalent groups.
- C 3 -C 10 cycloalkylene refers to a saturated and partially unsaturated (that is, one or more double bonds, but not fully conjugated) monocyclic or bicyclic or polycyclic ring with 3 to 10 carbon atoms Divalent cyclic hydrocarbon group.
- cycloalkylene includes monocyclic, bicyclic or tricyclic hydrocarbon divalent groups having 3 to 12 carbon atoms.
- Representative examples of monocyclic cycloalkylene include, but are not limited to, cyclopropylene, cyclobutylene, cyclopentylene, cyclopentenylene, cyclohexylene, cyclohexenylene, cycloheptylene, And cyclooctyl.
- Bicyclic and tricyclic cycloalkylene groups include bridged cycloalkylene, fused ringylene, and spirocycloalkylene, such as but not limited to decahydronaphthylene, octahydrocyclopentadienylene, and octahydro-1H -Indenylidene, 2,3-dihydro-111-indenylidene, spirocyclylene, adamantylene, noradamantyl, norbornylene (system named bicyclo[2.2.1] heptane Alkylene).
- the "cycloalkylene” is optionally mono- or poly-substituted, for example, but not limited to, 2,2-, 2,3-, 2,4-, 2,5- , Or 2,6-disubstituted cyclohexyl.
- the substituent of the substituted "cycloalkyl” is preferably one or more selected from halogen, cyano, Ci_ 3 alkyl, Ci_ 3 alkoxy, and halogenated Ci_ 3 alkyl (for example, trifluoromethyl) , Amino, hydroxy, heterocyclic group or any combination of substituents.
- C xy spirocycloalkyl or "C xy spirocyclic group” (x and y are each an integer) used alone or in combination refer to a spiro ring containing x to y carbon atoms alkyl.
- C 7-12 spirocycloalkyl used alone or in combination in the present invention refers to a spirocycloalkyl group containing 7 to 12 carbon atoms.
- C 7-n spirocycloalkyl include, but are not limited to, spiro[3.3]heptyl, spiro[2.5]octyl, spiro[3.5]nonyl, spiro[4.4]nonyl , Spiro [4.5] decane Base or spiro [5.5] Undecyl.
- C 7-12 spirocycloalkyl is optionally further selected from halogen, cyano, Ci_ 3 alkyl, Q_ 3 alkoxy, halogenated Q_ 3 alkyl (such as trifluoromethyl), amino One or more of the substituents of, oxo, hydroxy, heterocyclyl, or any combination thereof.
- heteroaryl used alone or in combination refers to containing one or more (for example, 1 to 6, or 1 to 5, or 1 to 4, or 1 to 3 A) 5- to 10-membered monocyclic or bicyclic aromatic ring groups independently selected from heteroatoms of oxygen, nitrogen and sulfur.
- heteroaryl groups include but are not limited to furyl, oxazolyl, isoxazolyl, oxadiazolyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrrolyl, Imidazolyl, pyrazolyl, triazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, indolyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzothienyl, Indazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzotriazolyl, benzo[2, 1,3] oxa Azolyl, benzo[2, 1,3]thiadiazolyl, benzo[1,2,3]thiadiazolyl, quinolinyl, is
- heteroaryl groups can be unsubstituted or substituted.
- a substituted heteroaryl group refers to a heteroaryl group substituted 1-3 times by a substituent, wherein the substituent is preferably selected from Ci_ 3 alkyl, Ci_ 3 alkoxy, cyano, trifluoromethyl, heterocyclic, Halogen, amino or hydroxyl.
- heteroarylene used alone or in combination means containing one or more (for example, 1 to 6, or 1 to 5, or 1 to 4, or 1 to 3) 5- to 10-membered monocyclic or bicyclic divalent aromatic ring groups independently selected from heteroatoms of oxygen, nitrogen and sulfur.
- heteroarylene groups include, but are not limited to, furanylene, oxazolyl, isoxazolyl, oxadiazolyl, thienylene, thiazolyl, isothiazolyl, Thiadiazole, pyrrolylene, imidazolylidene, pyrazolylidene, triazolylidene, pyridinylene, pyrimidinylene, pyridazinylene, pyrazinylene, indolylene, isoindylene Dole, benzofuranyl, isobenzofuranyl, benzothienylene, indazolylidene, benzimidazolylidene, benzoxazolylidene, benzisoxanyl, phenylene Thiazolyl, benzoisothiazolyl, benzotriazolyl, benzo[2, 1,3] oxadiazolyl, benzol[2, 1,3] thiadiazolyl, phenylene
- the heteroarylene group can be unsubstituted or substituted.
- the substituted heteroarylene group refers to a heteroarylene group substituted 1-3 times by a substituent, wherein the substituent is preferably selected from Q_ 3 alkyl, Q_ 3 alkoxy, cyano, trifluoromethyl, and heterocycle Group, halogen, amino or hydroxyl.
- heterocyclic group or “heterocyclic group” used alone or in combination means containing one or more (for example, containing 1 to 5 or 1 to 4) independently selected from sulfur, 3- to 12-membered monocyclic, bicyclic or tricyclic ring with heteroatoms of oxygen and nitrogen The saturated or partially unsaturated (that is, with one or more double bonds, but not fully conjugated) cyclic hydrocarbon group.
- heterocyclyl may preferably refer to a 3- to 6-membered monocyclic saturated or partially unsaturated ring containing one or more heteroatoms independently selected from sulfur, oxygen, and nitrogen (ie, having one Or multiple double bonds, but not fully conjugated) cyclic hydrocarbon group.
- Representative examples include, but are not limited to, azetidinyl, oxetanyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, pyridinyl, triazolyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyranyl Hydrothienyl, tetrahydrothiopyranyl, oxazolidinyl, thiazolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, dioxanyl, 1,4-diaza Cycloheptane-1-yl, 3,8-diazabicyclo[3.2.1]octane-3-yl, 2,5-diazabicyclo[2.2.2]octane-2-yl, and nitrogen Heterospiro ring group (especially 3-azaspiro [5.5] undecane-3-yl).
- the heterocyclic group may be unsubstituted or substituted as clearly defined, wherein the substituent may preferably be selected from Ci_ 6 alkyl (for example, Ci_ 3 alkyl), Ci_ 3 alkoxy, cyano, and trifluoromethyl , Heterocyclic group, halogen, amino or hydroxyl.
- heterocyclylene used alone or in combination refers to those containing one or more (for example, containing 1 to 5 or 1 to 4) independently selected from sulfur, oxygen and nitrogen Heteroatomic 3- to 12-membered monocyclic, bicyclic or tricyclic saturated or partially unsaturated (ie, having one or more double bonds, but not fully conjugated) cyclic hydrocarbon divalent group.
- heterocyclylene may preferably refer to a 3- to 6-membered monocyclic saturated or partially unsaturated ring containing one or more heteroatoms independently selected from sulfur, oxygen, and nitrogen (ie, having One or more double bonds, but not fully conjugated) A cyclic hydrocarbon divalent group.
- heterocyclylene examples include, but are not limited to, azetidinyl, oxetanylene, pyrrolidinylene, imidazolidinylene, pyrazolidinylene, pyridinylene, Triazolyl, tetrahydrofuranylene, tetrahydropyranyl, tetrahydrothiophenylene, tetrahydrothiopyranyl, oxazolidinylene, thiazolidinylene, piperidinylene, piperazinylene, sub Morpholinyl, thiomorpholinylene, dioxanyl and dioxanyl.
- the heterocyclylene may be unsubstituted or substituted as clearly defined, wherein the substituent may preferably be selected from Ci_ 3 alkyl, Ci_ 3 alkoxy, cyano, trifluoromethyl, heterocyclyl, halogen , Amino or hydroxyl.
- the term "quaternary ammonium salt group" used alone or in combination refers to a quaternary ammonium salt group represented by the formula N + R a R b R ⁇ X_, wherein R a , R b , R c each independently represents an alkyl group, and X_ represents F, Cl ⁇ Br_, or r; or wherein RjP R b and the N atom to which they are connected together form a four- to eight-membered heterocyclic group (especially five- to eight-membered A heterocyclic group, or a five-membered to six-membered heterocyclic group), the ring atoms of the five-membered to eight-membered heterocyclic group may optionally further include a heteroatom selected from oxygen, nitrogen and sulfur, R c represents C MO ⁇ Base, and X—represents F, cr, Br ⁇ or r.
- heterocyclic group in the five- to eight-membered heterocyclic group may be as defined above, and the heteroatom of the heterocyclic group may optionally further include an oxygen atom, a nitrogen atom, and/or a sulfur atom.
- exemplary heterocyclic groups include but are not limited to piperidinyl, morpholinyl, imidazolyl, triazolyl, piperazine
- heterocyclic quaternary ammonium salt groups include but are not limited to
- amantadine has a definition known to those skilled in the art.
- An example of “amantadine” may be adamantan-1-amine (its corresponding English chemical name is adamantan-1-amine or Tricyclo[3.3.1.1 3 ' 7 ]decan-l-amine; CAS: 768-94 -5), has the following structural formula:
- the salt of the compound of formula I, or the salt of the compound of formula (r), or a pharmaceutically acceptable salt thereof refers to a non-toxic inorganic or organic acid and/or Base addition salt.
- examples include: sulfate, hydrochloride, citrate, maleate, sulfonate, citrate, lactate, tartrate, fumarate, phosphate, dihydrophosphate, pyrophosphate Salt, metaphosphate, oxalate, malonate, benzoate, mandelate, succinate, glycolate or p-toluenesulfonate, etc.
- “Pharmaceutically acceptable carrier” refers to pharmaceutically acceptable materials, such as fillers, stabilizers, dispersants, suspending agents, diluents, excipients, thickeners, solvents or encapsulating materials,
- the compound useful in the present invention is carried or transported into the patient's body or administered to the patient so that it can perform its intended function. Typically, such constructs are carried or transported from one organ or part of the body to another organ or part of the body.
- the carrier is compatible with the other ingredients of the formulation (including the compound useful in the present invention) and is not harmful to the patient, and the carrier must be "acceptable.”
- pharmaceutically acceptable carrier materials include: sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose And cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository wax; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil ; Glycols, such as propylene glycol; Polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; Esters, such as ethyl oleate and ethyl laurate; Agar; Buffers, such as
- treatment refers to the administration of a compound of formula I, or a compound of formula (r), or a pharmaceutically acceptable salt thereof according to the present invention to a subject, or contains formula I as an active ingredient
- the beneficial or expected clinical results of the present invention include, but are not limited to: alleviation of symptoms, alleviation of disease severity, stabilization of disease state, delay or delay of disease progression, improvement or alleviation of disease, and alleviation of disease.
- the "therapeutically effective amount" of the compound of the present invention depends on the age, sex, and weight of the patient, the patient's current medical condition, and the cancer progression of the patient being treated. Those skilled in the art can determine the appropriate dosage based on these and other factors.
- room temperature in the present invention refers to the ambient temperature, such as a temperature of 20-30°C.
- Umemoto test unit Ll 2, 8 -difluoro-5-(trifluoromethyl)-5H-dibenzo[B,D]thiophene-5 -piper trifluoromethanesulfonate [00170]
- target compound sulfur group substituted pomalidomide alkyl carbon chain carboxylic acid series compound
- reaction solution was cooled to room temperature, and 3-(4-amino-1-oxoisoindoline-2-yl)piperidine-2,6-dione (namely lenalidomide) (8.0 g, 30.9 mmol), and finally, tert-butyl nitrite (4.78 g, 46.4 mmol) is slowly added dropwise, after the dropping, the temperature is raised to 80 ° C again and stirred for 8h. After the reaction, the reaction solution was cooled to room temperature, water (200 mL) was added, and ethyl acetate was extracted (2 x 200 mL).
- the eluent (v/v): acetonitrile/(water+0.05% TFA) 10% -100%, to obtain the corresponding tert-butanol ester intermediate product;
- the corresponding tert-butanol ester intermediate product was added to a 10 mL egg-shaped flask, 88% formic acid (3 mL) was added, and the mixture was stirred at room temperature for 12 h.
- the reaction solvent was evaporated under reduced pressure, and water was added to freeze-dry to obtain the corresponding target compound.
- step 1 The Boc-protected alkylation intermediate product obtained in step 1 was added to a 10 mL reaction flask, followed by anhydrous methylene chloride (2 mL) and trifluoroacetic acid (2 mL), and stirred at room temperature for 12 h.
- the reaction solvent was evaporated under reduced pressure, and the crude product was separated by a reversed-phase C18 column.
- the eluent (v/v): acetonitrile/(water+0.05% TFA) 10% -100%.
- the solvent was evaporated under reduced pressure and lyophilized to obtain the corresponding Target compound.
- reaction was quenched with saturated sodium bicarbonate, extracted with DCM, dried over anhydrous sodium sulfate and concentrated to obtain a colorless oil, added 2 mL of acetonitrile, separated on a C18 reverse phase column, eluent: 10%-100% (vl: v2 ) Acetonitrile: water, remove the solvent under reduced pressure to obtain the sulfoxide and sulfone target compounds.
- NHR 4 R 5 represents a linear or branched secondary or primary alkyl amine or a nitrogen-containing heterocyclic substrate.
- n can be an integer in the range of 1-20.
- Example 1 Preparation of 3-(4-(benzylthio)-1-oxoisoindoline-2-yl)piperidine-2,6-dione (SIAIS171088)
- the compound SIAIS 171 132 was prepared under appropriate conditions understandable in the art, except that the brominated substrate used was tert-butyl (5-bromopentyl) carbamate.
- the target compound SIAIS171 132 (light yellow solid, 95 mg, total yield of two steps 73%) was obtained.
- the compound SIAIS 171 136 is prepared under appropriate conditions understandable in the art, except that the brominated substrate used is tert-butyl (8-bromooctyl) carbamate.
- the target compound SIAIS171 136 (white solid, 100 mg, total yield of two steps 68%) was obtained.
- the compound SIAIS1210073 was prepared under appropriate conditions understandable in the art, except that the halogenated substrate used was methyl iodide.
- the target compound SIAIS 1210073 (yellow solid, 58 mg, yield 55%) was obtained.
- the compound SIAIS1210071 was prepared under appropriate conditions understandable in the art, except that the halogenated substrate used was methyl iodide.
- the target compound SIAIS 1210071 (white solid, 134 mg, yield 64%) was obtained.
- the compound SIAIS1213073 was prepared under appropriate conditions understandable in the art, except that the halogenated substrate used was bromoethane.
- the target compound SIAIS 1213073 (orange solid, 15 mg, yield 45%) was obtained.
- ⁇ NMR (500 MHz, DMSO) 5 10.99 1.0 Hz, 1H), T59-T50 (m, 2H), 5.12 13.3, 5.1 Hz, 1H), 4.36 (d, J 17.3 Hz, 1H), 4.22 (d, 17.4
- the compound SIAIS1213071 was prepared under appropriate conditions understandable in the art, except that the halogenated substrate used was 1-bromopropane.
- the target compound SIAIS1213071 (light yellow solid, 15 mg, yield 43%).
- the compound SIAIS1213075 was prepared under appropriate conditions understandable in the art, except that the halogenated substrate used was 2-bromopropane.
- the target compound SIAIS1213075 (light yellow solid, 12 mg, yield 34%) was obtained.
- Example 7 Preparation of 3-(1-oxo-4-(pentylthio)isoindoline-2-yl)piperidine-2,6-dior (SIAIS1213195)
- the compound SIAIS1213195 was prepared under appropriate conditions understandable in the art, except that the halogenated substrate used was 1-bromopentane.
- the target compound SIAIS1213195 (light yellow solid, 29 mg, yield 76%) was obtained.
- Example 8 Preparation of 3-(1-oxo-4-(pentylthio)isoindoline-2-yl)piperidine-2,6-dione (SIAIS1216025)
- the compound SIAIS1216025 was prepared under appropriate conditions understandable in the art, except that the halogenated substrate used was 1-bromooctane.
- the target compound SIAIS 1216025 (white solid, 22.4 mg, yield 58%) was obtained.
- the compound SIAIS1216189 was prepared under appropriate conditions understandable in the art, except that the halogenated substrate used was 3-bromo-1-propanol.
- the target compound SIAIS1216189 (light yellow solid, 20 mg, yield 60%) was obtained.
- the compound SIAIS 1220069 was prepared under appropriate conditions understandable in the art, except that the halogenated substrate used was 5-bromo-1-pentanol.
- the target compound SIAIS1220069 (white solid, 16 mg, yield 44%) was obtained.
- the compound SIAIS264006 was prepared according to the method of Scheme 9 under appropriate conditions understandable in the art, except that the halogenated substrate used was 8-bromo-1-octanol.
- the target compound SIAIS264006 (white solid, 40 mg, yield 55%) was obtained.
- the compound SIAIS1213145 was prepared according to the method of Scheme 9 under appropriate conditions understandable in the art, and The same is that the halogenated substrate used is 2-iodoacetamide.
- the target compound SIAIS1213145 (white solid, 14
- the compound SIAIS1216133 was prepared under appropriate conditions understandable in the art, except that the halogenated substrate used was 1,6-dibromohexane.
- the target compound SIAIS1216133 (white solid, 339 mg, yield 38%) was obtained.
- the compound SIAIS1216135 was prepared under appropriate conditions understandable in the art, except that the halogenated substrate used was 1,7-dibromoheptane.
- the compound SIAIS1216137 was prepared under appropriate conditions understandable in the art, except that the halogenated substrate used was 1,8-dibromooctane.
- the target compound SIAIS1216137 (white solid, 351 mg, yield 38%) was obtained.
- the compound SIAIS 1220013 was prepared under appropriate conditions understandable in the art, except that the halogenated substrate used was 1,10-dibromodecane.
- the target compound SIAIS1220013 was obtained (light yellow solid, 329 mg, yield 33%) o ! H NMR (500 MHz, DMSO) 5 11.01 7.5 Hz,
- Example 13 Preparation of 3-(4-(methylsulfonyl)-1-oxoisoindoline-2-yl)piperidine-2,6-dione (SIAIS1210083)
- Example 14 3-(4-((5-morpholinopentyl)thio)-1-oxoisoindoline-2-yl)piperidine-2,6-dione( SIAIS1216061)
- the compound SIAIS1216061 was prepared under appropriate conditions understandable in the art, except that the substrate used was 3-(4-((5-bromopentyl)thio)-1 - oxo-isopropyl [1 primer noise Lin 2-yl) -2,6-piperidine steep pay (SIAIS1216049) and morpholine.
- the hydrochloride of the target compound SIAIS 1216061 was obtained (light yellow solid, 7.3 mg, yield 34%) o i fi NMR (500 MHz, DMSO) 5 11.02 (s, 1H), 10.44 7.0 Hz, 1H),
- Example 15 3- (1-oxo- 4 -(( 5- (piperazin-1-yl)pentyl)thio)isoindoline- 2 -yl)piperidine- 2 , 6 -Diketone (SIAIS1216063)
- compound SIAIS 1216063 was prepared under appropriate conditions understandable in the art, except that the substrate used for rice was 3-(4-((5-bromopentyl)thio)- 1-oxo-isopropyl [1 primer noise Lin 2-yl) -2,6-piperidine steep pay (SIAIS 1216049) and piperazine. Obtain the target compound SIAIS1216063 hydrochloride (light yellow solid, 12 mg, yield 56%) o !
- Example 16 3-(4-((5-(methylamino)pentyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (SIAIS1216141)
- compound SIAIS1216141 was prepared under appropriate conditions understandable in the art, except that the substrate used for rice was 3-(4-((5-bromopentyl)thio)-1 - oxo-isopropyl [1 primer noise Lin 2-yl) -2,6-piperidine steep pay (SIAIS1216049) and methylamine hydrochloride.
- the hydrochloride (white solid, 5 mg, yield 13%) of the target compound SIAIS1216141 was obtained.
- Example 17 3-( 4 -(( 5 -(( 2- (diethylamino)ethyl)amino)pentyl)sulfanyl)-1-oxoisoindole- 2 _ Base) piperidine-2,6-dione (SIAIS1220035)
- the compound SIAIS 1220035 was prepared under appropriate conditions understandable in the art, except that the substrate used was 3-(4-((5-bromopentyl)thio)- 1-oxo-isopropyl [1 primer noise Lin 2-yl) -2,6-piperidine steep pay (SIAIS1216049) and N1, N1- diethyl-ethane-1,2 - diamine.
- the target compound SIAIS 1220035 was obtained as a hydrochloride (white solid, 20 mg, yield 43%).
- Example 18 3-( 4 -(( 6 -morpholinohexyl)sulfanyl)-1-oxoisoindoline- 2 -yl)piperidine- 2 , 6 -dione ( SIAIS1220027)
- the compound SIAIS 1220027 was prepared according to the method of Scheme 11 under appropriate conditions understood in the art, except that the substrate used was 3-(4-((6-bromohexyl)thio)-1- oxo-isopropyl [1 primer noise Lin 2-yl) -2,6-piperidine steep pay (SIAIS1216133) and morpholine.
- the hydrochloride (white solid, 17 mg, yield 39%) of the target compound SIAIS1220027 was obtained.
- Example 19 3-(4-((7-morpholinoheptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (SIAIS1220031 )
- the compound SIAIS 1220031 was prepared under appropriate conditions understandable in the art, except that the substrate used was 3-(4-((7-bromoheptyl)thio)- 1-oxo-isopropyl [1 primer noise Lin 2-yl) -2,6-piperidine steep pay (SIAIS1216135) and morpholine.
- Example 20 3-(4-((8-morpholinooctyl)thio)-1-oxoisoindoline-2-yl)piperidine-2,6-dione( SIAIS1216143)
- the compound SIAIS1216143 was prepared under appropriate conditions understandable in the art, except that the substrate used was 3-(4-((8-bromooctyl)thio)-1 - oxo-isopropyl [1 primer noise Lin 2-yl) -2,6-piperidine steep pay (SIAIS1216137) and morpholine.
- the target compound SIAIS1216143 hydrochloride (light yellow solid, 16 mg, yield 68%) was obtained.
- Example 21 3- (l-oxo- 4 -(( 8 _(piperazin-1-yl)octyltonyl)isoindoline- 2 -yl)piperidine- 2 , 6- Dione (SIAIS1216145)
- the compound SIAIS1216145 was prepared under appropriate conditions understandable in the art, except that the substrate used was 3-(4-((8-bromooctyl)thio)-1 -Oxoiso [ 1innoline-2-yl)piperidine-2,6-dione (SIAIS1216137) and piperazine.
- Example 22 3-(4-((8-(3,5-dimethylpiperazin-1-yl)octyl)sulfanyl)-1-oxoisoindoline-2-yl )Piperidine-2,6-dione (SIAIS1220057)
- compound SIAIS1220057 was prepared under appropriate conditions understandable in the art, except that the substrate used for rice was 3-(4-((8-bromooctyl)thio)-1 - oxo-isopropyl [1 primer noise Lin 2-yl) -2,6-piperidine steep pay (SIAIS 1216137) and 2, 6 - dimethyl piperazine.
- the substrate used for rice was 3-(4-((8-bromooctyl)thio)-1 - oxo-isopropyl [1 primer noise Lin 2-yl) -2,6-piperidine steep pay (SIAIS 1216137) and 2, 6 - dimethyl piperazine.
- Obtain the target compound SIAIS 1220057 hydrochloride (white solid, 30 mg, yield 60%) o !
- Example 23 3-(1-oxo-4-((8-(piperidin-1-yl)octylonyl)isoridolin-2-yl)piperidine-2, 6- Dione (SIAIS1220009)
- compound SIAIS 1220009 was prepared under appropriate conditions understandable in the art, except that the substrate used for rice was 3-(4-((8-bromooctyl)thio)- 1-oxo-isopropyl [1 primer noise Lin 2-yl) -2,6-piperidine steep pay (SIAIS1216137) and piperidine.
- the target compound SIAIS1220009 hydrochloride (white solid, 38 mg, yield 81%) was obtained. 4 NMR (500 MHz, DMSO) 5 11.71 (s, 1H), 11.02 (s, 1H), 7.63 (d, 7.4 Hz, 1H),
- Example 24 3-(4-((8-(4,4-difluoropiperidin-1-yl)octyl)thio)-1-oxoisoindoline-2-yl) Piperidine-2,6-dione (SIAIS1220055)
- the compound SIAIS 1220055 was prepared under appropriate conditions understandable in the art, except that the substrate used was 3-(4-((8-bromooctyl)thio)- 1-oxoiso [ 1innoline-2-yl)piperidine-2,6-dione (SIAIS 1216137) and 4,4-dihaloperidine.
- the target compound SIAIS 1220055 hydrochloride (white solid, 12 mg, yield 40%) was obtained.
- Example 25 3-(4-((8-(l,4-diazepan-1-yl)octyl)thio)-1-oxoisoindoline-2- Base) piperidine-2,6-dione (SIAIS1220017)
- compound SIAIS 1220017 was prepared under appropriate conditions understandable in the art, except that the substrate used was 3-(4-((8-bromooctyl)thio)- 1-oxo-isopropyl [1 primer noise Lin 2-yl) -2,6-piperidine steep pay (SIAIS1216137) and homopiperazine.
- the target compound SIAIS 1220017 was obtained as a hydrochloride (white solid, 33 mg, yield 67%).
- the compound SIAIS 1220019 was prepared under appropriate conditions understandable in the art, except that the substrate used was 3-(4-((8-bromooctyl)thio)- 1-oxo-isopropyl [1 primer noise Lin 2-yl) -2,6-piperidine steep pay (SIAIS1216137) and 1- (piperidin--4-- yl) piperazine.
- the target compound SIAIS 1220019 hydrochloride (white solid, 39 mg, yield 70%) was obtained.
- Example 27 3-(4-((8-(methylamino)octyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (SIAIS1216151)
- SIAIS1216151 3-(4-((8-(methylamino)octyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
- Example 28 3-(4-((8-((2-(Diethylamino)ethyl)amino)octyl)sulfanyl)-1-oxoisoindole-2-yl ) Piperidine-2,6-dione (SIAIS1220037)
- compound SIAIS 1220037 was prepared under appropriate conditions understandable in the art, except that the substrate used for rice was 3-(4-((8-bromooctyl)thio)- 1-oxo-isopropyl [1 primer noise Lin 2-yl) -2,6-piperidine steep pay (SIAIS 1216137) and N1, N1- diethyl-ethane-1,2 - diamine.
- the target compound SIAIS 1220037 hydrochloride (white solid, 16 mg, yield 36%) was obtained.
- Example 29 3-(4-((8-(4-methylpiperazin-1-yl)octyl)thio)-1-oxoisoindolin-2-yl)piperidine -2,6-dione (SIAIS1220011)
- the compound SIAIS 1220011 was prepared under appropriate conditions understandable in the art, except that the substrate used was 3-(4-((8-bromooctyl)thio)- 1-oxo-isopropyl [1 primer noise Lin 2-yl) -2,6-piperidine steep pay (SIAIS 1216137) and 1-methylpiperazine.
- the hydrochloride (white solid, 12 mg, yield 80%) of the target compound SIAIS 1220011 was obtained.
- compound SIAIS 1220065 was prepared under appropriate conditions understandable in the art, except that the substrate used was 3-(4-((9-bromononyl)thio)- 1-oxo-isopropyl [1 primer noise Lin 2-yl) -2,6-piperidine steep pay (SIAIS 1220059) and morpholine.
- the target compound SIAIS 1220065 hydrochloride (white solid, 7 mg, yield 17%) was obtained.
- Example 31 3- (4 - ((10- morpholino-decyl) thio) -1-oxo-isoindoline _ _ 2-yl) piperidine _ 2, 6 - dione ( SIAIS1220023)
- compound SIAIS 1220023 was prepared under appropriate conditions understandable in the art, except that the substrate used for rice was 3-(4-((10-bromodecyl)thio)- 1-oxo-isopropyl [1 primer noise Lin 2-yl) -2,6-piperidine steep pay (SIAIS 1220013) and morpholine.
- the target compound SIAIS 1220023 was obtained as a hydrochloride (light yellow solid, 24 mg, yield 60%).
- Example 32 3-(4-((11-morpholinoundecyl)sulfanyl)-1-oxoisoindolin-2-yl)piperaz-2,6-dione (SIAIS1220045)
- the compound SIAIS 1220045 was prepared under appropriate conditions understandable in the art. The difference is that the substrate used for ten meters is 3-(4-((11-bromoundecyl)sulfur Base) -1-oxoisoB-innosing Lin-2-yl) piperidine-2, 6-di unitary (SIAIS1220015) and morpholine.
- the target compound SIAIS 1220045 hydrochloride (white solid, 35 mg, yield 85%) was obtained. o !
- Example 33 3-(4-((5-(Diethylamino)pentyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-di Ketone (SIAIS1216139)
- the compound SIAIS1216139 was prepared under appropriate conditions understandable in the art, except that the substrate used was 3-(4-((5-bromopentyl)thio)-1 - oxo-isopropyl [1 primer noise Lin 2-yl) -2,6-piperidine steep pay (SIAIS 1216049).
- the target compound SIAIS1216139 was obtained as a hydrochloride (light yellow solid, 21 mg, yield 71%). !
- Example 34 3-(4-((6-(Diethylamino)hexyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dior (SIAIS1220029)
- compound SIAIS1220029 was prepared under appropriate conditions understandable in the art, except that the substrate used was 3-(4-((6-bromohexyl)thio)-1- oxo-isopropyl [1 primer noise Lin 2-yl) -2,6-piperidine steep pay (SIAIS1216133).
- the target compound SIAIS 1220029 hydrochloride (white solid, 23 mg, yield 53%) was obtained.
- Example 35 3-(4-((7-(Diethylamino)heptyl)sulfanyl)-1-oxoisoindolin-2-yl)piperidin-2,6-di Ketone (SIAIS1220033)
- the compound SIAIS 1220033 was prepared under appropriate conditions understood in the art, the difference is that the substrate used is 3-(4-((7-bromoheptyl)thio)-1 - oxo-isopropyl [1 primer noise Lin 2-yl) -2,6-piperidine steep pay (SIAIS1216135).
- the target compound SIAIS 1220033 hydrochloride (white solid, 18 mg, yield 40%) was obtained.
- Example 36 3-(4-((8-(Diethylamino)octyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-di Ketone (SIAIS1216147)
- compound SIAIS1216147 was prepared under appropriate conditions understandable in the art, except that the substrate used for rice was 3-(4-((8-bromooctyl)thio)-1 - oxo-isopropyl [1 primer noise Lin 2-yl) -2,6-piperidine steep pay (SIAIS1216137).
- the target compound SIAIS1216147 was obtained as a hydrochloride (white solid, 16 mg, yield 70%).
- Example 37 3-(4-((9-(Diethylamino)nonyl)sulfanyl)-1-oxoisoindolin-2-yl)piperidine-2,6-di Ketone (SIAIS1220067)
- the compound SIAIS1220067 was prepared under appropriate conditions understandable in the art, except that the substrate used was 3-(4-((9-bromononyl)thio)-1 - oxo-isopropyl [1 primer noise Lin 2-yl) -2,6-piperidine steep pay (SIAIS 1220059).
- the target compound SIAIS 1220067 hydrochloride (white solid, 19 mg, yield 79%) was obtained.
- Example 38 3-(4-((10-(Diethylamino)decyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-di Ketone (SIAIS1220025)
- the compound SIAIS1220025 was prepared under appropriate conditions understandable in the art. The difference is that the substrate used is 3-(; 4-(; (; 10-bromodecyl)sulfanyl )-1-oxoisoindolin-2-yl)piperidine-2,6-dione (SIAIS1220013).
- the target compound SIAIS 1220025 was obtained as the hydrochloride (light yellow solid, 23 mg, yield 59%).
- Example 3 9 3 - (4 _ ((ll- ( diethylamino) undec embankment yl) thio) -1-oxo-isoindoline _ _ 2-yl) piperidine _ 2, 6 -Dione (SIAIS1220047)
- Example 40 3-(4-((5-(dimethylamino)pentyl)sulfanyl)-1-oxoisoindolin-2-yl)piperidine-2,6-di Ketone (SIAIS1216089)
- the compound SIAIS1216089 was prepared under appropriate conditions understandable in the art, except that the substrate used was 3-(4-((5-aminopentyl)thio)-1 - oxo-isopropyl [1 primer noise Lin 2-yl) -2,6-piperidine steep pay (SIAIS171132).
- the target compound SIAIS1216089 hydrochloride (light yellow solid, 7 mg, yield 54%) was obtained. !
- Example 41 3-(4-((8-(dimethylamino)octyl)sulfanyl)-1-oxoisoindolin-2-yl)piperidine-2,6-two Ketone (SIAIS1216149)
- the compound SIAIS1216149 was prepared under appropriate conditions understandable in the art. The difference is that the substrate used is 3-(; 4-(; (; 8-aminooctyl) thiol. )-1-oxoisoindolin-2-yl)piperidine-2,6-dione (SIAIS171136).
- the target compound SIAIS1216149 hydrochloride (white solid, 14 mg, yield 63%) was obtained. !
- Example 42 3-(4-((8-(4-methyl-1,4-diazepan-1-yl)octyl)thio)-1-oxoisoindyl Dolin-2-yl)piperidine-2,6-dione (SIAIS1220051)
- the compound SIAIS1220051 was prepared under appropriate conditions understandable in the art, except that the substrate used was 3-(4-((8-(1,4-diaza heterocycle Heptan-1-yl)octyl)thio)-1-oxoisoindoline-2-yl)piperidine-2,6-dione (SIAIS 1220017).
- the target compound SIAIS 1220051 hydrochloride (white solid, 12 mg, yield 62%) was obtained.
- Example 43 3-(4-((8-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)octyl)crane)-1-oxoisoindyl Dolin-2-yl)piperidine-2,6-dione (SIAIS1220049)
- the compound SIAIS1220049 was prepared under appropriate conditions understandable in the art, except that the substrate used was 3-(1-oxo- 4 -(( 8- ( 4- (piperidine) (Azin-1-yl)piperidin-1-yl)octyl)thio)isoindoline- 2 -yl)piperidine-2,6-dione (SIAIS 1220019).
- the target compound SIAIS 1220049 hydrochloride (white solid, 5 mg, yield 63%) was obtained.
- the compound SIAIS 1227123 was prepared according to the method of Scheme 9 under appropriate conditions understandable in the art. The same is that the used generation substrate is 1,3-bis(bromomethyl)benzene.
- the target compound SIAIS 1227123 (light yellow oil, 357 mg, yield 39%) was obtained.
- Example 44 Preparation of 3-(4-(tert-butylsulfanyl)-1-oxoisoindoline-2-yl)piperidine-2,6-dione (SIAIS1213167)
- Example 46 Preparation of N-(5-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindoline-4-yl)thio)pentan Base) acetamide
- Example 48 Preparation of 3,3'-((octane-1,8-bis*bis(thiodiyl))bis(1-oxoisoindoline-4,2-bis*)) Di(piperidine-2,6-dione) (SIAIS1216137B)
- the compound SIAIS1216137B was prepared under appropriate conditions understandable in the art, except that the halogenated substrate used was 1,8-dibromooctane.
- the target compound SIAIS1216137B (white solid, 10 mg, yield 12%) was obtained.
- Example 49 Preparation of 3,3'-((Nonyl-1,9-diylbis(thiodiyl))bis(1-oxoisoindoline-4,2-diyl)) Di(piperidine-2,6-dione) (SIAIS1220059B)
- the compound SIAIS1220059B was prepared according to the method of Scheme 9 under appropriate conditions understandable in the art, except that the halogenated substrate used was 1,9-dibromononane.
- the target compound SIAIS1220059B (white solid, 12 mg, yield 13%) was obtained.
- Step 1 Preparation of 3-(5-(benzylthio)-1-oxoisoindoline-2-yl)piperidine-2,6-dione (SIAIS1213173)
- Step 2 Preparation of 3-(5-mercapto-1-oxoisoindoline-2-yl)piperidine-2,6-dione (SIAIS1213175)
- the compound SIAIS1213111 was prepared according to the method of Scheme 9 and under appropriate conditions understandable in the art, except that the substrate used was 3-(5-mercapto-1-oxoisoindoline- 2-yl)piperazine-2,6-dione (SIAIS1213175) and methyl iodide.
- the target compound SIAIS1213111 (gray solid, 7 mg, yield 12%) was obtained.
- the compound SIAIS1213163 was prepared with reference to the method of Example 49, except that the substrate used was 3-(5-bromo-1-oxoisoindolin-2-yl)piperidine-2,6-di Ketones and tert-butyl mercaptan.
- the target compound SIAIS1213163 (yellow solid, 19 mg, yield 56%) was obtained.
- the compound SIAIS1220141 was prepared under appropriate conditions understandable in the art, with the difference that the substituted substrate used was 1,4-bis(bromomethyl)benzene.
- Example 5 4 Preparation of 3-( 4 -(( 4- (morpholinomethyl)benzyl)thio)-1-oxoisoindoline- 2 -yl)piperidine- 2 , 6 -Dione (SIAIS1220167)
- the compound SIAIS1220167 was prepared under appropriate conditions understandable in the art, except that the substrate used was 3-(4-((4-(bromomethyl)benzyl) Sulfuryl)-1-oxoisoH-innoline-2-yl)piperazin-2,6-dione (SIAIS1220141) and morpholine.
- the compound SIAIS1220165 was prepared under appropriate conditions understandable in the art, except that the substrate used was 3-(4-((4-(bromomethyl)benzyl)sulfur Base)-1-oxoisoH-innoline-2-yl)piperazin-2,6-dione (SIAIS1220141) and piperidine.
- the hydrochloride (white solid, 12 mg, yield 52%) of the target compound SIAIS1220165 was obtained.
- Example 56 Preparation of 3-(1-oxo-4-((7-(pyrrolidin-1-yl)heptyl)sulfanyl-indolin-2-yl)piperidine-2,6 -Er (SIAIS1220161)
- the compound SIAIS1220161 was prepared under appropriate conditions understandable in the art, except that the substrate used was 3-(4-((7-bromoheptyl)thio) -1 -OxoisoH-innoline-2-yl)piperidine-2,6-dione (SIAIS1216135) and tetrahydropyrrole.
- the hydrochloride of the target compound SIAIS1220161 pale yellow solid, 14 mg, yield 45% was obtained.
- Example 57 Preparation of 3-(1-oxo-4-((7-(piperidin-1-yl)heptyl)thio)isoindolin-2-yl)piperidine-2, 6-diketone (SIAIS1220105)
- compound SIAIS1220105 was prepared under appropriate conditions understandable in the art, except that the substrate used was 3-(4-((7-bromoheptyl)thio)-1 - oxo-isopropyl [1 primer noise Lin 2-yl) -2,6-piperidine steep pay (SIAIS1216135) and piperidine.
- the target compound SIAIS1220105 hydrochloride (light yellow solid, 14 mg, yield Rate 63%).
- Example 58 Preparation of 3-(4-((7-(azeppan-1-yl)heptyl)sulfanyl)-1-oxoisoindoline-2-yl)piperidine -
- the compound SIAIS1220163 was prepared under appropriate conditions understandable in the art, except that the substrate used was 3-(4-((7-bromoheptyl)thio)-1 - oxo-isopropyl [1 primer noise Lin 2-yl) -2,6-piperidine steep pay (SIAIS1216135) and azepane.
- the target compound SIAIS1220163 hydrochloride pale yellow solid, 14 mg, yield 67%) was obtained.
- ⁇ NMR (500 MHz, DMSO) 5 11.02 (s, 1H), 10.22 (s, 1H), T63 ( ( ⁇ , 7 75,
- Example 59 Preparation of 3-(4-((7-(diisopropylamino)heptyl)sulfanyl)-1-oxoisoindoline-2-yl)piperidine-
- the compound SIAIS1220107 was prepared under appropriate conditions understandable in the art, except that the substrate used was 3-(4-((7-bromoheptyl)thio)-1 - oxo-isopropyl [1 primer noise Lin 2-yl) -2,6-piperidine steep pay (SIAIS1216135) and diisopropylamine.
- the hydrochloride (white solid, 2 mg, yield 8%) of the target compound SIAIS1220107 was obtained. !
- Example 60 Preparation of 3-(4-((7-(( ⁇ -1-yl)amino)heptyl)thio)-1-oxoisoindoline-2-yl)piperidine -2,6-dione (8 181220155)
- the compound SIAIS1220155 was prepared under appropriate conditions understandable in the art, except that the substrate used was 3-(4-((7-bromoheptyl)thio)-1 -Oxoiso [ 1innoline-2-yl)piperidine-2,6-dione (SIAIS1216135) and amantadine-1-amine.
- the target compound SIAIS 1220155 hydrochloride (white solid, 6 mg, yield 22%) was obtained.
- ⁇ NMR (500 MHz, DMSO) 5 11.01 (s, 1H), 8.42 (s, 2H), T63 (d, J 7.3 Hz,
- Example 61 Preparation of 3-(4-((7-((3,5-dimethyladamantan-1-yl)amino)heptyl)thio)-1-oxoisoindoline -2-yl)piperidine-2,6-dione (SIAIS1220157)
- the compound SIAIS1220157 was prepared under appropriate conditions understandable in the art, except that the substrate used was 3-(4-((7-bromoheptyl)thio)-1 - oxo-isopropyl [1 primer noise Lin 2-yl) -2,6-piperidine steep pay (SIAIS1216135) and 3, 5 - dimethyl adamantane-1-amine.
- the target compound SIAIS1220157 hydrochloride (white solid, 10 mg, yield 34%) was obtained.
- Example 62 Preparation of 3-(4-((7-((adamantan-2-yl)aminoephedyl)thio)-1-oxoisoindolin-2-yl)piperidine- 2,6-Diketone (8 181220159)
- the compound SIAIS1220159 was prepared under appropriate conditions understandable in the art, except that the substrate used was 3-(4-((7-bromoheptyl)thio)-1 - oxo-isopropyl [1 primer noise Lin 2-yl) -2,6-piperidine steep pay (SIAIS1216135) and adamantane -2-- amine.
- the hydrochloride (white solid, 7 mg, yield 25%) of the target compound SIAIS1220159 was obtained.
- Example 63 Preparation of 3-(4-((8-((adamantan-1-yl)amino)octyl)thio)-1-oxoisoindoline-2-yl pyridine- 2, 6 -dione (SIAIS1220087) [00373] According to the method of Scheme 11, compound SIAIS1220087 was prepared under appropriate conditions understandable in the art, except that the substrate used for rice was 3-(4-((8-bromooctyl)thio)-1 - oxo-isopropyl [1 primer noise Lin 2-yl) -2,6-piperidine steep pay (SIAIS1216137) and adamantane-1-amine.
- Example 64 Preparation of 3-(4-((8-((adamantan-2-yl)amino)octyl)thio)-1-oxoisoindoline-2-yl)piperidine -2, 6 -dione (SIAIS1220089)
- the compound SIAIS1220089 was prepared under appropriate conditions understandable in the art, except that the substrate used was 3-(4-((8-bromooctyl)thio)-1 - oxo-isopropyl [1 primer noise Lin 2-yl) -2,6-piperidine steep pay (SIAIS1216137) and adamantane -2-- amine.
- the target compound SIAIS 1220089 hydrochloride (white solid, 14 mg, yield 50%) was obtained.
- Example 65 Preparation of 3,3'-(((piperazine-1,4-diylbis(octane-8,1-diyl))bis(thiodiyl))bis(1-oxygen) (Isoindoline-4,2-diyl))bis(piperidine-2,6-dione) (SIAIS1220061)
- the compound SIAIS 1220061 was prepared under appropriate conditions understandable in the art.
- the difference is that the substrate used is different in that the substrate used is 3-(4-((8- Bromooctyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (SIAIS1216137) and piperazine (0.5 equivalent).
- the target compound SIAIS 1220061 (white solid, 30 mg, yield 70%) was obtained.
- Example 66 Preparation of 3-(1-oxo-4-((4,4,5,5,5-pentafluoropentyl)thio)isoindolin-2-yl)piperidine- 2,6-Diketone (SIAIS1220133)
- the compound SIAIS 1220133 was prepared by referring to the method of step 3 in Example 44, except that 4, 4, 5, 5, 5-pentafluoropentane-1-thiol was used instead of tert-butyl mercaptan.
- the target compound SIAIS1220133 (brown solid, 4 mg, yield 8%) was obtained.
- Example 67 Preparation of 3-(1-oxo-4-((9-((4,4,5,5,5-pentafluoropentyl)thio)nonyl)thio)isoindyl Dolphen-2-yl)piperidine-2,6-dione (8 181220131)
- SIAIS 1220131 the difference lies in the use of 3-(4-((8-bromooctyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (SIAIS1216137) And 4,4,5,5,5-pentafluoropentane-1-thiol as raw materials.
- the target compound SIAIS1220131 (white solid, 8 mg, yield 27%) was obtained.
- Example 68 Preparation of 3-(1-oxo-4-((9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)thio)iso Indoline-2-yl)piperidine-2,6-n
- Steps 1 and 2 [00384] Add 4, 4, 5, 5, 5-pentafluoropentyl-1-thiol (194.2 mg, 1 mmol), potassium carbonate (414.6 mg, 3 mmol) and DMF (5 mL) into 100 mL single In the bottle, add 1,9-dibromononane (582.5 mg, 3 mmol) under stirring at 50 ° C and react for 3 h.
- compound SIAIS1220145 was prepared under appropriate conditions understandable in the art, except that the halogenated substrate used was 9-((4, 4, 5, 5, 5-pentafluoropentane Group) sulfoxide group) 1 bromononane (SIAIS1220139) to obtain the target compound SIAIS1220145 (white solid, 17 mg, yield 50%). !
- Example 69 Preparation of 3-(1-oxo-4-((9-((4,4,5,5,5-pentafluoropentyl)sulfo)nonyl)thio)isoindyl Dolin-2-yl)piperidine-2,6-dione (SIAIS1220147)
- the compound SIAIS 1220147 was prepared with reference to the method of Example 68, except that the halogenated substrate used in step 3 was 9-((4,4,5,5,5-pentafluoropentyl)sulfone)1 -Bromononane (81 ⁇ 181220140) (white solid, 8 mg, yield 20%).
- Example 72 Preparation of 7-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindoline-4-yl)thio)-N ,N-Diisopropylheptanamide (SIAIS1220117)
- the compound SIAIS 1220117 was prepared with reference to the method of Example 71, except that diisopropylamine was used instead of piperidine.
- the target compound SIAIS1220117 (white solid, 13 mg, yield 8%) was obtained.
- Example 75 Preparation of 1-(3-chloro-4-methylphenyl)-3-(2-((2-(2,6-dioxopiperidin-3-yl)-1- Oxoisoindoline-4 -yl)
- Example 76 Preparation of 3-(1-oxo-4-((8-(2-oxopiperidin-1-yl)octyl)thio)isoindolin-2-yl)piper Pyridine-
- Example 77 3-(4-((6-((( ⁇ -1-yl)amino)hexyl)thio)-1-oxoisoindole-2-yl)piperidine- 2,6-Diketone (SIAIS1220177)
- the compound SIAIS1220177 was prepared under appropriate conditions understandable in the art, except that the substrate used was 3-(4-((6-bromohexyl)thio)-1- oxo-isopropyl [1 primer noise Lin 2-yl) -2,6-piperidine steep pay (SIAIS1216133) and adamantane-1-amine.
- the hydrochloride of the target compound SIAIS1220177 was obtained as a pale yellow solid, 7 mg, yield 28%.
- Example 78 3-(4-((6-((adamantan-2-yl)amino))sulfanyl)-1-oxoisoindoline-2-yl)piperidine-2, 6-Diketone (SIAIS1220179)
- compound SIAIS1220179 was prepared under appropriate conditions understandable in the art, except that the substrate used was 3-(4-((6-bromohexyl)sulfanyl)-1- Oxo iso [ 1 Yinnolin-2-yl) called steep-2,6-dione (SIAIS1216133) and adamantane-2-amine.
- the hydrochloride of the target compound SIAIS1220179 was obtained as a pale yellow solid, 22 mg, and the yield was 87%.
- the compound SIAIS1221003 was prepared under appropriate conditions understandable in the art, except that the substrate used was 3-(4-((4-(bromomethyl)benzyl) sulfur (Base)-1-oxoisoH-innoline-2-yl)piperazin-2,6-dione (SIAIS1220141) and adamantane-1-amine.
- Example 80 3-(4-((4-((adamantan-2-ylamino)methyl)sulfanyl)-1-oxoisoindoline-2-yl)piperidine- 2,6- ⁇ H(SIAIS1221005)
- the compound is prepared under appropriate conditions understandable in the art, except that the substrate used is 3-(4-((4-(bromomethyl)benzyl)thio) -1-oxoiso n-innoline-2-yl) piperidone-2, 6-dione (SIAIS 1220141) and adamantane-2-amine.
- Example 81 3-(4-((6-((adamantan-1-ylmethyl)amino)hexyl)thio)-1-oxoisoindoline-2-yl)piperidine -2,6- ⁇ M(SIAIS1221013)
- the compound was prepared under appropriate conditions understandable in the art, except that the substrate used was 3-(4-((6-bromohexyl)thio)-1-oxo Isoindolin-2-yl) piperazine-2,6-dione (SIAIS1216133) and 1-adamantane methylamine.
- the hydrochloride of the target compound SIAIS1221013 was obtained as a white solid, 23 mg, yield 88%.
- Example 82 3-(4-((7-(adamantan-1-ylthio)heptyl)thio)-1-oxoisoindoline-2-yl)piperidine-2 ,6-Diketone (SIAIS1221025)
- the compound is prepared under appropriate conditions understandable in the art, except that the substrate used is 3- ( 4 -(( 7 -bromoheptyl)thio)-1-oxy Substitute isoindoline_ 2 _ yl) piperazine_ 2 , 6 _ dione (siAismu 35 ) and adamantane-1-thiol.
- the substrate used is 3- ( 4 -(( 7 -bromoheptyl)thio)-1-oxy
- Example 83 3-(4-((7-(((adamantan-1-yl)methyl)amino)heptyl)thio)-1-oxoisoindoline-2-yl ) Piperidine-2,6-dione (81 181220171)
- the compound was prepared under appropriate conditions understandable in the art, except that the substrate used was 3-(4-((7-bromoheptyl)thio)-1-oxy Substituting isoindoline-2-yl) piperazine-2,6-dione (SIAIS1216135) and 1-adamantane methylamine.
- the target compound SIAIS1220171 was obtained as the hydrochloride salt, white solid, 16 mg, yield 59%.
- Example 84 N- (adamantan-1-yl)-7-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindoline-4 -Yl)thio)heptanamide (SIAIS1220195)
- Example 85 N-(3,5-Dimethyladamantan-1-yl)-7-((2-(2,6-dioxopiperidin-3-yl)-1-oxy (Isoindoline-4-yl)thio)heptanamide (SIAIS1220197)
- the compound SIAIS 1220197 was prepared with reference to the method of Example 71, except that 3,5-dimethyladamantane-1-amine was used instead of piperidine.
- Target compound SIAIS1220197 white solid, 21 mg, yield 75%.
- Example 86 N- (adamantane-2-yl)-7-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindoline-4 -Yl)thio)heptanamide (SIAIS1220199)
- the compound SIAIS 1220199 was prepared with reference to the method of Example 71, except that adamantane-2-amine was used instead of piperidine.
- the target compound SIAIS1220199 was obtained, white solid, 21 mg, yield 78%.
- Example 87 3-(4-((6-(cyclohexylamino)hexyl)thio)-1-oxoisoindolin-2-yl)piperidin-2,6-dione ( SIAIS1220183)
- the compound is prepared under appropriate conditions understandable in the art, except that the substrate used is 3-(4-((6-bromohexyl)thio)-1-oxo Isoindolin-2-yl)piperazine-2,6-dione (SIAIS1216133) and cyclohexylamine.
- the hydrochloride of the target compound SIAIS1220183 was obtained as a white solid, 18 mg, and the yield was 78%.
- Example 88 3-(4-((7-(Cyclohexylamino)heptyl)thio)-1-oxoisoindolin-2-yl)piperazin-2,6-dione (SIAIS1220185)
- the compound is prepared under appropriate conditions understandable in the art, except that the substrate used is 3- ( 4 -(( 7 -bromoheptyl)thio)-1-oxy Substitute isoindoline _ 2 _ yl) piperazine _ 2 , 6 _ dione (SIAISm 6 l 35 ) and aniline to obtain the target compound SIAIS1220187, white solid, 8 mg, yield 35%.
- H NMR 500 MHz , CDC1 3 ) 5 8.69 (s, 1H), T75 (d, 6.7 Hz, 1H), T59 (d, 6.9 Hz, 2H), T53 (d, 6.9 Hz, 1H),
- Example 90 3-(4-((7-(Methyl(phenyl)amino)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2, 6-diketone (SIAIS1220189)
- the compound was prepared under appropriate conditions understandable in the art, except that the substrate used was 3-(4-((7-bromoheptyl)thio)-1-oxy Substitute isoindolin-2-yl) piperazine-2,6-dione (SIAIS1216135) and N-methylaniline to obtain the target compound SIAIS1220189, white solid, 13 mg, yield 54%. !
- Example 91 3-(4-((7-(Azacyclooctane-1-yl)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine -2,6- Dione (SIAIS1220193)
- the compound was prepared under appropriate conditions understandable in the art, except that the substrate used was 3- ( 4 _(( 7 -bromoheptyl)thio) -1-oxy Substitute isoindoline_ 2 _ yl) piperazine_ 2 , 6 _dione (SIAISm 6 l 35 ) and azetidine to obtain the hydrochloride of the target compound SIAIS1220193, pale yellow solid, 22 mg, yield 92%.
- Example 92 3-(1-oxo-4-((7-(((lR,2S,4R)-l,7,7-trimethylbicyclo[2.2.1]heptane- 2-yl)amino)heptyl)thio)#indoline-2-yl)piperidine-2,6-:
- the compound is prepared under appropriate conditions understandable in the art, except that the substrate used is 3-(4-((7-bromoheptyl)thio)-1-oxy Substitute isoindolin-2-yl) piperazine-2,6-dione (SIAIS1216135) and norbornamine to obtain the target compound SIAIS1221019 hydrochloride, white solid, 14 mg, yield 54%. ! H NMR (500 MHz, DMSO) 5 10.99 (s, 1H), 8.64 (s, 1H), 8.22 7.5 Hz, 1H),
- Example 93 3-(4-((7-(3-azaspiro[5.5]undec-3-yl)heptyl)sulfanyl)-1-oxoisoindoline-2 -Yl) piperidine-2,6-dione (81 181221015)
- Example 94 3-(4-((7-(3,5-dimethylpiperidin-1-yl)heptyl)sulfanyl)-1-oxoisoindolin-2-yl ) _ Steep-2,6-dione (81 181221021)
- the compound is prepared under appropriate conditions understandable in the art, except that the substrate used is 3-(4-((7-bromoheptyl)thio)-1-oxy (Substituted isoindolin-2-yl) piperidine-2,6-dione (SIAIS1216135) and
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020217030392A KR20210142114A (ko) | 2019-02-25 | 2020-02-25 | 글루타르이미드 골격을 기초로 하는 황 함유 화합물 및 그 응용 |
CA3132308A CA3132308A1 (en) | 2019-02-25 | 2020-02-25 | Sulfur-containing compounds based on glutarimide skeleton and use thereof |
US17/433,462 US20220143002A1 (en) | 2019-02-25 | 2020-02-25 | Sulfur-containing compound based on glutarimide skeleton and application thereof |
EP20763786.9A EP3932922A4 (en) | 2019-02-25 | 2020-02-25 | SULPHUR-CONTAINING COMPOUND BASED ON A GLUTARIMIDE FRAMEWORK AND ITS USE |
JP2021549312A JP2022521746A (ja) | 2019-02-25 | 2020-02-25 | グルタルイミド骨格に基づく硫黄含有化合物及びその応用 |
AU2020228803A AU2020228803B2 (en) | 2019-02-25 | 2020-02-25 | Sulfur-containing compound based on glutarimide skeleton and application thereof |
JP2023199850A JP2024023405A (ja) | 2019-02-25 | 2023-11-27 | グルタルイミド骨格に基づく硫黄含有化合物及びその応用 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910138460.3 | 2019-02-25 | ||
CN201910138460 | 2019-02-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020173426A1 true WO2020173426A1 (zh) | 2020-09-03 |
Family
ID=72201479
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2020/076578 WO2020173426A1 (zh) | 2019-02-25 | 2020-02-25 | 基于戊二酰亚胺骨架的含硫化合物及其应用 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20220143002A1 (zh) |
EP (1) | EP3932922A4 (zh) |
JP (2) | JP2022521746A (zh) |
KR (1) | KR20210142114A (zh) |
CN (1) | CN111606883B (zh) |
AU (1) | AU2020228803B2 (zh) |
CA (1) | CA3132308A1 (zh) |
WO (1) | WO2020173426A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3778590A4 (en) * | 2018-04-09 | 2021-12-22 | ShanghaiTech University | COMPOUND TARGETING PROTEIN DEGRADATION, ANTITUMOR USE, INTERMEDIATE AND USE OF THE INTERMEDIATE |
EP4112614A4 (en) * | 2020-02-25 | 2023-09-06 | Shanghaitech University | GLUTARIMIDE BACKGROUND-BASED COMPOUNDS AND USE THEREOF |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020014489A2 (en) | 2018-07-11 | 2020-01-16 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Dimeric immuno-modulatory compounds against cereblon-based mechanisms |
CN111747924B (zh) * | 2019-03-29 | 2023-11-10 | 华东师范大学 | 一类来那度胺/泊马度胺类似物及其应用 |
CN114456173B (zh) * | 2020-11-10 | 2023-09-19 | 江苏恒瑞医药股份有限公司 | 稠环基取代的环己二酰亚胺类衍生物、其制备方法及其在医药上的应用 |
WO2023025136A1 (zh) * | 2021-08-27 | 2023-03-02 | 杭州格博生物医药有限公司 | 异吲哚啉酮化合物及其用途 |
WO2024051766A1 (zh) * | 2022-09-08 | 2024-03-14 | 标新生物医药科技(上海)有限公司 | 基于cereblon蛋白设计的分子胶化合物及其应用 |
WO2024064358A1 (en) * | 2022-09-23 | 2024-03-28 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103787802A (zh) * | 2014-02-11 | 2014-05-14 | 华东师范大学 | 一类芳基烷基硫醚化合物及其合成方法 |
US20180099940A1 (en) * | 2016-10-11 | 2018-04-12 | Arvinas, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
CN110357889A (zh) * | 2018-04-09 | 2019-10-22 | 上海科技大学 | 蛋白降解靶向化合物、其抗肿瘤应用、其中间体及中间体应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8927725B2 (en) * | 2011-12-02 | 2015-01-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Thio compounds |
JP6778114B2 (ja) * | 2014-04-14 | 2020-10-28 | アルビナス・オペレーションズ・インコーポレイテッドArvinas Operations, Inc. | イミド系タンパク質分解モジュレーター及び関連する使用方法 |
-
2020
- 2020-02-25 US US17/433,462 patent/US20220143002A1/en active Pending
- 2020-02-25 CA CA3132308A patent/CA3132308A1/en active Pending
- 2020-02-25 AU AU2020228803A patent/AU2020228803B2/en active Active
- 2020-02-25 KR KR1020217030392A patent/KR20210142114A/ko not_active Application Discontinuation
- 2020-02-25 CN CN202010116398.0A patent/CN111606883B/zh active Active
- 2020-02-25 WO PCT/CN2020/076578 patent/WO2020173426A1/zh unknown
- 2020-02-25 EP EP20763786.9A patent/EP3932922A4/en active Pending
- 2020-02-25 JP JP2021549312A patent/JP2022521746A/ja active Pending
-
2023
- 2023-11-27 JP JP2023199850A patent/JP2024023405A/ja active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103787802A (zh) * | 2014-02-11 | 2014-05-14 | 华东师范大学 | 一类芳基烷基硫醚化合物及其合成方法 |
US20180099940A1 (en) * | 2016-10-11 | 2018-04-12 | Arvinas, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
CN110357889A (zh) * | 2018-04-09 | 2019-10-22 | 上海科技大学 | 蛋白降解靶向化合物、其抗肿瘤应用、其中间体及中间体应用 |
Non-Patent Citations (6)
Title |
---|
"PDR Pharmacopoeia, Tarascon Pocket Pharmacopoeia 2000", 2000, TARASCON PUBLISHING |
CAS, no. 32511-34-5 |
LI YIMING: "A Highly Efficient Cu-Catalyzed S‑Transfer Reaction: From Amine to Sulfide", ORG. LETT., no. 16, 6 May 2014 (2014-05-06), XP055642038 * |
LI YIMING: "Selective Late-Stage Oxygenation of Sulfides with Ground-State Oxygen by Uranyl Photocatalysis", ANGEW. CHEM. INT. ED., vol. 131, no. 38, 8 August 2019 (2019-08-08), pages 13633 - 13640, XP055729591 * |
See also references of EP3932922A4 |
XIAO DONGHUAI: "Design, synthesis and biological evaluation of the thioethercontaining lenalidomide analogs with anti-proliferative activities", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 176, 15 May 2019 (2019-05-15), pages 419 - 430, XP085707343 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3778590A4 (en) * | 2018-04-09 | 2021-12-22 | ShanghaiTech University | COMPOUND TARGETING PROTEIN DEGRADATION, ANTITUMOR USE, INTERMEDIATE AND USE OF THE INTERMEDIATE |
EP4112614A4 (en) * | 2020-02-25 | 2023-09-06 | Shanghaitech University | GLUTARIMIDE BACKGROUND-BASED COMPOUNDS AND USE THEREOF |
Also Published As
Publication number | Publication date |
---|---|
KR20210142114A (ko) | 2021-11-24 |
EP3932922A4 (en) | 2022-05-11 |
AU2020228803B2 (en) | 2023-05-18 |
CN111606883B (zh) | 2023-05-09 |
AU2020228803A1 (en) | 2021-09-30 |
CA3132308A1 (en) | 2020-09-03 |
EP3932922A1 (en) | 2022-01-05 |
JP2022521746A (ja) | 2022-04-12 |
JP2024023405A (ja) | 2024-02-21 |
CN111606883A (zh) | 2020-09-01 |
US20220143002A1 (en) | 2022-05-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2020173426A1 (zh) | 基于戊二酰亚胺骨架的含硫化合物及其应用 | |
US10947213B1 (en) | TLR7/8 antagonists and uses thereof | |
JP7073359B2 (ja) | ユビキチン特異的プロテアーゼ7の阻害剤としてのピペリジン誘導体 | |
WO2021078301A1 (zh) | 蛋白降解剂及其在疾病治疗中的应用 | |
EP3538526A1 (en) | Cyclobutane- and azetidine-containing mono and spirocyclic compounds as alpha v integrin inhibitors | |
WO2006022454A1 (ja) | 塩基性基を含有する化合物およびその用途 | |
EP2976341B1 (en) | Acyclic cyanoethylpyrazolo pyridones as janus kinase inhibitors | |
WO2007049771A1 (ja) | 塩基性基を含有する化合物およびその用途 | |
TW200902526A (en) | Aminodihydrothiazin derivative substituted with a cyclic group | |
WO2021219078A1 (zh) | 基于杂环和戊二酰亚胺骨架的化合物及其应用 | |
EA036965B1 (ru) | Ингибиторы деацетилаз гистонов и композиции и способы их применения | |
JP2023525951A (ja) | グルタルイミド骨格に基づく化合物及びその使用 | |
CN108137608B (zh) | Janus激酶1选择性抑制剂及其药物用途 | |
TW201416363A (zh) | C型肝炎病毒抑制劑 | |
WO2022216680A1 (en) | Nek7 inhibitors | |
WO2011113293A1 (zh) | 二氢喋啶酮类衍生物、其制备方法及其在医药上的应用 | |
WO2023151635A1 (zh) | 基于喹唑啉取代戊二酰亚胺骨架的化合物及其应用 | |
CN117813309A (zh) | 作为pd-l1相互作用的免疫调节剂的化合物 | |
WO2024083246A1 (en) | Kras inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20763786 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2021549312 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 3132308 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2020228803 Country of ref document: AU Date of ref document: 20200225 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2020763786 Country of ref document: EP Effective date: 20210927 |